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ABSTRACT
BIO-FUNCTIONALIZED GRAPHENE FIELD-EFFECT
TRANSISTORS FOR THE DETECTION OF NUCLEIC
ACIDS AND DRUG TARGETS

Ramya Vishnubhotla
A.T. Charlie Johnson

The need for scalable, rapid, sensitive, label-free detection of small biomolecules and
chemicals such as proteins, nucleic acids or market drugs is central to the field of
biomolecular and chemical sensing. Detection of these biomolecules and chemicals is
relevant for early disease diagnostics and therapeutic drug monitoring to prolong
lifespans, treat patients in a brief timeframe, and decrease medical costs. Various
ailments, such as cancers, are the source of up-regulation or down-regulation of certain
biomolecules, or “biomarkers” in human fluids, and are indicative of the presence of the
disease when compared to human fluids from a healthy subject. By detecting these
biomarkers in low concentrations, or by tracking their change in concentration in human
samples, scientists could create an effective early disease diagnostics tool that would be
used at the point-of-care. In parallel, detection of market drugs in human samples could
replace the need for more expensive and time-consuming analytical techniques such as
liquid chromatography-mass spectrometry (LC-MS).
The work presented here explores the necessary proof-of-concept for the creation of
point-of-care devices for medical diagnostics and therapeutic drug monitoring. It details
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the process of synthetic nucleic acid detection down to attomolar concentrations, the
detection of single base-pair mismatches in nucleic acid strands, and drug target detection
in concentrations (1-10 ng/mL) far less than those found in human fluid, the latter for the
purpose of therapeutic drug monitoring or “drug compliance” testing. Such sensitivity
could only be achieved with the nanomaterial graphene, a two-dimensional allotrope of
carbon with the highest electron mobility at room temperature of any material currently
known, and with exceptional robustness and biocompatibility. The work here is based on
the use of graphene field-effect transistors, or GFETs, for nucleic acid and drug target
sensing, and further explores the various uses of graphene for protein and pH sensing, as
well as binding of protein-nanoparticle assemblies and neuropeptide-receptor binding,
through either rigid or flexible substrates.
Keywords: graphene, field-effect transistor, ssDNA, biosensing, nanomaterials
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Chapter 1: Overview of Thesis
Since the discovery of graphene, the research surrounding it has expanded from its
characterization and the study of its physical properties to the application of the
nanomaterial for various sensing endeavors. Graphene related research is particularly
exciting because of the unique properties of the material, including high sensitivity and
robustness which make it an excellent candidate for the detection of biomolecular and
chemical targets through a scalable methodology. Benefits of such sensitive detection
reach beyond academia and create promise in the fields of engineering and medical
diagnostics.
It has been shown that the change in concentration of certain biomolecules, such as
nucleic acids, proteins, or volatile organic compounds (VOCs) can up-regulate or downregulate in human fluids when a patient suffers from a specific ailment. The change in
concentration of these “biomarkers”, as they are called, is indicative of the presence of
the disease and their detection could serve as an inexpensive, rapid method for early
disease diagnostics. This could lead to prolonging lifespans for diseases such as
pancreatic cancer or ovarian cancer, for which there are currently no standard earlydetection methods. Consequentially, patients suffering from these diseases are generally
not diagnosed until the late stages of the cancer, leading to a low survival rate and
sometimes, high medical bills.
Through the detection of market drugs for therapeutic drug monitoring, these devices
have the potential to replace current analytical techniques, such as gas/liquid
chromatography-mass spectrometry (GC-MS, LC-MS), which are expensive and time-
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consuming. Therefore, the research surrounding the development of scalable devices that
aim to address these clinical issues through low-concentration detection is essential not
just for the advancement of science and engineering, but for modern medicine as well.
The work presented in this thesis focuses on the proof-of-concept of graphene field-effect
transistors for the detection of nucleic acids and drug targets in addition to employing it
as a sensing medium for protein detection, pH sensing, protein-nanoparticle assembly
detection, and measuring neuropeptide-receptor binding, all as initial steps for eventual
disease diagnostics or drug detection in human samples that could be used at the point-ofcare.
The technical background details of nanomaterials are found in Chapter 2, which
describes the properties of low-dimensional materials. Beginning with graphene, this
chapter explains why physicists believed it couldn’t exist in a thermodynamically stable
form before discussing its eventual discovery and superior electronic properties. Later,
this chapter touches on other low-dimensional materials, such as transition metal
dichalcogenides (TMDs) and carbon nanotubes (CNTs) as sensing-medium alternatives
to graphene. This chapter also discusses the insulator, hexagonal boron nitride (hBN),
which can be paired with graphene or TMDs to block interactions with dangling bonds on
a SiO2 substrate, or act as a protective layer from photoresist contamination during device
fabrication. Each of these alternative nanomaterials is appealing and has its own
exclusive characteristics, but none of them are as effective for sensing as graphene, which
is central to this thesis.
Chapter 3 describes the graphene growth, transfer and characterization processes.
Graphene was grown via chemical vapor deposition in-lab on a copper foil substrate and
2

transferred using an electrolysis bubbling method. Raman spectroscopy verified the highquality nature of the low-defect, monolayer graphene, and atomic force microscopy
(AFM) determined the surface-cleanliness and height of the sample. Optical microscopy
confirmed the continuous nature of the film. This chapter ends with how field-effect
transistors operate and are measured.
In Chapter 4, the fabrication method of these field-effect transistors is explained, which
includes photolithography, thermal evaporation and oxygen plasma etching. Later in this
chapter, the cleaning, surface chemistry and functionalization steps are described,
followed by data collection and analysis of the sensors.
Chapter 5 illustrates some of the uses of graphene FETs for nucleic acid detection and
market drug detection. Here, it is shown that GFETs are adept at detecting ssDNA down
to concentrations of 1 fM and later, 1 aM, as well as being able to detect single base pair
mismatches between probe and target DNA strands. Furthermore, GFETs demonstrate
detection of a long target strand (100 nucleotides) with a short probe (20 nucleotides).
Next, this chapter discusses graphene aptasensors for the detection of market drugs, such
as the HIV treatment market drug tenofovir, as well as an azole class antifungal drug. The
purpose of these graphene aptasensors is for therapeutic drug monitoring, or, in other
words, drug compliance, at the point of care. The benefit is the potential to serve as a
replacement for more laborious lab techniques, such as liquid chromatography-mass
spectrometry (LC-MS), which are expensive, time-consuming and require the
employment of highly-skilled lab technicians. These graphene aptasensors detected drug
concentrations down to ~1 ng/mL for tenofovir and ~ 10 ng/mL for the azole antifungal
drug, both of which are much lower than what is found in the human body.
3

Chapter 6 discusses the uses of graphene sensors for the detection of other biomolecules,
such as the protein HER3, which is a biomarker for breast cancer, flexile graphene
devices for pH sensing in complex fluids, graphene devices for protein-nanoparticle
assembly detection and graphene devices for measuring the binding between
neuropeptides and their receptors. Each of these projects explores new uses for graphene
and its ability for sensing.
Chapter 7 concludes this work and gives an overview of the thesis and the type of
projects that can develop from moving forward in this field of research, including the
impact this type of research could make on various fields beyond science and
engineering, such as healthcare and its associated costs.
Chapter 8 gives some background information about the thesis dedication.
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Chapter 2: Graphene Discovery, Properties, and Beyond
Graphene

Low-dimension materials such as graphene, transition metal dichalcogenides (TMDs),
and carbon nanotubes (CNTs) show promise for the development of novel, scalable, and
point-of-care biosensors and chemical sensors due to high electron mobility, superior
sensitivity, and biocompatibility when compared with more traditional device channels
like silicon or gallium arsenide.
Section 2.1 of this chapter discusses why theorists believed graphene could not exist in a
stable form, followed by the discovery of graphene in 2004 by Geim and Novoselov
through a method known as mechanical exfoliation. This discovery was a significant
breakthrough in condensed matter physics, and motivated scientists to study graphene in
addition to other novel 2D materials. This section also explains the methods for
acquiring graphene through both mechanical exfoliation and chemical vapor deposition
(CVD), including the benefits of CVD graphene over exfoliated graphene for scalable
sensors.
Section 2.2 is dedicated to the properties of graphene, most notably its lack of a band gap,
its high electron mobility, and its sensitivity. These qualities are what make graphene
such a desirable material for low-concentration sensing.
In section 2.3, we briefly explore other low-dimension semiconducting nanomaterials,
including transition metal dichalcogenides (TMDs) and carbon nanotubes (CNTs). While
these materials do not possess the same sensitivity as graphene, their devices have their
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own benefits, such as ease of fabrication and a band gap, and have been incorporated into
various types of biomolecular and chemical sensors.
In section 2.4, we introduce a different 2D material, the insulator hexagonal boron nitride
(hBN). This material has a very similar lattice structure compared to graphene, making it
appropriate for stacking on top of or underneath graphene, either to serve as a screening
layer from dangling bonds on a SiO2 substrate, or atop graphene, as a protective layer
against contamination. Additionally, it can also serve as a protective layer atop TMDs to
prevent degradation in atmosphere.

6

2.1 Graphene Discovery, Exfoliated Graphene and CVD Graphene

Until recently, many two-dimensional (2D) materials were theorized but not explicitly
studied, as they simply had not yet been discovered. The material that spurred the
fascination with 2D materials was graphene, an allotrope of carbon of sp2 hybridization,
and, in more general terms, a single atomic layer of graphite, more commonly known as
pencil lead. The structure of graphene consists of carbon atoms arranged in a continuous
honeycomb lattice.
For years, graphene was said to be unstable in physical form due to its sensitivity to
thermal fluctuations which were assumed to be so strong that they would displace atoms
in the lattice1,2. However, in 2004, Geim and Novoselov at the University of Manchester
proved this to be incorrect, and showed that a rigid substrate can provide stability for the
graphene film. Interestingly, it was also discovered that graphene is visible to the naked
eye provided a substrate of SiO2 with a thickness of ~ 285nm 3.
The discovery of graphene has humble beginnings, and was done so through the “scotchtape method”, or “mechanical exfoliation” method, where Geim and Novoselov used
store-bought scotch-tape and adhered it to the surface of graphite, removing a thin film.
By repeatedly pulling apart this film into thinner and thinner films with the tape, they
were able to isolate a single atomic layer of graphite in a stable form in small flakes4.
Thus, graphene was born and its research expanded 5.
This breakthrough led to the Nobel prize in physics in 2010 for Geim and Novoselov, and
a further boost in interest in the study of graphene. Since then, a second type of graphene
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has garnered a great deal of attention, and that is chemical vapor deposition (CVD)
graphene. In this form, graphene is “grown” on a metallic substrate in continuous, largearea sheets using a carbon gas source, high heat (~1000 C) and sometimes, low
pressure6,7.
Benefits and caveats exist for both exfoliated and CVD graphene. Exfoliated graphene is
the most pristine, low-defect form of graphene available. Its mobilities can reach up to
10,000 cm2/Vs on an oxidized silicon substrate 4, and as high as 200,000 cm2/Vs when
suspended8, and takes minimal time to synthesize. Unfortunately, exfoliated graphene
flakes are quite small (~ 1-100 μm), and as a result, it is difficult to achieve precise
placement of them in application.
CVD graphene is wafer-scale, and can be grown in sheets of several square inches9 (see
Appendix A). Because of its large-area nature, the scientist has more control over her
experiments and applications and can dictate the size and placement of the graphene film.
This creates the possibility of scalable graphene devices, where the scalability factor is
crucial for both applications and statistically relevant results. However, mobilities for
CVD graphene are much lower compared to exfoliated graphene’s, around 1,000-3,000
cm2/Vs for good quality, monolayer CVD graphene devices10,11. This difference in
quality is most likely from the formation of defects in the lattice during CVD growth,
combined with exposure to chemicals during the transfer process, neither of which
presents itself in mechanical exfoliation sample preparation. For more information on
CVD graphene growth and transfer, please see Chapter 3. Various cleaning methods are
employed to reduce the contamination for CVD devices, but are never able to achieve an
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unadulterated state of the graphene. However, such challenges come with the territory of
application.
Despite the limited uses of graphene outside of research, the material shows promise for
future applications, on which this thesis sheds more light.
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2.2 Properties of Graphene

Graphene, a 2D allotrope of carbon with sp2 hybridization exists as a single atomic layer
of carbon atoms arranged in a honeycomb lattice. Graphene’s unit cell contains two
atoms, making up the “A” and “B” sublattices, and it has a lattice constant of 2.46
angstroms (Å), a carbon-carbon bond length of 𝑎 = 1.42Å, and its basis vectors (𝑎1 , 𝑎2 )
and reciprocal lattice vectors (𝑏1 , 𝑏2 ), written in terms of 𝑎 are:
𝑎

𝑎1 = (3, √3)
2
𝑏1 =

2𝜋

(1, √3)
3𝑎

𝑎

𝑎2 = (3, −√3)
2
𝑏2 =

2𝜋
3𝑎

(1, −√3)

(2.1)

(2.2)

The two sublattices of the graphene structure can be seen in Figure 2.2.1 4:

𝑎1
𝑎2

Fig 2.2.1 Graphene honeycomb lattice showing basis vectors and separate sub-lattices in
blue and green.
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To further understand the lattice of graphene and the properties that arise from it, Figure
2.2.2 demonstrates the first Brillouin zone (FBZ) of graphene, which is defined as a
primitive cell in reciprocal space, and can be found by drawing lines to the nearest
neighbors of an atom and bisecting each of these lines perpendicularly to enclose the
FBZ. There are a total of six points at the edge of the FBZ of graphene known as “Dirac
points”12, although only two differing values exist, labeled K and K’ in Figure 2.2.213.
Their values are stated in Equation 2.3.

Figure 2.2.2. First Brillouin zone (red) of the graphene honeycomb lattice, with 6 Dirac
points. Of these six points, there are only two differing values, labeled as K and K’.

𝐾=

2𝜋
3𝑎

(1,

1
√3

) 𝐾′ =
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2𝜋
3𝑎

(1,

−1
√3

)

(2.3)

The values for K and K’ are necessary for the tight binding model for graphene, which
represents the meeting of the valence and conduction band at these six Dirac points at the
edge of the FBZ, described by the following equation:
𝑘𝑦 𝑎

𝐸 = ±𝛾0 √1 + 4𝑐𝑜𝑠 2 (

2

𝑘𝑦 𝑎

) + 4 𝑐𝑜𝑠 (

2

√3𝑘𝑥 𝑎
)
2

) 𝑐𝑜𝑠 (

(2.4)

Here, 𝛾0 represents the nearest-neighbor hopping energy, which is 2.5 eV based on
density functional theory13. By inputting the values for 𝑘𝑥 and 𝑘𝑦 based on the values for
K and K’ in Equation 2.3, we see that at the edge of the FBZ, the energy is zero,
meaning there is no band gap for graphene (Figure 2.2.3). Due to the lack of a band gap,
there is an inability to ever have a zero current flow, or “turn off” the device14. Its lack of
a band gap allows it to conduct both holes and electrons, categorizing it as “ambipolar”3.

Fig 2.2.3. Graphene band structure demonstrating the lack of bandgap, where the
valence and conduction bands meet at the Dirac point [Ref: electronic properties of
graphene]
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Despite graphene’s superior mobility and sensitivity as every atom of the surface is
exposed, it is not ideal for digital logic devices, as its lack of a band gap leaves it
inefficient for modern-day electronics. This could be counteracted by engineering a band
gap in graphene by doping it with atoms of a different element, such as boron or
nitrogen15, or patterning it into nanoribbons (GNRs)16, which are thin strips of graphene
for which there is a band gap coming from a lateral confinement of electrons in the GNR
(usually being less than 50 nm in width). However, doping can lead to decreased electron
mobility, and GNR patterning is not a viable process for scalable fabrication. Thus, the
sensitivity and scalability of large-area CVD graphene is what makes it most suitable for
biosensing techniques, where an on/off property is irrelevant, and the surface can be large
enough, with every atom exposed, to detect biomolecules and chemicals in low
concentrations.
Graphene’s high electron mobility is ascribed to the massless nature of fermions in the
material17, meaning that the appropriate equation to describe the charge carriers is not the
Schrodinger equation, but the Dirac equation. This is shown through the Dirac-like
Hamiltonian:
0
̂ = ℏ𝑣𝐹 (
𝐻
𝑘𝑥 + 𝑖𝑘𝑦

𝑘𝑥 − 𝑖𝑘𝑦
)
0

(2.5)

For which the solution is:
𝐸 = ℏ𝑣𝐹 𝝈 • 𝒌

(2.6)

From this solution, we can see that the energy of the electrons in graphene are dependent
on the Fermi velocity 𝑣𝐹 which plays the role of the speed of light, the Pauli matrix 𝝈,
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and the momentum k. The Fermi velocity for electrons in graphene is ~ 106

𝑚 3
.
𝑠

The

electron mobility, or speed at which charge carriers travel in graphene, is greater at room
temperature than those found in any other material measured18, and is described through
the following equation:
𝑣𝑑 = µ𝐸

(2.7)

In this relationship, 𝑣𝑑 is the drift velocity, or average velocity, of the charge carriers, µ
is the mobility, and E is the electric field. Therefore, because the drift velocity of the
charge carriers in graphene is so high due to their massless nature, the mobility of these
carriers will also be high for some fixed electric field.
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2.3 Beyond Graphene: Transition Metal Dichalcogenides and Carbon
Nanotubes

Apart from graphene, FET sensing can be carried out with other materials such as
transition metal dichalcogenides (TMDs) or carbon nanotubes (CNTs). TMDs are
semiconductors with a band gap that take the form MX2, where ‘M’ is a transition metal
and ‘X’ is a chalcogen atom (S Se, Te). This lattice layout is shown in Figure 2.3.1. In
this structure, element ‘M’ is sandwiched between layers of element ‘X’ – this defines a
single layer of the TMD. The most widely studied TMD is molybdenum disulfide, or
MoS2, which has an indirect bandgap of 1.23 eV that is tunable19, robust20, and has
exceptional photoresponsivity21.

Fig 2.3.1 MoS2 lattice with molybdenum atoms in blue and sulfur atoms in yellow

MoS2 can be synthesized both with the exfoliation method22 and through CVD growth,
although placement of the material is challenging, as it often grows in flakes23,24, though
there have been some reports of large-area CVD MoS2 growth25,26. In the past, MoS2 has
15

been used for the detection of opioids27, gas sensing of CO, CO2 and NO28, and detection
of biomolecules such as prostate specific antigen29.
A benefit of MoS2 (and other TMD) devices is that there is less photolithographic
contamination than graphene devices, as the CVD flakes do not need to be patterned in
the device channel27 (please see Chapter 4 for more information on device fabrication),
although placement of the flakes on the substrate can be imprecise.
One study has reported the growth and transfer of full sheets of CVD grown MoS2 in
dimensions of 2x2 inches30, although, currently, there are no other reports of executing
this method successfully and with limited contamination.
Beyond MoS2, there are a number of other TMD materials that have been used for
various applications, such as tungsten disulfide (WS2) used for humidity sensing31, gas
sensing for acetone and NO232, and devices incorporated with graphene for DNA
hybridization sensing33. MoTe2 has been used for gas sensing of NO2 and NH334 and for
adsorption of various SF6 decomposition molecules35. Tungsten ditelluride (WTe2) is
another TMD that can be grown via CVD36,37, although due to its sensitivity to
atmosphere and its relative newness, there are currently no reports for WTe2 sensors.
While these additional TMDs are interesting and hold their own unique properties, they
are still problematic for fabricating scalable arrays of FETs for low-concentration
sensing, either due to their lack of sensitivity compared to graphene, or their instability in
atmosphere.
Apart from 2D materials, sensors can also be fabricated with carbon nanotubes,
sometimes described as 1D carbon, or graphene “rolled” into a cylinder. They are a
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viable option for sensing purposes and exist as single-walled NTs or multiwall NTs,
which describe many concentric CNTs, and possess a band gap.
The chirality of the nanotube, or angle at which it is rolled, determines its properties, and
is described by the equation below:
𝑪 = 𝒏𝒂𝟏 + 𝒎𝒂𝟐

(2.8)

where C is the circumference of the nanotube and is comprised of the integer sum of the
graphene basis vectors 𝒂𝟏 and 𝒂𝟐 with ‘m’ and ‘n’ being integers38.
Carbon nanotubes can be grown via CVD, and may also be purchased synthetically. The
biggest deterrent to CVD-grown CNTs is the fact that approximately one third of them
will be metallic, compromising the on-off ratio. The desired CNT type for FET sensors is
semiconducting, and therefore, it is beneficial to purchase nanotubes with the desired
chirality and properties in a water-soluble fluid. In the past, CNTs have been used for
glucose sensing39, prostate cancer biomarker detection40, Lyme disease detection41, and
complex vapor mixtures42. CNT FETs do not need to undergo any photoresist exposure
following attachment to their substrate, and, if they are purchased commercially in a
solution, can be pipetted by hand onto the desired device area. Even with these benefits,
CNTs are, ultimately, less sensitive than graphene, as CNT networks will not be perfectly
continuous like a graphene film.

Despite neither TMDs nor CNTs possessing the electron mobility or sensitivity that
graphene does, these materials do, indeed, have a band gap, meaning that they are more
realistic for use in modern-day electronics than graphene, and each has its ease of
use/fabrication over scalable graphene devices.
17

2.4 A Two-Dimensional Insulator: Hexagonal Boron Nitride

A different type of low-dimensional material is hexagonal boron-nitride (hBN), which
consists of alternating boron and nitrogen atoms in the ‘A’ and ‘B’ sublattices in a 2D
hexagonal lattice structure similar to that of graphene, and can be obtained via exfoliation
or through CVD growth. This material, an insulator with a band gap of 5.2 eV 43, has a
lattice mismatch of only 1.5% when compared to graphene44 and can therefore be stacked
neatly on top of or underneath graphene.
By stacking it underneath, one can prevent graphene’s charge carriers from interfering with
dangling bonds of a SiO2 substrate, maintaining the graphene’s high electron mobility45-47.
Alternately, hBN can be stacked atop graphene for scalable device fabrication, and behaves as
a protective layer for graphene against photolithographic contamination. Atop metals, hBN
serves as a protective layer from oxidation in air48, and can also be used as a protective layer
for TMDs, making it an interesting and versatile material for improving the quality of GFET
of TMD-FET sensors. Please see Appendix B for growth details on hBN.
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Chapter 2 Conclusions

Graphene is an unusual material with alluring properties such as high robustness and
superior electron mobility at room temperature. Despite the long-held belief that
graphene could not exist in a stable state, Geim and Novoselov from the University of
Manchester isolated flakes of graphene via mechanical exfoliation in 2004, which led to
the Nobel Prize in Physics in 2010, the shortest time between discovery and award in
Nobel Prize history. Its superior sensitivity makes it an excellent nanomaterial for
sensing.
Although graphene is central to this work, there are other nanomaterials that are worth
researching and exploring, such as semiconducting transition metal dichalcogenides
(TMDs), and the 1D version of graphene, carbon nanotubes (CNTs), which can be
purchased with the desired chirality, and which have been studied long before graphene
was discovered. The benefits of TMDs and CNTs is that they pose fewer contamination
obstacles during device fabrication, as they are smaller area than large-area CVD
graphene and do not need to be patterned, and they possess a band gap, which graphene
lacks. Because of this band gap, these materials are more suitable for digital logic
technology, as they can be turned “on” and “off”.
Finally, hexagonal boron nitride (hBN), an insulator that can be exfoliated or grown
through CVD, is another intriguing nanomaterial with a similar lattice structure of that of
graphene, and which is advantageous when used in conjunction with graphene or even
TMDs to improve device sensitivity and quality.
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Both TMDs and CNTs have their own benefits and challenges in sensing, although
neither possess the sensitivity of graphene, which is the most suitable of these materials
for biomolecular and chemical detection. However, this cannot be achieved without good
quality graphene, which will be discussed in the next chapter.

20

Chapter 2 References
1

Peierls, R. Quelques propriétés typiques des corps solides. Annales de l'institut
Henri Poincaré 5, 177-222 (1935).

2

Laundau, L. D. Zur Theorie der phasenumwandlungen II. Physikalische
Zeitschrift der Sowjetunion 11, 26-35 (1937).

3

Geim, A. K. & Novoselov, K. S. The rise of graphene. Nature Materials 6, 183
(2007).

4

Novoselov, K. S. et al. Electric Field Effect in Atomically Thin Carbon Films.
Science 306, 666-669 (2004).

5

Pham, V. P., Jang, H.-S., Whang, D. & Choi, J.-Y. Direct growth of graphene on
rigid and flexible substrates: progress, applications, and challenges. Chem. Soc.
Rev. 46, 6276-6300 (2017).

6

Kim, K. S. et al. Large-scale pattern growth of graphene films for stretchable
transparent electrodes. Nature 457, 706 (2009).

7

Xuesong, L., Luigi, C. & S., R. R. Synthesis of Graphene Films on Copper Foils
by Chemical Vapor Deposition. Advanced Materials 28, 6247-6252 (2016).

8

Bolotin, K. I. et al. Ultrahigh electron mobility in suspended graphene. Solid State
Communications 146, 351-355 (2008).

9

Ping, J., Vishnubhotla, R., Vrudhula, A. & Johnson, A. T. C. Scalable Production
of High-Sensitivity, Label-Free DNA Biosensors Based on Back-Gated Graphene
Field Effect Transistors. ACS Nano 10, 8700-8704, doi:10.1021/acsnano.6b04110
(2016).

10

Rajesh et al. Genetically Engineered Antibody Functionalized Platinum
Nanoparticles Modified CVD‐Graphene Nanohybrid Transistor for the Detection
of Breast Cancer Biomarker, HER3. Adv. Mater. Inter. 3 (2016).

11

Gao, Z. et al. Scalable Production of Sensor Arrays Based on High-Mobility
Hybrid Graphene Field Effect Transistors. ACS Applied Materials & Interfaces 8,
27546-27552 (2016).

12

Wallace, P. R. The Band Theory of Graphite. Physical Review 71, 622-634
(1947).

21

13

Castro Neto, A. H., Guinea, F., Peres, N. M. R., Novoselov, K. S. & Geim, A. K.
The electronic properties of graphene. Reviews of Modern Physics 81, 109-162
(2009).

14

Wang, H., Hsu, A., Wu, J., Kong, J. & Palacios, T. Graphene-Based Ambipolar
RF Mixers. IEEE Electron Device Letters 31, 906-908 (2010).
S., P. L. et al. Synthesis, Structure, and Properties of Boron‐ and Nitrogen‐Doped
Graphene. Advanced Materials 21, 4726-4730 (2009).

15

16

Han, M. Y., Özyilmaz, B., Zhang, Y. & Kim, P. Energy Band-Gap Engineering of
Graphene Nanoribbons. Physical Review Letters 98, 206805 (2007).

17

Novoselov, K. S. et al. Two-dimensional gas of massless Dirac fermions in
graphene. Nature 438, 197 (2005).

18

Bolotin, K. I., Sikes, K. J., Hone, J., Stormer, H. L. & Kim, P. TemperatureDependent Transport in Suspended Graphene. Physical Review Letters 101,
096802 (2008).

19

Zhu, J. et al. Thickness-dependent bandgap tunable molybdenum disulfide films
for optoelectronics. RSC Adv. 6, 110604-110609 (2016).

20

Kobayashi, K. & Yamauchi, J. Electronic structure and scanning-tunnelingmicroscopy image of molybdenum dichalcogenide surfaces. Physical Review B
51, 17085-17095 (1995).

21

Li, X. & Zhu, H. Two-dimensional MoS2: Properties, preparation, and
applications. J. Materiomics 1, 33-44 (2015).

22

Li, H., Wu, J., Yin, Z. & Zhang, H. Preparation and Applications of Mechanically
Exfoliated Single-Layer and Multilayer MoS2 and WSe2 Nanosheets. Accounts of
Chemical Research 47, 1067-1075 (2014).

23

Wang, X., Feng, H., Wu, Y. & Jiao, L. Controlled Synthesis of Highly Crystalline
MoS2 Flakes by Chemical Vapor Deposition. Journal of the American Chemical
Society 135, 5304-5307 (2013).

24

Schmidt, H. et al. Transport Properties of Monolayer MoS2 Grown by Chemical
Vapor Deposition. Nano Letters 14, 1909-1913 (2014).

25

Yi‐Hsien, L. et al. Synthesis of Large‐Area MoS2 Atomic Layers with Chemical
Vapor Deposition. Advanced Materials 24, 2320-2325 (2012).

26

Li, L. et al. A General Method for the Chemical Synthesis of Large‐Scale,
Seamless Transition Metal Dichalcogenide Electronics. Advanced Materials 30,
1706215 (2018).
22

27

Naylor, C. H. et al. Scalable Production of Molybdenum Disulfide Based
Biosensors. ACS Nano 10, 6173-6179, (2016).

28

Shokri, A. & Salami, N. Gas sensor based on MoS2 monolayer. Sensors and
Actuators B: Chemical 236, 378-385 (2016).

29

Lee, J. et al. Two-dimensional Layered MoS2 Biosensors Enable Highly
Sensitive Detection of Biomolecules. Scientific Reports 4, 7352 (2014).

30

Ma, D. et al. A universal etching-free transfer of MoS2 films for applications in
photodetectors. Nano Research 8, 3662-3672 (2015).

31

Luo, Y. et al. Tungsten disulfide (WS2) based all-fiber-optic humidity sensor.
Opt. Express 24, 8956-8966 (2016).

32

Ko, K. Y. et al. Improvement of Gas-Sensing Performance of Large-Area
Tungsten Disulfide Nanosheets by Surface Functionalization. ACS Nano 10,
9287-9296 (2016).

33

Rahman, M. S., Hasan, M. R., Rikta, K. A. & Anower, M. S. A novel graphene
coated surface plasmon resonance biosensor with tungsten disulfide (WS2) for
sensing DNA hybridization. Optical Materials 75, 567-573 (2018).

34

Zhihong, F. et al. Highly sensitive MoTe 2 chemical sensor with fast recovery
rate through gate biasing. 2D Materials 4, 025018 (2017).

35

Wang, D.-W. et al. MoTe2: A Promising Candidate for SF6 Decomposition Gas
Sensors with High Sensitivity and Selectivity. iEEE Electron Dev. Lett. 9, 292295 (2017).

36

Naylor, C. H. et al. Large-area synthesis of high-quality monolayer 1T’-WTe 2
flakes. 2D Materials 4, 021008 (2017).

37

Jiadong, Z. et al. Large‐Area and High‐Quality 2D Transition Metal Telluride.
Advanced Materials 29, 1603471 (2017).

38

Dresselhaus, M. S., G. Dresselhaus, and P. Avouris. Carbon nanotubes : synthesis,
structure, properties, and applications. Topics in applied physics, 447 (2001).

39

Lerner, M. B. et al. Scalable, non-invasive glucose sensor based on boronic acid
functionalized carbon nanotube transistors. Applied Physics Letters 102, 183113
(2013).

23

40

Lerner, M. B. et al. Hybrids of a Genetically Engineered Antibody and a Carbon
Nanotube Transistor for Detection of Prostate Cancer Biomarkers. ACS Nano 6,
5143-5149 (2012).

41

Lerner, M. B., Dailey, J., Goldsmith, B. R., Brisson, D. & Johnson, A. T. C.
Detecting Lyme Disease Using Antibody-Functionalized Single-Walled Carbon
Nanotube Transistors. Biosensors & bioelectronics 45, 163-167 (2013).

42

Kybert, N. J., Lerner, M. B., Yodh, J. S., Preti, G. & Johnson, A. T. C.
Differentiation of Complex Vapor Mixtures Using Versatile DNA–Carbon
Nanotube Chemical Sensor Arrays. ACS Nano 7, 2800-2807 (2013).
Hoffman, D. M., Doll, G. L. & Eklund, P. C. Optical properties of pyrolytic boron
nitride in the energy range 0.05---10 eV. Physical Review B 30, 6051-6056
(1984).

43

44

Wang, J., Ma, F. & Sun, M. Graphene, hexagonal boron nitride, and their
heterostructures: properties and applications. RSC Advances 7, 16801-16822
(2017).

45

Qi, J. Z. et al. Electronic Transport in Heterostructures of Chemical Vapor
Deposited Graphene and Hexagonal Boron Nitride. Small 11, 1402-1408 (2015).

46

Dean, C. R. et al. Boron nitride substrates for high-quality graphene electronics.
Nature Nanotechnology 5, 722 (2010).

47

Gannett, W. et al. Boron nitride substrates for high mobility chemical vapor
deposited graphene. Applied Physics Letters 98, 242105 (2011).

48

Galbiati, M., Stoot, A. C., Mackenzie, D. M. A., Bøggild, P. & Camilli, L. Realtime oxide evolution of copper protected by graphene and boron nitride barriers.
Scientific Reports 7, 39770 (2017).

24

Chapter 3: Graphene Growth, Transfer and Characterization

Proper growth of graphene and its characterization are crucial aspects of graphene sensor
fabrication to ensure high quality devices. Here, the methods of graphene growth and
transfer are explained, along with graphene film characterization to verify the quality of
the nanomaterial.
This chapter begins with Section 3.1, defining the standardized growth of wafer-scale
CVD graphene on a copper foil substrate, before moving on to its transfer through a lowcontamination electrolysis bubbling method.
Section 3.2 describes the characterization process of the graphene film via Raman
spectroscopy, which uses a laser to measure the low-energy vibrational and rotational
modes of a material’s lattice. The process depends on the inelastic scattering of the
laser’s photons as they interact with the material’s lattice, creating a unique spectrum of
the material.
In Section 3.3, atomic force microscopy (AFM) is presented as a second means of
material characterization, which uses a cantilever and tip to scan the surface of materials
to determine their height.
Optical microscopy, the simplest method of characterization, is explained in Section 3.4,
and is employed to ensure the continuity and lack of bilayer growth in the film. Without
good quality growth and transfer steps, or high-quality graphene, the yield of the sensors
will be low and ineffective at detecting molecules.
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The chapter ends with section 3.5, which focuses on the structure of the leading type of
graphene sensor in this work, the graphene field-effect transistor, and how it operates.
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3.1 Graphene Growth and Transfer

Graphene is grown in-lab via a method known as chemical vapor deposition (CVD). This
process utilizes a low-pressure furnace, H2 and Ar carrier gases and methane as a carbon
feedstock to produce continuous, large-area, low-defect monolayer graphene on a copper
foil substrate. Graphene nucleates around defects on the surface of the copper foil,
adatoms, and surface contaminants, and the carbon atoms from the methane detach from
the hydrogen in the methane molecules and adsorb onto the copper foil, resulting in a
layer of graphene1. The H2 is necessary to etch away carbon that is not of the sp2
hybridization2. More details on this process are provided in Appendix A.
To transfer graphene, the copper foil with graphene was coated with a sacrificial layer of
polymethyl methacrylate (PMMA, A4 950, Microchem) to improve visibility of the film
and provide structural support, and baked at 150 C for 2 min to ensure proper adhesion of
the PMMA to the graphene. Transfer was carried out via an electrolysis bubbling
method3 in a 0.05 M sodium hydroxide (NaOH) solution connected to a power source of
voltage 20 V with the cathode resting in the NaOH solution and the anode connected to
the Cu foil/graphene/PMMA stack. Upon immersion of the stack in the solution, the
circuit is completed and current begins to flow. H2 bubbles form at the interface of the
graphene/PMMA stack and the Cu foil, and the two separate (Fig 3.1.1), leaving the
graphene/PMMA film floating in the NaOH solution.
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Fig. 3.1.1 Electrolysis bubbling method of graphene with 0.05M sodium hydroxide
(NaOH) solution with the anode connected to the copper foil/graphene/PMMA stack and
the cathode in the NaOH solution. This leaves a film of graphene/PMMA floating in the
solution.

The film was then transferred to a series of deionized (DI) water baths to remove the
NaOH residue, and finally transferred onto the desired substrate and left to dry for ~1
hour. The benefit of this transfer method compared to others, for example, using copper
etchant4 is that it is low-contamination, as NaOH residue is easier to remove than copper
etchant, and that it is a rapid process.
Once the graphene/PMMA stack is dry, the sample is baked at 150 C for 2 minutes to
ensure adhesion of the graphene to the substrate. Next, the PMMA is removed with
acetone and the sample rinsed with IPA and dried with compressed N2.
At this point, what is left is a clean graphene film on the desired substrate. The following
steps for fabrication are explained in more detail in Chapter 4.
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3.2 Raman Spectroscopy of Graphene
Raman spectroscopy is a highly useful technique to provide information about the quality
of a nanomaterial. This method of characterization uses a laser to measure the low-energy
vibrational and rotational modes of the material’s lattice, creating a unique “fingerprint”
of the material. It relies on inelastic scattering of the laser’s photons which interact with
the lattice, causing a shift in the photons’ energies and providing information about the
lattice itself. Here, Raman spectroscopy was carried out on bare, un-transferred graphene
on copper foil.
Raman profiles of the graphene grown in-lab were consistent with good-quality,
monolayer graphene, exhibiting the correct placement and intensity of the three most
important bands, the D band, the G band, and the G’, or 2D band. The D band, ~ 1300
cm-1, represents the defects in the graphene caused by sp3 hybridized carbon. The G band,
at ~ 1600 cm-1, describes the in-plane vibrational mode involving sp2 carbon-carbon
bonds, and the G’ band, or the 2D band, found ~ 2700 cm-1, is the second order of the D
band, the result of a two phonon lattice vibrational process, is the strongest band in the
spectrum, and does not represent defects5.
For high quality, monolayer graphene, the ratio between the 2D/G peaks is ~2, with a
very low D/G ratio ( < 0.05)6. This can be seen in Fig. 3.2.1, which shows the Raman
spectrum of monolayer graphene on copper foil. From this Raman spectrum, we verify
that the graphene quality is high and ready for use in sensing.
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Figure 3.2.1. Raman spectrum of monolayer graphene on copper foil, with a low D peak
and a ratio of ~2 between the 2D and G peaks.

This spectrum looks very different than the spectrum for graphite, for which the G peak
far exceeds the height of the 2D peak7:

Figure 3.2.2. Raman spectrum of graphite compared to graphene
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3.3 Atomic Force Microscopy of Graphene
Scanning probe microscopy methods are standard for determining the quality of samples,
especially ultra-thin samples such as 2D materials. One such form of scanning probe
microscopy is atomic force microscopy (AFM), which aims to provide information about
the height of thin materials by wielding a cantilever with a thickness of a few nanometers
to scan the surface of the sample. When the surface is scanned in tapping mode, the
cantilever oscillates close to its resonant frequency while moving laterally across the
surface of the sample. As the cantilever and tip come into contact with the sample, the
cantilever varies in distance from the substrate depending on the height of the material
(Fig. 3.3.1). This distance variation is due to the damping of the cantilever’s oscillations
coming from the intramolecular forces between the atoms of the sample and the tip.

Figure 3.3.1 Atomic force microscopy schematic. A cantilever scans the surface of the
substrate and sample in a tapping mode and increases or decreases in height depending
on the thickness of the scanned material, yielding a height profile.
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AFM is sensitive to even atomically thin films, making it excellent for scanning materials
like graphene and verifying that no bilayer or amorphous growth is present. Additionally,
upon scanning the surface, it can determine the surface roughness and cleanliness of the
sample, as the height profile will change due to contamination.
AFM profiles for bare graphene on a SiO2 substrate yield a height of ~1 nm with a
Bruker Icon AFM in tapping mode, where the cantilever and tip continuously tap the
sample while scanning the surface. A height of ~1 nm is the expected experimental value
for graphene on this type of substrate8 (Fig. 3.3.2).
It behooves the experimentalist to conduct AFM on a substrate where the graphene is
visible, seen through a small camera in the AFM set-up. Otherwise, it is impossible to
know where (or what) one is scanning. Therefore, AFM directly on the copper foil
substrate is not an option, as there is a need for color contrast. AFM scans for graphene
are typically carried out on a SiO2 substrate of ~ 285 nm, so that the graphene film is
visible. The necessity of film visibility is to locate an effective place for scanning, usually
beginning with the edge of a small tear in the center of the film, as the edges of the full
film are often contaminated from transfer, where PMMA residue can be stubborn to
remove and can result in an inaccurate height profile. To create a sample of graphene on
SiO2, the film must be transferred via the electrolysis bubbling method mentioned in
section 3.1.
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Figure 3.3.2. Atomic force microscopy of bare graphene on SiO2 (left) and height profile
associated with the image (right), showing a height of ~1 nm.
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3.4 Optical Microscopy of Graphene
The final characterization for graphene, and the simplest, is optical microscopy. By
observing the graphene under magnification, one can determine the existence of bilayer
growth (often seen as darker areas on the graphene), and, moreover, ascertain the
continuity of the sample, as discontinuous graphene leads to poor device quality and
yield. Optical microscopy is helpful because the Raman laser only provides information
about the quality of small areas of the graphene, but not necessarily the continuity, and
AFM only provides information about the cleanliness and continuity of small areas (a
few µm).
Therefore, optical microscopy, when used on high magnification, is the best way to
determine continuity, as without a continuous sheet, problems may arise with adhesion to
the substrate during device fabrication. Figure 3.4.1 represents continuous monolayer
graphene on a SiO2 substrate.

Figure 3.4.1 Continuous, monolayer bare graphene on SiO2
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In the event that the graphene contains significant bilayer growth, which will appear as
spotty, darker areas under an optical microscope, a possible fix to the growth recipe is to
either decrease the methane flow, or to decrease the time of the growth. If the film is
discontinuous in its growth, which will appear as hexagonal flakes that are beginning to
form a film, with empty spaces in between, then the graphene growth step should be
extended by a few minutes (see Appendix A for more details on the graphene growth
recipe).
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3.5 Electrical Characterization of Graphene Field-Effect Transistors
The high-quality, monolayer, large-area graphene described in this thesis is used
primarily for the fabrication of field-effect transistors (FETs), which are pervasive in
modern electronics. A field-effect transistor is an electrical device with three terminals: a
gate, a source, and a drain. A fixed “bias voltage” (VB) is applied across the source and
drain, and an electric field associated with the “gate voltage” (VG) alters the Fermi level
of the conducting channel, and thus, modulates the flow of current through this channel.
Typically, for devices described here, the substrate is SiO2 of thickness ~285 nm on
heavily doped p-type silicon.
The most frequently employed type of FET is the metal-oxide semiconductor FET, or
MOSFET, which incorporates semiconductors such as silicon, which are used to form the
channel9. Although there is an abundance of silicon, it possesses a band gap, and silicon
devices have been well studied and understood for decades, it simply does not have the
same level of detection sensitivity as graphene, as every atom of the lattice is not exposed
as in the case of graphene, nor does it have the high electron mobility of graphene at
room temperature. Therefore, while silicon is a viable choice for modern day electronic
devices such as computers and smartphones that need to be turned on and off, it is not the
best option for low-concentration biomolecular or chemical sensing.
The work presented here centers around graphene FETs on a Si/SiO2 wafer, with silicon
as the gate of the device and silicon dioxide acting as the gate dielectric. CVD graphene
serves as the channel, with source and drain electrodes of chromium and gold (5 nm, 40
nm, respectively). Unlike metal-semiconducting devices, which have a potential energy
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barrier for the electrons to overcome, known as the Schottky barrier, GFET devices
possess no such barrier, and instead have Ohmic contact (conductor-conductor junction)
between their metal electrodes and graphene channel, classifying the devices as “nonrectifying”. Owing to the fact that graphene is an excellent conductor of both electrons
and holes and therefore, there is no potential energy barrier for electrons to overcome
between the electrodes and the channel. In these devices, the silicon gate and the
graphene channel are capacitively coupled, illustrated in the schematic below (Fig. 3.5.1)

Figure 3.5.1. Schematic of a graphene field effect transistor with chromium (Cr) and
gold (Au) contacts, a bias voltage across the source and drain (VB), and a gate voltage
(VG) from the source to the silicon/silicon dioxide body.

All readout was done electronically by sweeping the gate of the device. This resulted in a
profile of current versus gate voltage (I-VG) which provides information about the
electron mobility in the GFETs and the Dirac voltage, or “Dirac point”, described as the
minimum point of conductance. For bare graphene, the Dirac voltage generally lies
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between 0-10 V, with mobilities up to about 2,000-2,500 cm2/Vs, and a GFET device
yield of > 90% 10. An example of a single such device is shown in the figure below:

Current (mA)
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0.0
-20

0

20

40

Gate Voltage (V)
Figure 3.5.2. I-VG characteristics of a single GFET, with a Dirac voltage between 0-10 V
In this graph, the current never reaches zero, and the Dirac voltage is roughly 3-4 V. In
theory, the Dirac voltage should be zero, as explained in Chapter 2, section 2, and the
mobility thousands of cm2/Vs higher than 2,000-2,500 cm2/Vs. Unfortunately, dangling
bonds on the SiO2 surface can interfere with these values, and the use of the substrate is
not avoidable in this instance. High mobilities can be achieved with suspended graphene,
however, these devices are difficult to engineer in large quantities, and therefore, this is
not a suitable method for scalable fabrication.
The details of the I-VG curve and how it changes due to chemical functionalization on the
surface of the graphene will be explained in more detail in Chapter 4.
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Chapter 3 Conclusions
The verification of proper graphene growth and quality is critical for fabricating highcaliber graphene devices with superior sensitivity. By using Raman spectroscopy, one
can determine the nature of the graphene on a copper foil substrate and confirm that it is
monolayer. With atomic force microscopy, the cleanliness and height of the sample can
be measured, and finally, by using optical microscopy at high magnification (50x, 100x)
of graphene on a SiO2 substrate, the continuity of the film becomes apparent. Without a
clean transfer method and film quality verification from the necessary characterization
steps, it is likely that device quality can be poor due to contamination or discontinuous
growth.
Once the quality of the graphene has been established, the next step is its use in graphene
biosensors, or, in the case of this work, graphene field effect transistors (GFETs), and
measurements of their electrical characteristics for data collection. The fabrication,
functionalization, and data collection of these biosensors is discussed in the next chapter.
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Chapter 4: Graphene Field Effect Transistor Fabrication and
Functionalization
After verification of the high quality of the graphene and its effective, clean transfer to a
desired substrate, the next step is the fabrication of graphene field-effect transistors
(GFETs) and the functionalization of these devices for sensing. Upon fabrication
completion, the devices are functionalized with a linker molecule, followed by a probe
molecule which is tailored to bind specifically to a desired target. AFM verified the
binding of each of these functionalization steps to the surface of the graphene.
In section 4.1, we describe the fabrication procedure including photolithography, thermal
evaporation, oxygen plasma etching, and annealing to create arrays of GFETs ready for
functionalization. In section 4.2, we explore the functionalization of the graphene’s
surface with a linker molecule and the probe molecule and ascertain their binding through
atomic force microscopy (AFM). Section 4.3 explains the binding of the target to the
probe.
The collection of data via an all-electronic readout method is illustrated in section 4.4,
where the current is measured as a function of gate voltage (VG). The shift of the Dirac
voltage is defined, and how this shift can be quantified in terms of the amount of charge
on the graphene’s surface. Finally, this chapter ends with section 4.5, and how the data of
current and gate voltage is analyzed by a linear fitting of the hole branch of the curves.
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4.1 GFET Fabrication
To fabricate GFETs, a Si/SiO2 wafer was patterned using traditional photolithography
and thermal evaporation. The details of this process are explained in Appendix C, and
result in arrays of scalable GFETs.
The final step of the GFET fabrication process before chemical functionalization was
annealing. Annealing requires exposing the sample to heat and gas flow to either correct
defects in a lattice, as is the case for the copper foil during graphene growth, or, in this
instance, to decrease contamination of the GFETs from photoresist residue. The GFETs
were annealed at 225 C with argon flow of 1000 sccm and hydrogen flow of 250 sccm
for one hour. The end result at this stage was low-contamination graphene FETs ready for
functionalization. GFET yield was over 90%, with a Dirac point between 0-10V. This can
be seen in Figure 4.1.1 (below), which shows one GFET (left) under optical microscopy,
and the I-VG characteristics of GFETs in one array, with high yield and good device
uniformity.
The details of I-VG data collection and analysis will be described in more detail later in
this chapter.
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Figure 4.1.1 (a) Single “chip” with 52 GFETs, 13 in each quadrant; (b) magnified image
of a single GFET, with a grey box depicting placement of the graphene channel; (c) I-VG
curves for GFETs on one chip, with a yield of > 90%.
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4.2 GFET Linker and Probe Molecule Functionalization
The molecules used to functionalize a GFET depend on the most effective method for
trapping the desired target molecule. The focus of this thesis is the sensing of nucleic
acids and drug targets, and one highly effective linker molecule for detecting these targets
is 1-pyrenebyuteric N-hydroxysuccinimide ester (Sigma Aldrich), also known as
“Pyrene-NHS”, or “P-BASE”. This molecule forms a non-covalent bond with the carbon
atoms through π-π stacking between the aromatic rings of P-BASE and the graphene.
Other linker molecules, such as diazonium salt, may also be used, although diazonium
salt creates a covalent (therefore, perturbative) bond with graphene, and can induce
defects in the graphene and affect the electronic properties unfavorably1,2.
Beginning immediately after the annealing step, the GFETs were soaked in a 1 mM
solution of the solvent dimethylformamide (DMF) and P-BASE for ~20 hours to ensure
full coverage of the P-BASE on the graphene. Afterward, they were removed from the
DMF solution and rinsed with DMF, IPA and DI water.
Following P-BASE attachment, the second functionalization step was attachment of the
“probe” molecule. A probe molecule is a molecule that specifically binds to the desired
target. For single strand DNA (ssDNA) target detection, the probe was the
complementary DNA strand.
If the target was a drug molecule, then an aptamer, or a series of nucleotides in a
particular orientation selected to bind to a specific target acted as the appropriate probe.
The correct aptamer for a target can be found through “synthetic evolution of ligands
through exponential enrichment”, or SELEX, which is a combinational chemistry
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technique involving some 1012-1018 randomly generated DNA strand sequences in
various orientations carefully being selected through several rounds of exposure to the
target molecule3. Those that bind fully or partially are kept for the next round, and all
other sequences are discarded, eventually leading to a few select aptamers that bind
strongly to the desired target. The SELEX method has proven successful for various
target molecules, including the HIV drug tenofovir4, an azole-class antifungal drug5,
glucagon receptors6, as well as proteins, cells, and microorganisms7.
Determination of a selective probe molecule is a vital step, as without it, there can be no
target detection, or worse, one could have non-selective binding of the probe to other
molecules. When the linker molecule is Pyrene-NHS, the binding of the probe to the
NHS group is imperative. This was carried out by use of a synthetic probe molecule,
which was either ssDNA for the detection of a ssDNA target, or an aptamer for drug
detection, each with an amine group attached to one end. The related crosslinker
chemistry equation is shown below (ThermoFisher Scientific):

(4.1)
Here, “R” represents the pyrene with its NHS group attached, and “P” is the probe
molecule with an amine group at one end. In this instance, incubation was executed in DI
water, and the end result was the probe-amine combination taking the place of the NHS
group, which detached and got washed away through cleaning steps8. Through this linker
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chemistry, the probe was bound to the P-BASE and became immobilized on the
graphene, assuming the necessary configuration, which was either rigid for ssDNA, or
some unknown configuration through heat treatment for an aptamer. All probe solutions
were kept at the same concentration, regardless of the experiment, which was 1 μM. The
GFETs incubated in the probe solution for approximately 3 hours, at which point they
were rinsed with DI water and dried with compressed N2. Atomic force microscopy
determined the binding of these molecules to the graphene. Seen in Fig. 4.2.1, it is
evident that the P-BASE and probe molecule attached properly, as the height profile
increased after each functionalization step, as expected. The height profile of graphene on
SiO2 was what was expected, around ~1 nm. Although the thickness of a graphene film is
around 0.34 nm, because of dangling bonds on the SiO2, the thickness, experimentally,
can end up being closer to 1 nm.
Pyrene-NHS atop graphene yields a height of an additional ~1 nm, and with the binding
of the probe (~1 nm), the overall height of the sample was around 3 nm above the
substrate, which is in agreement with the accepted sizes of the molecules9.

Figure 4.2.1 Atomic force microscopy images of bare graphene on SiO2, then
functionalized with pyrene-NHS, and again with probe DNA
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Next, the devices were exposed to the desired target molecule, which was left to bind to
the probe, discussed in more detail in the following section.
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4.3 GFET Target Molecule Binding
Target molecule binding was generally the same. Following probe attachment, the target
solution of a known concentration was pipetted onto the chip and incubated in a humid
environment, anywhere from 30 minutes to 4 hours, depending on the target strand length
and concentration. This is because long DNA strands need more time to hybridize with
their probes fully and low concentration solutions need more time to diffuse through the
fluid medium. Assuming correct selection of the probe molecule for the desired target,
the target molecule should bind to the probe and nothing else, given proper cleaning steps
after each functionalization step.
A schematic of this binding is seen in Fig. 4.3.1, where the P-BASE is bound to the
graphene, shown as aromatic rings in the image, and the probe molecule, in red, is bound
to the pyrene through the cross-linking chemistry of Equation 4.1. It was then able to
hybridize into a double helix upon exposure to the target, in blue, which is its perfect
complementary strand.

Figure 4.3.1 Graphene field effect transistor schematic with pyrene, probe DNA (red)
and target DNA (blue)
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If detecting a drug target, then an aptamer with an amine group at the end acted as the
probe, as mentioned in the previous section.
For examples of other types of linker, probe and target molecules, see Chapter 6.
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4.4 Functionalized GFET Data Collection
Data for the GFETs was collected via an all-electronic readout method by sweeping the
gate voltage and measuring the associated current. This resulted in a profile of current
versus gate voltage, or I-VG. From the I-VG characteristics, we were able to determine the
position of the Dirac voltage, and more importantly, the shift in the Dirac voltage based
on the target attachment. In order to measure this shift, the GFET characteristics were
measured after probe molecule attachment and again after target molecule attachment.
The shift in the Dirac voltage of the GFETs between these two steps is related to the
target’s composition and, in the case of ssDNA, its length. Dirac voltage shifts are due to
the chemical gating effect, which occurs when a target molecule of negative/positive
charge binds to the probe molecule and as a result, induces an increase in the
positive/negative charge carriers in the graphene channel, thus shifting the Dirac voltage
to the right/left, respectively10.
For DNA, the strands are diluted in a solution of DI water. The DNA strands deprotonate
in the water due to the ionization of the phosphate groups, and acquire a negative charge
for both the probe and the target. Because of this charge, and due to the chemical gating
effect, the Dirac voltage shifts in the positive direction, ascribed to an induced increase in
the positive charge carriers in the graphene channel. This can be seen in Figure 4.4.1.
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Figure 4.4.1 Functionalization of plain graphene with pyrene (grey), probe (blue) and
target (red) molecules. Each of these steps creates a shift in the Dirac point, or minimum
point of conductance, due to the chemical gating effect.
Since the probe and the target strands both become negatively charged prior to
attachment, it seems counterintuitive that binding would occur for two negatively charged
strands without the help of an ionic solution. However, graphene creates an exception to
this, as both positive and negative charge carriers can be induced in the material. Binding
of the negatively charged probe molecule engenders an increase in the positive charge
carriers in the graphene, which balances out the negative charge of the probe. As a result,
the target molecule, which is also negatively charged, can bind to its probe without the
aid of an ionic solution.

The shifts of these curves can be quantified into an associated charge for each
functionalization step by recalling that in the GFET, the graphene and the silicon are
capacitively coupled. The relationship between charge and shift in the Dirac voltage can
be expressed as a combination of the following equations:
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Q=CΔV and C=

𝐾𝜀0 𝐴
𝑑

(4.2)

Here, Q represents the amount of charge coming from the functionalization step, C is the
capacitance, ΔV is the shift in the Dirac voltage due to said functionalization step, K is
the dielectric constant, in this case, about 3.9 for SiO2, 𝜀𝑜 is the commonly known
permittivity constant of 8.85 x 10-12 F/m, A is the area of the plates, in this instance, the
area of the channels, which is 10µm x 100µm, and d is the distance between the plates, or
the thickness of the oxide, which is 285 nm for these devices.

Looking at Figure 4.4.1, the shift in the Dirac voltage from probe to target is ~20V,
which, according to Equation 4.2, corresponds to a charge of 2.42x10-12 Coulombs.
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4.5 Data Analysis
I-VG curves of the graphene FETs were analyzed in OriginPro 8 by fitting the following
equation to the hole branch, or left-handed linear branch of the curves:
𝐼 −1 = [𝑒𝛼µ(𝑉𝐺 − 𝑉𝐷 )]−1 + 𝐼𝑆 −1

(4.3)

Here, I represents the current, µ is the charge carrier mobility, 𝑉𝐺 is the back-gate
voltage, 𝑉𝐷 the Dirac voltage, α the constant relating gate voltage to carrier number
density, and 𝐼𝑆 is the saturation constant due to short-range scattering. This equation gives
the Dirac voltage and mobility of each GFET. The Dirac voltage of each device was
recorded after probe attachment and again after target attachment, and the shift associated
with each device was averaged, with the error being the standard deviation of the mean.

Figure 4.5.1 OriginPro fitting of the hole branch for GFETs to extract the Dirac voltage
using fitting Equation 4.3;
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Each Dirac shift average is attributed to a specific target of a known concentration. This
process was repeated several times for various target concentrations, and one for baseline
solution, to determine the true value of the target signals.
Any baseline salt solution will undoubtedly have charge, and create a shift of its own,
even without any target molecules. In this case of DI water, although water molecules are
neutrally charged, they do create a small shift when bound to the graphene’s surface. This
is most likely due to the autoionization of water, and creates a shift in the Dirac voltage in
the positive direction, usually between 4-6 V.
After testing the GFETs at various target concentrations (with one “chip” per
concentration), a relationship between relative Dirac shift and concentration became
apparent, which takes on Hill-Langmuir behavior for ligand-receptor binding and
provides information about the limit of detection, the saturation limit, and the dissociation
constant, all described in more detail in the next chapter.
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Chapter 4 Conclusions

In this chapter, a standardized process for graphene FET arrays has been described, in
addition to how to keep contamination of these sensors to a minimum to preserve the
quality of the graphene and produce a high device yield.
Upon completion of the fabrication and cleaning steps, the GFETs were ready to be used
for sensing purposes, and were functionalized with the necessary linker molecules and
probe molecules for detection of nucleic acids and drug targets, both of which can be
done with nucleic acid probes, either through single strand DNA or aptamers. The
chapter ends with data collection and analysis of these sensors through an all-electronic
readout method, as well as how the electronic properties are altered due to the binding of
molecules to the graphene.
The next chapter (Chapter 5) goes into detail concerning the detection of nucleic acids
and drug targets using the devices that were described in this chapter.
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Chapter 5: Graphene-DNA Hybrid Biosensors for Nucleic
Acid and Drug Target Detection
Graphene’s high sensitivity lends itself to be an excellent material for biomolecular and
chemical detection. Nucleic acids, in particular, are proven biomarkers for various
diseases, most notably, different types of cancers such as pancreatic, colon, and breast
cancer. The detection of synthetic nucleic acids in low concentrations diluted in DI water
with DNA-decorated graphene field effect transistors serves as a primary step towards
eventual point-of-care diagnosis through human fluid samples.
Graphene aptasensors, or GFETs functionalized with aptamers, which are series of
nucleotides selected to bind to a specific target, are an interesting and convenient type of
device for low-concentration market drug detection. The purpose of market drug sensing
is to act as a more rapid and inexpensive method for therapeutic drug monitoring (TDM)
in place of traditional methods such as liquid/gas chromatography mass spectrometry
(LC-MS)/(GC-MS), which are time-consuming, costly, and require the employment of
highly skilled personnel.
Section 5.1 details the techniques and results for detecting ssDNA with GFETs down to
concentrations of 1 fM and detecting single base pair mismatches between a ssDNA
probe molecule and its complementary target.
Section 5.2 serves as an extension of section 5.1, where GFETs were prepared for
detecting ssDNA in lower concentrations than 1 fM. A limit of ~ 1 aM was reached by
increasing the length of the probe and target DNA strands. The GFETs also demonstrated
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that they could detect a long target (100 nucleotides) by using a short probe (20
nucleotides) with an increase in signal.
In section 5.3, we explore graphene functionalized with aptamers, or series of nucleotides
selected to bind to a particular target, for the detection of the HIV drug, tenofovir. These
graphene aptasensors, as they are called, can detect tenofovir down to concentrations of 1
ng/mL, which is lower than what is found in the human body for patients taking this
medication.
Section 5.4 uses a method known as “systematic evolution of ligands by experimental
enrichment”, or “SELEX” to select an aptamer for an azole class of antifungal drug. The
process relied on a large library, in this case, one of over 1014 sequences, exposed to the
target. The sequences that produced no binding with the target were removed, and the
cycle was repeated in this manner until the correct sequence for target binding was left.
This aptamer was then used for fabrication of graphene aptasensors to detect the drug
down to concentrations of ~10 ng/mL.
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5.1 Scalable Graphene Field Effect Transistors for Nucleic Acid
Detection
The work presented here also appears in the publication: Jinglei Ping* Ramya
Vishnubhotla*, Amey Vrudhula, A.T. Charlie Johnson, ACS Nano, 2016, 8700-8704
*denotes equal contribution

Abstract
Scalable production of all-electronic DNA biosensors with high sensitivity and selectivity
is a critical enabling step for research and applications associated with detection of DNA
hybridization. We have developed a scalable and very reproducible (> 90% yield)
fabrication process for label-free DNA biosensors based upon graphene field effect
transistors (GFETs) functionalized with single-stranded probe DNA. The shift of the GFET
sensor Dirac point voltage varied systematically with the concentration of target DNA. The
biosensors demonstrated a broad analytical range and limit of detection of 1 fM for 60-mer
DNA oligonucleotide. In control experiments with mismatched DNA oligomers, the
impact of the mismatch position on the DNA hybridization strength was confirmed. This
class of highly sensitive DNA biosensors offers the prospect of detection of DNA
hybridization and sequencing in a rapid, inexpensive, and accurate way.

Introduction
All-electronic DNA biosensors offer considerable promise for rapid genetic screening
and nucleic acid detection for gene-expression investigations, pharmacogenomics, drug
discovery, and molecular diagnostics1. In order to enable these applications, the
electronic DNA biosensors need to be sensitive, selective, and based upon a scalable
fabrication process. Wafer-scale graphene, a one-atom thick sheet of carbon with
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remarkable electronic sensitivity, outstanding biocompatibility2, and extremely low
signal-to-noise ratio3, can be prepared via chemical vapor deposition4,5. However, very
few previous reports on graphene field-effect-transistors (GFETs) for DNA sensing6-10
were based on scalable fabrication methods. To this point there are no reports of more
than 10 functional devices fabricated on a single chip, and the sensitivity has been limited
to 100 fM7.
Here we describe the development of scalable biosensors based on back-gated GFETs with
for detection of DNA (Fig. 5.1.1 a) with sensitivity as low as 1 fM (~ 6 × 105 DNA
molecules in a 1 mL drop). We prepared graphene by chemical vapor deposition (CVD)
and fabricated GFETs with conventional photolithography. The GFETs demonstrated high
yield (> 90%) and consistent transport properties. The GFETs were functionalized using a
well-controlled chemical treatment that enabled high surface coverage with single-stranded
probe DNA. DNA biosensors created in this way exhibit a wide analytical range (three
decades in concentration) and excellent selectivity against non-complementary DNA
oligomers. The sensitivity of the DNA biosensors depends systematically on the length of
the oligomer, and for 60-mer DNA 1 fM limit of detection was achieved. The response
calibration curves of the DNA biosensors were in excellent agreement with predictions of
the Sips model11 for DNA-hybridization. Our control experiments confirmed that sensor
responses were determined by hybridization between the probe and target DNA oligomers,
and the results were consistent with earlier reports of hybridization using DNA
microarrays. Our methodology has the potential to be developed into a rapid and
convenient point-of-care tool with clinically relevant sensitivity.
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Figure 5.1.1 (a) Detection of DNA by a graphene field-effect transistor functionalized with
complementary DNA. (b) Raman spectrum of the channel region of a graphene field effect
transistor (GFET) after processing. Inset: Optical micrograph of an array of 52 GFETs.
(c) I-VG characteristics for an array of 52 GFET devices showing excellent reproducibility.
(d) Histogram of the Dirac voltage extracted from the I-VG characteristics of panel (b)
along with a Gaussian fit to the data (red curve).

Fabrication Process
A 2.5 × 2.5 cm graphene sample was prepared via chemical vapor deposition on a copper
growth substrate and transferred using an electrolysis bubbling method12 onto a 2 × 2.5 cm
oxidized silicon substrate with pre-fabricated, 45-nm thick Cr/Au electrodes for an array
of 52 GFETs. We find that this transfer method effectively limits contamination, doping,
and damage associated with graphene transfer. The GFET channels were then defined
using photolithography and oxygen plasma etching (Fig. 5.1.1 b, inset). The sensor array
was cleaned by annealing in an argon/hydrogen atmosphere before further characterization
or chemical functionalization (see Methods for additional details of the fabrication
process). This method is compatible with scale up to thousands of GFETs or more, as well
as integration with prefabricated CMOS signal processing circuitry13.

The graphene in the GFET channels was single-layer with low defect density, as verified
by the 2D/G ratio (~2) and the minimal D peak intensity in the Raman spectrum 14 (Fig.
5.1.1 b). The excellent quality of the graphene enables consistent GFET transport
properties and high fabrication yield (>90%), based on more than 30 arrays fabricated for
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this experiment. As shown in Fig. 5.1.1 c, the current-gate voltage (I-VG) characteristics
for all 52 GFETs in a single array are very similar. The Dirac point of the GFETs, where
the I-VG characteristic has a minimum, lies in a narrow range near zero back-gate voltage,
3.6 ± 4.0V (Fig. 5.1.1 d), indicating low doping effects induced in our methodology.

Figure 5.1.2 (a) AFM line scans of (1) annealed graphene, (2) PBASE-functionalized
graphene, and (3) graphene functionalized with PBASE and aminated DNA. Inset: AFM
images showing the scan lines plotted in the main figure. Scan lines are 2.5 μm. Z-scale 8
μm. (b) I-VG characteristics for a typical GFET that was annealed, functionalized with
PBASE, reacted with 22mer aminated probe DNA, and exposed to 10 nM target DNA in
deionized water.

After annealing, the GFET channels were functionalized by incubation for 20 hrs in a
solution of the bifunctional linker molecule 1-Pyrenebutyric acid N-hydroxysuccinimide
ester (PBASE) in dimethylformamide (DMF) (See Methods for details). The aromatic
pyrenyl group of PBASE binds to the basal plane of graphene through the non-covalent  interaction15,16. This process yields a uniform, ~ 1 nm thick monolayer17 of selfassembled PBASE on the graphene (see linescan (1) in Fig. 5.1.2 a), except at wrinkles (~
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nm high) in the CVD graphene created by the transfer process18. The aminated (5’) probe
DNA (22mer, 40mer, or 60mer) was then bound to the PBASE linker by a Nhydroxysuccinimide (NHS) crosslinking reaction (See Methods for details). Due to the
high coverage of the PBASE monolayer, the probe DNA molecules were immobilized on
the graphene channel at such high density that individual DNA molecules could not be
distinguished in AFM images (Fig. 5.1.2 a) acquired using a NCST AFM cantilever (Nano
World). The average height increase of the GFET due to attachment of the 22mer probe
DNA is ~ 1.2 nm, consistent with the molecular size. After attachment of the probe DNA,
GFET DNA biosensors were tested against the complementary single strand DNA “target”
and various controls.

Results and Discussion
The I-VG characteristics of the GFET devices were measured in the dry state5 after each
step of functionalization chemistry and again after exposure to the target. The value of the
Dirac voltage for each I-VG characteristic is determined using a curve-fitting method19
through the equation

𝐼 −1 = [𝑒𝛼𝜇(𝑉𝑏𝑔 − 𝑉𝐷 )]

−1

+ 𝐼𝑠−1.

(5.1)

Here 𝐼 is the current, 𝜇 the mobility, 𝑉𝑏𝑔 the back-gate voltage, 𝑉𝐷 the Dirac voltage, 𝛼=7.2
 1016 cm-2 V-2 the constant relating gate voltage to carrier number density, and 𝐼𝑠 the
saturation current due to short-range scattering20. Formation of the PBASE monolayer
leads to an increase in 𝑉𝐷 of ~ 23  3.3 V (Fig. 5.1.2 b). This is explained by considering
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chemical gating effects associated with residual water on the device surface. Here, we
assume that NHS groups are hydrolyzed into carboxyl groups, which deprotonate and
acquire a negative charge. Attachment of 22mer probe DNA led to a further 40V increase
in the Dirac voltage, which is explained quantitatively through the chemical-gating effect19
of probe-DNA molecules that become negatively charged due to ionization of phosphate
groups in residual water. This Dirac voltage shift corresponds to an increase in the positive
(hole) carrier density in the graphene by ~ 3.0 × 1012 cm-2. Assuming chemical gating of
22 negative charges for each oligomer, the density of immobilized probe DNA is ~ 1.3 ×
103 μm-2, more than an order of magnitude higher than the level of protein attachment
achieved using a very similar functionalization approach5,19. This corresponds to a
separation of ~ 25 nm between DNA molecules, consistent with the uniform DNA coverage
observed by AFM (Fig. 5.1.2 a).
In response experiments, all 52 GFET sensors on a single chip were tested against a
solution with a known concentration of target DNA or a related control in deionized water.
The Dirac voltage of the I-VG characteristic showed a reproducible shift to positive voltage,
∆𝑉𝐷 , as seen in Fig. 4.1.2 (b). To compare results across the three different DNA targets,
0
for each concentration tested we plot the Dirac voltage shift relative to DVD , the shift
REL
0
measured upon exposure to pure deionized water, i.e., DVD = DVD - DVD , with the results

shown in Fig.5.1.3 a. For all DNA oligomers tested, the relative shift varied systematically
with target concentration, and it is ascribed to an increase in the positive carrier
concentration in the GFET channel induced by the negatively-charged phosphate groups
of target DNA molecules that have hybridized with probe DNA on the GFET surface.
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Figure 5.1.3 (a) Relative Dirac voltage shift as a function of concentration for DNA targets
of different lengths. Error bars (standard deviation of the mean) are approximately equal
to the size of the plotted point. Solid curves are fits to the data based on the Sips model. (b)
Variation of the fit parameters 𝐴 (red data) and 𝐾𝐴 (blue data) in Eqn. (1) with DNA
oligomer length. The red and blue lines are fits to the data, as discussed in the main text.

The Sips model11,21 for describing DNA hybridization provides an excellent fit to the
REL
measured data for DVD as a function of target concentration:

∆𝑉𝐷𝑅𝐸𝐿 = 𝐴

(𝑐⁄𝐾𝐴 )𝑎
1+(𝑐⁄𝐾𝐴 )𝑎

(5.2)

where 𝑐 is the concentration of the target DNA solution, 𝐴 the maximum response with all
binding sites occupied, and 𝐾𝐴 the equilibrium dissociation constant. The parameter 𝑎 in
the Sips model represents a Gaussian distribution of DNA binding energies where 𝑎=1
corresponds to single binding energy level. The best fit to the data for the 22mer target
yields fit parameter values: 𝐴 = 5.9 ± 0.4 V, 𝐾𝐴 = 2.9 ± 0.9 nM, and 𝑎 = 0.56 ± 0.07. The
analytic range of the fit (Fig. 5.1.3 a) covers three orders of magnitude, from ~100 pM to
~100 nM, with sensitivity ~1.4 V/decade. The dataset presented in Fig. 5.1.3 a indicates
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that GFET-based DNA biosensors can differentiate between DI water and a solution
containing the 22mer target at a concentration of < 100 pM. Although this is higher than
an earlier report7 with a detection limit of 100 fM for 20mer DNA, our approach offers the
advantages of scalable fabrication and device miniaturization (52 devices per array). The
best fit value of 𝐾𝐴 , 2.4 ± 0.8 nM, agrees well with that expected for 20-mer DNA
hybridization22, 1.7 nM. The best fit value of 𝑎 = 0.56 ± 0.07 implies a heterogeneous
adsorption isotherm with a distribution of binding energies rather than a single value DNADNA binding energy, which would yield 𝑎 = 1. This binding energy distribution is assumed
to reflect significant interactions between the probe and/or target DNA and the graphene
surface23.

𝐴

𝐾𝐴

𝑎

22mer

5.9 ± 0.4 V

2.9 ± 0.9 nM

0.56 ± 0.07

40mer

11.0 ± 1.0 V

17.8 ± 9.8 pM

0.64 ± 0.14

60mer

16.5 ± 1.0 V

18.1 ± 9.0 fM

0.60 ± 0.17

Table 5.1.1 Fitting parameters for all probe DNA sequences tested.
We also tested GFET DNA biosensors based on 40mer probe DNA and 60mer probe DNA.
As shown in Fig. 5.1.3 a, the limit of detection (LOD) using 40mer probe DNA is ~ 100
fM, and the 60mer target DNA was reliably detected at a concentration of 1 fM (~ 6 × 105
DNA molecules in a 1 mL drop). The Sips model fit parameters for the three probe DNA
sequences are shown in Table 1. The distribution function index is roughly the same for
the different DNA targets, indicating comparable degree of binding energy heterogeneity.
The fit values for 𝐴 and 𝐾𝐴 demonstrate two advantages of using longer DNA oligomers.
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First, the maximum signal level (A) increases nearly linearly with DNA length, at a rate of
0.27 V/mer (see Fig. 5.1.3 b, red data points). This is assumed to reflect that the charge
carried by each DNA chain increases as the DNA length increases, enhancing the chemical
gating effect on the graphene and leading to a proportionately larger Dirac voltage shift.
Second, the dissociation constant decreases exponentially for longer DNA. As seen in Fig.
5.1.3 b, in the log(𝐾𝐴 )-length relationship is approximately linear, with slope of -0.225 ±
0.024. This is in good agreement with the slope of -0.138 ± 0.006 that was found using a
quartz crystal microbalance approach22.
Multiple control experiments were conducted with 22mer DNA biosensors to verify that
the biosensor responses reflected specific binding of the complementary target DNA. A
variety of control samples were used, with all control solutions having a concentration of
1 μM in DI water. In Fig. 5.1.4, we report the results as the Dirac voltage shift induced by
the target or control at a concentration of 1 μM, relative to the shift induced by pure DI
water. The target 22mer DNA gives the largest value for the relative Dirac Voltage shift
(∆𝑉𝐷𝑅𝐸𝐿 =5.7 ± 0.4 V), which is expected since it should have the highest binding affinity
for the probe DNA and therefore the largest associated change in GFET carrier
concentration. The single base-mismatch controls are expected to interact more weakly
with the probe DNA. It is intriguing to note that the control with a single base-mismatch at
the 5’ end shows a slight response decrease (~ +4.6 ± 0.7 V or 80 ± 12% of that for the
target DNA), while the response to control DNA with the mismatch at the center is strongly
suppressed (+0.7 ± 0.5 V), only ~10% of that for the target DNA. Experiments based on
DNA oligonucleotide microarrays24,25 show similar effects in how the response depends
on the position of a single base mismatch. The reason why a mismatch at the center of the
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strand has such a strong effect on hybridization can be understood through a positionaldependent-nearest-neighbor model25,26. The control oligomer with two mismatches, one at
the center and one at the 5’ end, gave a sensor response that was indistinguishable from the
response to DI water, and the same was true for the response to a 1 M solution of a random
sequence DNA oligomer (32% consistent with the target DNA).

Figure 5.1.4 Relative response of GFET-based 22mer DNA biosensors to the target
sequence and various controls, all at a concentration of 1 μM. The base sequences of the
oligomers tested are listed, with mismatches shown in red. Starting from the bottom, the
oligomers tested are: target DNA, single mismatch at the 5’ end, single mismatch at the
center, two mismatches at the 5’ end and the center, and random sequence DNA. Error
bars are standard deviation of the mean.

Conclusions
We have developed a scalable fabrication approach for arrays of graphene-based DNA
biosensors with all-electronic readout, and we measured their responses to the
complementary DNA target and multiple control oligomers. The fabrication process is
based upon conventional photolithographic processing and should be suitable for mass
production. The GFETs fabricated for the experiments were of very high quality, as
evidenced by Raman spectroscopy, Atomic Force Microscopy, and electronic
measurements. The DNA biosensors have a wide analytical range and a sensitivity that
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depends systematically on the length of the DNA. For 60mer DNA, we achieved a
detection limit of 1 fM, enabled by the use of graphene as the transduction material,
functionalized with high coverage of probe DNA. Measured sensor responses over a range
of six orders of magnitude in concentration were well fit by the Sips model. Control
experiments verified that the sensor response was derived from specific binding of the
probe DNA to the target DNA, and also confirmed that the complementary DNA with a
mismatch at the center hybridizes much more weakly with the probe DNA than at the 5’
end.
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5.2 Graphene Field Effect Transistors for ssDNA at aM Concentrations
and Capture of Long Targets with Short Probes

The work presented here also appears, in some form, in the publication: Vishnubhotla,
Ping, Sriram, Dickens, Mandyam, Adu-Beng, Johnson, 2018 (in preparation)

Abstract
Graphene-enabled biosensors can be produced in a scalable manner at reasonable cost,
and they show significant promise for sensitive detection of small molecules and
biomarkers such as proteins, single strand nucleic acids, aptamers, and drug targets. Here,
we describe an approach that enables a limit of detection of ~ 1 aM of a ssDNA target, or
about 100 strands per mL of deionized water, without amplification. Furthermore, we
have shown that a short probe (20mer) has the capability to trap a longer target strand
(100mer) with a proportional increase in signal, as expected for an electrostatic
transduction mechanism. These results show the potential utility of this technology in
nucleic acid detection for disease diagnostics.

Introduction
Graphene field effect transistors (GFETs) show great promise as a platform for DNA
detection. GFET DNA sensors can be implemented without need for molecular labeling,
which offers reduced complexity and cost compared to more conventional sensor
approaches based on PCR, optical detection, or electrochemistry.27 Early reports showing
sub-pM sensitivity7 and single nucleotide polymorphism (SNP) detection28 were based on
fabrication approaches suitable only for few-device production. More recently, scalable
fabrication methods were developed for GFET DNA sensors for detection of
complementary single strand nucleic acid targets at fM concentrations with excellent
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specificity against single base pair mismatches29. GFET-based DNA sensors might
eventually find use in multiple domains, including cancer detection based on the presence
of cell-free nucleic acids in body fluids.30,31 Through the use of DNA aptamers,
reproducible graphene aptasensors have also been used for detection of small molecule
targets32-34. These reports were based on graphene grown by chemical vapor deposition, a
large-area material in a “layer” format that is compatible with photolithographic
processing, which enables reproducible performance across devices and fabrication
runs35. This gives graphene advantages over one-dimensional nanomaterials (e.g., carbon
nanotubes36 and silicon nanowires37) or two-dimensional materials that are less well
developed, including the transition metal dichalcogenides38,39.
The promise of GFETs for nucleic acid detection motivates efforts to enhance the limit of
detection for this system. Here, we demonstrate two methods for improving the
sensitivity of DNA-graphene biosensors functionalized with single-stranded probe DNA
strand for detection of the complementary target strand detection. First, we found that
increasing the length of the probe and target to 80 nucleotides each (80mer) enabled a
limit of detection (LOD) of ~1 aM without amplification, representing a 1000x
improvement over earlier reports6,7,28,29. Second, we used a short probe (20mer) to bind to
a section of a longer target (100mer), which in the best case led to a ~3x increase in
output signal, offering another possibility to lower the LOD for long targets.
For these experiments, monolayer graphene was grown via CVD on a copper foil
substrate (~ 8 cm x 10 cm) using methane as the carbon feedstock40. We used a waferscale process where the full graphene film was coated with a sacrificial layer of
polymethyl methacrylate (PMMA) and transferred using an electrochemical hydrolysis
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method onto a 4-inch Si/SiO2 wafer12, where electrodes for 11 arrays of 52 GFET sensors
had been previously fabricated using photolithography and thermal evaporation of Cr/Au
electrodes (5 nm/40 nm; Figure 1). A second round of photolithography followed by O2
plasma etching was used to define the GFET channels with dimensions 10 μm x 100 μm.
After photolithographic processing and etching, the GFETs were cleaned in 1165
(Microposit), acetone and IPA, dried with N2, and annealed to remove resist residues with
a final device yield exceeding 90%. The quality of the graphene after processing was
assessed using Raman spectroscopy, which showed a 2D/G peak ratio of ~ 2, and a low
D/G ratio, consistent with that of low-defect, monolayer graphene14.

Figure 5.2.1 (a) Example of a 4-inch substrate used for wafer-scale processing. Four
inch wafer patterned with 11 arrays of field effect transistors. (b) graphene-PMMA film
on patterned wafer substrate

For chemical functionalization, the GFET array was first incubated in a 1 mM solution of
the linker molecule 1-pyrenebutyric acid N-hydroxysuccinimide ester (P-BASE), which
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binds to the graphene surface by non-covalent π-π stacking and allows for immobilization
of the probe molecule on the graphene’s surface.
This step was immediately followed by incubation in a 1 µM solution of aminated probe
ssDNA in deionized (DI) water for 3 hours, followed by rinsing with DI water and drying
with compressed N2 to complete the biosensor fabrication. These functionalization steps
yielded full coverage of pyrene and probe DNA on the graphene’s surface, which was
verified by atomic force microscopy (AFM) (Fig. 5.2.2), which confirmed the height
profiles expected for as-grown graphene (~1 nm), graphene functionalized with P-BASE
(~ 1.5 nm), and graphene functionalized with P-BASE and probe ssDNA (~1.5 nm).

Figure 5.2.2. Atomic force microscopy with z-scale nm height of ~ 3.5 nm for bare
graphene (a), graphene functionalized with pyrene (b) and graphene functionalized with
pyrene and an aminated 20mer probe DNA strand (c). The height profiles (d) were as
expected for graphene on bare SiO2 (~1 nm), pyrene (~1.5 nm) and probe DNA (~1.5
nm), verifying that each molecule is binding as expected during functionalization.
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To test the sensor response, the current – gate voltage characteristic (I-VG) was measured
for each device in the array, and the array was then exposed to a solution of target DNA
at a known concentration in DI water to allow for target binding. Following incubation in
the target solution, the array was blown dry, and the I-VG curve was measured again for
each device (see Methods for more details on sensor fabrication, functionalization, and
testing). The signal transduction mechanism is assumed to be the “chemical gating”
effect41, where deprotonation of the phosphate backbone of bound target DNA leaves it
negatively charged, leading to an increase in the hole carrier density in the GFET. This
leads to a reproducible positive shift in the Dirac voltage, ∆𝑉𝐷 , which varies
systematically with the concentration of target DNA in the solution. The sensor response
is reported as this Dirac voltage shift, relative to ∆𝑉0, the shift observed for DI water with
no added target:
∆𝑉𝐷𝑅𝐸𝐿 (𝑐) = ∆𝑉𝐷 (𝑐) − ∆𝑉0 .

(5.3)

Current versus gate voltage statistics of the GFETs showed over a 90% device yield
through a standardized growth/transfer process42, with a Dirac voltage of approximately
10 V, and an average mobility of ~2,000 cm2/Vs (Fig 5.2.3 a) both of which are
promising for statistically accurate results. Data was quantified by measuring the shift of
the Dirac voltage through I-Vg characteristics measurements, following probe and target
attachment, which is seen in Fig. 5.2.3.
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Figure. 5.2.3. I-Vg shift between probe and target of ~ 20V for attachment of a 1 pM
target

To accurately quantify the shift in the Dirac voltage between probe and target attachment,
the following equation was used to fit the hole branch of the I-VG curves:

𝐼 −1 = [𝑒𝛼µ(𝑉𝑏𝑔 − 𝑉𝐷 )]

−1

+ 𝐼𝑆 −1

(5.1)

Here, I represents the current, µ is the charge carrier mobility, 𝑉𝑏𝑔 is the back-gate
voltage, 𝑉𝐷 the Dirac voltage, α the constant relating gate voltage to carrier number
density, and 𝐼𝑆 is the saturation constant due to short-range scattering20.
Building on our earlier report where a 1 fM LOD was achieved with a 60mer probe and
target,1 probe and target strands of length 80 were used to achieve the goal of aM scale
detection. The sensor response was reported as the measured Dirac voltage shift
(Equation 5.3) for many different concentrations. The relationship between this known
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target concentration and the relative Dirac voltage shift can be described by the Sip’s
model for DNA hybridization.11

∆𝑉𝐷𝑅𝐸𝐿 = 𝐴

(𝑐 ⁄𝐾𝐴 )𝑛
1+(𝑐 ⁄𝐾𝐴 )𝑛

(5.2)

where A represents the maximum response with all binding sites occupied, c is the DNA
concentration, 𝐾𝐴 is the dissociation constant and is the concentration producing half
occupation of a binding site, and n is the Hill coefficient, which expresses the degree to
which the DNA interacts with its surroundings, where n=1 denotes no interaction. It also
indicates the relationship between target concentration and chain length on signal
strength, in that a longer chain is comprised of a greater amount of charge, has greater
binding affinity, and as a result, lowers the dissociation constant while increasing the
shift in the Dirac voltage for a given concentration. This is demonstrated in Figure 5.2.4
a for an 80mer probe and target and its dissociation constant, 𝐾𝐴 , which was found to be
~ 0.9 fM ± 0.38 fM. Although this value is lower than 𝐾𝐴 for a 60mer, it does not quite
follow the expected linear trend between 𝐾𝐴 versus chain length22.
According to Guo et. al, DNA maintains a roughly rod-like structure up until ~75
nucleotides, about half the accepted value of the persistence length. This persistence
length quantifies the stiffness of polymers and is due to the electrostatic effects of the
strand that dominate for longer chain sequences and result in twisting and bending of the
strands. Based on Guo’s study, it is believed that at 80 nucleotides, full hybridization is
unable to occur due to the loss of rigidity in the DNA strand, thus influencing the value of
𝐾𝐴 43. The commencement of the non-linear behavior can be seen in Fig. 5.2.4 b, where
𝐾𝐴 begins to deviate from the expected linear behavior. Our data is in agreement with
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Guo et. al, as non-linearity becomes apparent around ~75 nucleotides, likely due to the
cessation of a rod-like structure as electrostatic effects in the chain begin to dominate.

Figure 5.2.4. (a) Hill-Langmuir curve of Dirac voltage shift versus target concentration
of 80mer probe/target (purple) with a 𝐾𝐴 of 0.9 fM and a detection limit of ~ 1 aM,
compared to our previous study that tested 22mer (red), 40mer (blue) and 60mer
(green)1; (b) Relationship between 𝐾𝐴 and DNA length. Note that the relationship
between𝐾𝐴 and length ceases linear behavior for higher strand lengths.

In addition to reaching a LOD of 1 aM, experimentation confirmed that a short probe
(20mer) is adept at trapping a longer target (100mer) depending on the probe’s placement
along the target sequence. Three different probes, each 20 nucleotides in length, were
used to detect a 100mer target strand. Of these three probes, one was complementary to
the 20 nucleotides at the 3’ end of the 100mer target, another complementary to the 20
nucleotides at the 5’ end of the 100mer target, and the last being complementary to the
middle 20 nucleotides of the 100mer target. All probe concentrations were 1 µm and all
target concentrations were 10 nM.
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The various probe and target lengths, along with placement, are described in Table 5.2.1.
Here, it is evident that although a 20mer probe-target combination provides a
considerable signal at a 10 nM concentration normalized to a baseline of DI water
(∆𝑉𝐷𝑅𝐸𝐿 ), the signal is much larger for a 20mer probe that binds to a 100mer strand in the
middle. This is due to the electrostatic transduction mechanism, and is roughly equal to
the signal from a 40mer probe/target combination at the same concentration, which yields
a LOD of 100 fM1. These results exhibit that the chemical gating effect is still
appreciable even with partial binding of the target, provided that the probe binds to the
center of the target. We notice a trivial signal for a 20mer probe binding to a 100mer
target at either the 3’ end or the 5’ end, possibly due to the loss of rigidity of the 100mer
strand length combined with uneven weighting of the target about the probe, hindering
the binding and therefore the signal, although this is still not well understood.

Table 5.2.1. Table clarifying the probe/target combinations and binding placement of
short probe/long target compared to a probe/target of equal length and the Dirac shift
associated for each combination.

Table 5.2.1 shows that a 100mer target with a 20mer probe in the middle (‘100M’) yields
a signal roughly three times the signal of a 20mer probe/target combination, illustrated in
Fig.5.2.5.
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Figure 5.2.5. 20mer probe DNA binding to the 20 nucleotides in the middle of a 100mer
target sequence.

This portion of the study verifies that long target detection is possible, and does not
require the use of an equally long probe, and that nucleotides that do not hybridize can
still contribute to the electrostatic signal.

Conclusions
This study demonstrates that reaching ~ 1 aM sensitivity of ssDNA targets with ssDNA
probes on graphene biosensors is possible without amplification by increasing both the
length of the probe and target DNA strands. Furthermore, graphene has exhibited its
ability to trap a long target using a short probe, yielding a signal roughly 3 times in
magnitude, provided binding of the probe to the middle of the target. The results
presented here have been discovered through the use of scalable, sensitive back-gated
graphene field effect transistors which are rapid and inexpensive to fabricate, making
them ideal for point-of-care diagnostics. Improving detection limits of nucleic acids down
to the aM range through this methodology is directly correlated with early disease
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diagnosis for ailments with nucleic acid biomarkers for which biomarker upregulation
might occur in very small concentrations and with nucleic acid strands that are thousands
of nucleotides in length. This report details the lowest detection limit with graphene FETs
up to this point.

Methods
Graphene Growth Please refer to Appendix A
Graphene Transfer
A sacrificial layer of polymethyl methacrylate (PMMA, A4 950K) was spin-coated onto
the surface of the graphene on Cu foil. Transfer of graphene was carried out via an
electrolysis bubble method utilizing a NaOH solution (0.05 M) with one electrode
attached to the Cu foil and another in contact with the NaOH solution. The formation of
H2 bubbles at the interface of the PMMA/graphene and the Cu foil separated the film
from the foil, and the film was then transferred to a series of DI water baths to remove
NaOH residue before finally being transferred onto the desired substrate, a Si/SiO2 wafer
with an array of Cr/Au electrodes (5 nm/40 nm) that had been previously fabricated using
photolithography and physical vapor deposition.

GFET Fabrication
Please refer to Appendix C

GFET Functionalization
GFETs were soaked in a 1 μM solution of P-BASE and dimethylformamide (DMF) for
~20 hours to ensure uniform coverage of the P-BASE onto the graphene. The devices
were then removed from the DMF bath and soaked in a series of DMF, IPA, and DI
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water baths for 2 minutes each before being dried with N2. The chip was incubated in an
aminated probe molecule solution, also of 1 μM in DI water for 3 hours before being
rinsed with DI water and dried with N2. To attach the target, a target solution of known
concentration in DI water was pipetted onto the chip and left to incubate in a humid
environment either for 30-60 minutes (20mer, 20mer/100mer), 2.5 hours (concentrations
above Ka), or 4 hours (aM concentrations) before being rinsed with DI water again and
dried with N2. I-VG curves were measured following probe attachment and target
attachment, so as to determine the concentration-dependent shift in the Dirac voltage.
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5.3 GFETs for HIV Drug Detection
The work presented here also appears in the publication: Ramya Vishnubhotla*,
Jinglei Ping*, Zhaoli Gao, Abigail Lee, Olivia Saouaf, Amey Vrudhula, A.T. Charlie
Johnson, AIP Advances (2017) 7 (11), 115111
*denotes equal contribution

Abstract
Simpler and more rapid approaches for therapeutic drug-level monitoring are highly
desirable to enable use at the point-of-care. We have developed an all-electronic approach
for detection of the HIV drug tenofovir based on scalable fabrication of arrays of graphene
field-effect transistors (GFETs) functionalized with a commercially available DNA
aptamer. The shift in the Dirac voltage of the GFETs varied systematically with the
concentration of tenofovir in deionized water, with a detection limit less than 1 ng/mL.
Tests against a set of negative controls confirmed the specificity of the sensor response.
This approach offers the potential for further development into a rapid and convenient
point-of-care tool with clinically relevant performance.

Introduction
Therapeutic drug monitoring (TDM) is crucial for treating patients safely and appropriately
as well as for developing new medications. It is particularly important to oversee the
consumption of drugs with narrow therapeutic ranges and marked pharmacokinetic
variability in target concentrations that are difficult to monitor, and drugs known to cause
adverse effects44 both in individuals and communities. Conventional TDM, however, is
based on analytical techniques, such as liquid chromatography and mass spectrometry (LCMS) that are expensive, time-consuming, and not suitable for clinical use45. In this study,
we describe the fabrication of nanosensors potentially useful for monitoring the HIV
82

medication tenofovir, with a methodology that leverages the remarkable sensitivity of the
two-dimensional material graphene2, a highly reproducible and robust fabrication method
for graphene field effect transistors (GFETs), and an effective, commercially-obtained
aptamer with high affinity for tenofovir, a relevant drug metabolite.
Aptamers are oligonucleotide biorecognition elements selected to bind to a particular
target46, for which there are relatively few reports of use with scalable GFETs47-50. It is
also possible to integrate aptamer biorecognition layers with metal-oxide-silicon field
effect transistors (MOSFETs) using an extended gate geometry51. The aptamer used here
was obtained commercially (Base Pair Technologies) and has been selected to bind to a
metabolite of the HIV market prodrug tenofovir alafenamide. Tenofovir detection is of
particular interest as the medication is often used to treat patients affected with HIV by
reducing the virus count in the blood of the patient, and therefore decreasing the chance
of the development of AIDS. Additionally, hepatitis B virus (HBV) is an accompanying
ailment in HIV patients, and tenofovir treatments have shown to reduce the likelihood of
HBV forming drug-resistant mutations, making it more suitable for the treatment of HIV
than competing drugs52. In 2015, Koehn et al reached tenofovir detection limits of 0.5
ng/mL in plasma and cell samples using a method based on liquid chromatography-mass
spectrometry (LC-MS)53. Such testing is potentially useful for monitoring therapy and to
prevent drug accumulation and toxicity in patients with kidney or liver problems.
However, despite the fact that this detection limit is much more sensitive than required
for TDM of tenofovir, the cost and slow speed of LC-MS make the approach
inconvenient for a clinical setting. All-electronic nano-enabled sensors offer a promising
pathway towards a low-cost, rapid testing method suitable for use in the clinic or home.
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Here we report development of scalable graphene aptasensors for tenofovir based on
back-gated GFETs functionalized with a tenofovir aptamer with a limit of detection of
approximately 300 pg/mL (∼1 nM). We prepared graphene by chemical vapor deposition
and fabricated GFETs using a robust and reproducible photolithographic process, with
the GFETs showing a high yield (>90%) and consistent electronic properties29. The
chemical functionalization procedure provided high surface coverage with the aptamer,
as determined using atomic force microscopy (AFM). The aptasensors showed a wide
useful range (about a factor of 1000 in concentration) and high selectivity against related
drug compounds. Our approach offers the potential for further development into a rapid
and convenient point-of-care tool with clinically relevant performance.
Experiments were based on arrays of 52 devices, with graphene grown by chemical vapor
deposition (CVD) on a catalytic copper foil using methane as the carbon feedstock. The
monolayer graphene film was transferred onto a pre-patterned array of Cr/Au contacts on
an Si/SiO2 wafer (chip size of 2.5 cm x 2 cm) through an electrolysis bubbling
method12. The quality of the graphene was confirmed via Raman spectroscopy (Fig. 5.3.1
a), showing 2D/G ratio of about 2, as expected for monolayer graphene14. GFET channels
(10 μm x 100 μm) were defined using photolithography and plasma etching, and the
completed GFET arrays (Fig. 5.3.1 b,c) were cleaned by annealing in forming gas to
minimize contaminants. Additional details of the fabrication are provided in the Methods
section.
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Figure 5.3.1. (a) Raman spectrum of chemical-vapor-deposition-grown graphene on
copper foil. (b) Three optical images of the sensor array. The left panel is a photograph of
an array of 52 graphene field effect transistors (GFETs). The right panel has two optical
micrographs at different magnifications. The top micrograph shows a region with vertical
source electrodes and horizontal drain electrodes. The lower micrograph is zoomed in to
show a single GFET, with a box outlining the graphene channel. (c) Current-gate voltage
characteristic of graphene field effect transistors, showing good device uniformity. (d)
Atomic Force Microscope (AFM) line scan for annealed graphene on SiO2. The height of
the graphene is ∼1 nm, as expected for monolayer graphene after transfer onto SiO2. Inset:
AFM topographic image with the scan line indicated in blue. (e) AFM line scan of annealed
graphene on SiO2 after functionalization with 1-Pyrenebutyric acid N-hydroxysuccinimide
ester linker and the tenofovir aptamer. The step height is ∼3 nm, consistent with the
expected heights for the molecular structure. Inset: AFM topographic image with the scan
line shown in blue.

Current-backgate voltage (I-VG) measurements showed good device-to-device uniformity
across the array (Fig. 5.3.1 d), and the I-VG characteristics were analyzed by fitting the
data to the form19:
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𝐼 −1 = [𝑒𝛼µ(𝑉𝑏𝑔 − 𝑉𝐷 )]

−1

+ 𝐼𝑆 −1

(5.1)

where I is the measured current, μ the carrier mobility, Vbg the back-gate voltage, VD the
Dirac voltage, α the constant relating gate voltage to carrier number density, and IS the
saturation constant due to short-range scattering20. The best fit values for the Dirac
voltage and carrier mobility were typically in the range 0-5 V (2.35 ± 1.76 V) with an
average mobility of 2,654 ± 115 cm2/V-s.
As-fabricated GFETs were functionalized with a commercial tenofovir aptamer using a
well-controlled chemical treatment. First, the GFET array was incubated for ∼ 20 hours
in a solution of the linker molecule 1-Pyrenebutyric acid N-hydroxysuccinimide ester (PBASE) at a concentration of 1μM in dimethylformamide (DMF). P-BASE is known to
bind with high affinity to graphene via π-π stacking15. Following the instructions of the
manufacturer, the aminated tenofovir aptamer solution (1 μM in phosphate-buffer of pH
= 7.6) underwent a heat treatment in order to obtain the desired conformation of the
aptamer, and the devices were incubated in this solution for 3 hours following pyrene
attachment. Results of the functionalization process were visualized by AFM (Fig. 5.3.1
d,e). The height of bare graphene on silicon oxide was ∼ 1 nm, while after binding of the
linker and aptamer, the height of the structure had increased to ∼ 3 nm, consistent with
expectations given the molecular structures as well as our earlier report for
functionalization of graphene with single-stranded DNA using the same linker
molecule29.
For testing of sensor responses, all 52 aptasensors in a single array were tested against a
solution with a known concentration of tenofovir or a related control compound in

86

deionized (DI) water. The solution was pipetted onto the array and left for one hour in order
to allow the tenofovir target to bind to the aptamer layer. After incubation, we observed a
consistent shift of the Dirac point to more positive gate voltage (Fig. 5.3.2 a), ∆𝑉𝐷 . The
sensor array response was taken to be the average Dirac voltage shift relative to ∆𝑉𝐷0 , the
shift measured upon exposure to deionized water: ∆𝑉𝐷𝑅𝐸𝐿 = ∆𝑉𝐷 − ∆𝑉𝐷0 . This relative shift
varied systematically with tenofovir concentration (Fig. 5.3.2 b) and is attributed to an
increase in the hole concentration in the GFET due to chemical gating41 induced by
tenofovir binding. Tenofovir contains an amine group and a phosphate group, so it is
expected to take on a charge of –e at pH 7.
The Hill-Langmuir model for ligand binding in equilibrium provides an excellent fit to the
data for ∆𝑉𝐷𝑅𝐸𝐿 as a function of tenofovir concentration
(𝑐 ⁄𝐾 )𝑛

∆𝑉𝐷𝑅𝐸𝐿 = 𝐴 1+(𝑐⁄𝑎𝐾

𝑎)

𝑛

+𝑍

(5.2)

In this equation, A represents the maximum response with all binding sites occupied, c is
the tenofovir concentration, Ka is the tenofovir concentration producing half occupation of
a binding site, and n is the Hill coefficient. For the data in Fig. 5.3.2 b, the best-fit
parameters are A= 9.2 ± 0.2 V, Ka = 3.8 ± 1.5 ng/mL, and n = 1.1 ± 0.3, which is consistent
with independent binding of the target54. Assuming a charge of –e for tenofovir, the shift
of ~9 V corresponds to a tenofovir density of 1.1x103 μm-2 when binding is saturated. The
GFET tenofovir aptasensors described here have a limit of detection below 1 ng/mL,
comparable to that reported for LC-MS, but implemented in a simpler, manufacturable, allelectronic format.
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To verify that the sensor response reflected specific binding of tenofovir to the aptamer,
tests were conducted against three different HIV drugs as negative controls (lamivudine,
abacavir, and emtricitabine), each at a concentration of 200 ng/mL, which for tenofovir
would saturate the sensor response. As shown in Fig. 5.3.2 b, the sensor response to
emtricitabine was zero within statistical error, while abacavir and lamivudine gave small
but statistically significant responses. This is ascribed to a degree of structural similarity
between these compounds and tenofovir that allows for some small binding probability to
the aptamer. In a separate control experiment, an array of unfunctionalized graphene FETs
was tested against tenofovir at a concentration of 3 𝜇g/mL, a concentration that would
saturate the response of the graphene aptasensor. As shown in Fig. 5.3.2 b, the response of
the FET array was zero, within statistical error. Overall the results of these control
experiments provide strong evidence that the aptasensor response to tenofovir reflects
specific binding to the immobilized aptamer.

Figure 5.3.2. (a) I-VG curves for an as-fabricated graphene field effect transistor (GFET;
black data), the GFET after functionalization with the aptamer (blue data) and after
exposure to tenofovir at 3 µg/mL. (b) Relative Dirac voltage shift as a function of tenofovir
concentration. The error bars are calculated as the standard error of the mean. The red
curve is a fit to the data based upon the Langmuir-Hill model as described in the text. The
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limit of detection is < 1 ng/mL. Data points associated with negative control experiments
are also shown; when no error bar is plotted, the error bar is smaller than the size of the
plotted symbol. The near null response for the negative controls provides very strong
evidence that the dose-response curve reflects specific binding of the tenofovir target and
the aptamer.

Conclusions
We have successfully created a scalable approach for fabrication of arrays of GFET-based
aptasensors and demonstrated sensitive (~1 nM) and specific detection of the target
tenofovir, with a process based on CVD-grown graphene and photolithographic
processing, making it suitable for scale-up to industrial production35.

Our GFET

aptasensors have a wide analytical range and sensitivity comparable to LC-MS. Further
work is required to optimize the aptasensor performance when applied to real human
samples, but their simpler electronic format could make them more suitable for use in a
point-of-care setting. For this work, the aptamer was obtained commercially, but we have
recently extended the approach to a novel aptamer against azole class antifungal drugs55,
suggesting the ability to incorporate any aptamer into this process.

Methods
Growth of Large-Area graphene by CVD Please refer to Appendix A
Graphene Transfer Please refer to Appendix A
GFET Fabrication Please refer to chapter 4 Section 1
GFET Functionalization and Testing
To functionalize the GFET channels, the chip was placed in a solution of 25 mL of
dimethylformamide (DMF, Thermo Fisher) and 2 mg of 1-Pyrenebutyric acid N89

hydroxysuccinimide ester (P-BASE, Sigma Aldrich), for 20 hours. After this time, the chip
was removed, sprayed with DMF and soaked in DMF (2 min), sprayed with IPA and
soaked in IPA for 2 min, and finally, sprayed with DI water and soaked in DI water (2 min)
before being removed and dried with compressed N2 gas. AFM imaging of samples after
this attachment step showed a height of ~2 nm for graphene plus P-BASE (data not shown).
To prepare the aptamer solution, 10 µL of a 100 µM aptamer/DI water solution was diluted
in 10 mL of phosphate buffer solution (MgCl2, 1mM, pH = 7.4), which was heated from
35 °C to 90 °C, held at 90 °C for 15 minutes, and cooled to room temperature to obtain the
necessary configuration of the aptamer. The devices were incubated in this solution for 3
hours. After aptamer attachment (which further increased the AFM height to ~3 nm for
graphene, P-BASE and aptamer, as seen in Fig. 5.3.1 e), the array was thoroughly cleaned
with DI water.
The I-VG curves of the aptamer functionalized GFET array were measured using a bias
voltage of 100 mV, while the gate voltage was swept over the range 0 – 90 V, with a step
size of 2V and a scan rate of ~ 0.3 V/s. Next, a tenofovir/DI water solution of known
concentration was pipetted onto the chip and left to incubate for one hour in a humid
environment to prevent evaporation of the solution and allow for specific binding of
tenofovir to the aptamer surface. After incubation, the sample was again thoroughly
washed with DI water and blown dry. Finally, the I-VG curves were measured again, and
the data was analyzed to determine the Dirac voltage shift due to target binding.
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5.4: Graphene Aptasensors for the Azole Class of Antifungal Drugs
The work presented here also appears in the publication: Wiedman, Zhao, Mustaev, Ping,
Vishnubhotla, Johnson, Perlin, mSphere (2017), 2 (4)

Abstract
This technical report describes the development of an aptamer for sensing azole
antifungal drugs during therapeutic drug monitoring. Modified synthetic evolution of
ligands through exponential enrichment (SELEX) was used to discover a DNA aptamer
recognizing azole class antifungal drugs. This aptamer undergoes a secondary structural
change upon binding to its target molecule, as shown through fluorescence anisotropybased binding measurements. Experiments using circular dichroism spectroscopy
revealed a unique G-quadruplex structure that was essential and specific for binding to
the azole antifungal target. Aptamer-functionalized graphene field effect transistor
(GFET) devices were created and used to measure the strength of binding of azole
antifungals to this surface. In total, this aptamer and the supporting sensing platform
provide a valuable tool for therapeutic drug monitoring of patients with invasive fungal
infections.

Importance
We have developed the first aptamer directed toward the azole class of antifungal drugs
and a functional biosensor for these drugs. This aptamer has a unique secondary structure
that allows it to bind to highly hydrophobic drugs. The aptamer works as a capture
component of a graphene field effect transistor device. These devices can provide a quick
and easy assay for determining drug concentrations. These will be useful for therapeutic
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drug monitoring of azole antifungal drugs, which is necessary to deal with the complex
drug dosage profiles.

Introduction
Understanding a drug’s pharmacokinetics is crucial to safely and effectively treating
patients. Unfortunately, drug levels in patients can vary significantly, and the factors
contributing to this variability are frequently misunderstood. For some critically ill
patients, it is essential to gauge levels of a drug in real time. The best therapeutic
management can be achieved by maintaining a therapeutic level in a patient’s
bloodstream and by optimizing individual dosage regimens. These analyses generally
rely upon trough and peak monitoring and real-time kinetic drug modeling. For this
reason, therapeutic drug monitoring (TDM) of some drugs is a critical component of
successful therapy44. It is particularly important to monitor drugs with narrow therapeutic
ranges, marked pharmacokinetic variability, target concentrations that are difficult to
monitor, and known to cause adverse events.
The azole antifungal drugs posaconazole, fluconazole, voriconazole, and itraconazole are
an important class of lanosterol 14α-demethylase enzyme-inhibiting molecules56, which
compromise fungal cell membranes by preventing the synthesis of the key component
ergosterol57. A number of these drugs are highly hydrophobic, which creates analytical
challenges. Furthermore, because of their hydrophobic nature it is difficult to know how
much of the drug is freely available in the blood at any given time. Wide variances in the
pharmacokinetics of critically ill patients have been observed for triazole drugs like
voriconazole and posaconazole, which has resulted in a need for TDM58. Furthermore,
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posaconazole and voriconazole have been shown to have drastically different
bioavailabilities depending on how they are administered and if they are coadministered
with other drugs59,60. Therapeutic drug monitoring in conjunction with antifungal therapy
has been shown to promote a more favorable outcome than in non-TDM groups61.
Unfortunately, TDM requires blood to be drawn from patients and then drug levels in
blood to be evaluated by analytical instrumentation at some later point in time. Analytical
techniques such as liquid chromatography (LC) and mass spectrometry (MS) require
skilled staff and resources that are not found in all hospitals45. These barriers become
especially difficult to overcome when treating patients in community hospitals, at home,
or in resource-limited settings. Effective methods for sensing small drug molecules in
blood samples would make it easier to determine drug concentrations.
Any effective TDM method requires a way to capture the drug target from a patient
sample. Antibodies provide specificity and sensitivity as a capture probe, but they are
typically unstable over a wide range of assay conditions. As a more robust alternative,
oligonucleotide-based aptamer capture probes were developed here as a stable and
selective capture molecule for small-molecule drugs. Oligonucloetide aptamers can bind
to a wide variety of target molecules with high affinity. Such oligonucleotides (i.e., DNA
and RNA libraries of 1014 to 1016 molecules) can be quickly synthesized and screened
using in vitro synthetic evolution of ligands through exponential enrichment (SELEX)
methods46,62.
In this report, azole-specific aptamers were created by using a modified SELEX method
to screen a library of more than 1014 DNA sequences. Furthermore, graphene field effect
transistors (GFETs) were developed as a biosensing platform for detection of azole
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antifungal drugs with these aptamers. These devices represent a newly emerging type of
biosensor that relies on electronic measurements of the transistor itself rather than the
flow of an electrolyte solution, binding of antibodies, or fluorescence labeling. Taken
together, these results provide a possible path forward for development of an azole
antifungal sensing device with potential broader downstream capability of improving
therapeutic drug monitoring of small-molecule drugs.

Results
SELEX process results
Azole-binding aptamers were generated from a random 40-mer library using a modified
SELEX process (Fig. 5.4.1). PCR output and Oligreen dye intensity were used to track
the enrichment of posaconazole binders. The output of the PCR experiments for each
selection round was plotted after both 15 and 25 cycles of PCR amplification. In addition,
the intensity of Oligreen dye on DNA-containing counter-SELEX and SELEX (target)
beads (Fig. 5.4.2 a, b) was used to track enrichment. During rounds of increased
pressure, such as rounds 5 and 6, the total PCR output initially decreased but then
recovered over the next rounds. This pattern was most evident past round 10, when the
beads were first washed with the competitive molecule fluconazole. This wash allowed
for weakly binding molecules to be eluted from the sample. Denaturing polyacrylamide
gels were used to assess whether or not the aptamer’s molecular weight changed during
SELEX. Each round displays two bands, which are a result of leftover double-stranded
DNA not digested by λ exonuclease (Fig. 5.4.3 a). The single-strand bands from rounds 1
to 10 are the same size as the single-strand control library. The larger bands from rounds
11, 12, and 13 are distinct from the library band even when denatured (Fig. 5.4.3 c). Each
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band was separated as described in the Materials and Methods section and further
analyzed. This study also included several control sequences to further investigate the
importance of the structure of the round 13 aptamer (Rd 13): Rd 13 Scrambled (S), Rd 13
T6, and Rd 13 T1 were created with various middle lengths. Rd 13 Scrambled was
carefully reordered from the original sequence to fully prevent the formation of Gquadruplex structures. The two other sequences maintained the G-quadruplex regions but
with two different distances between them.

Figure 5.4.1 Possible stem-loop structures of Rd 13 and Rd 9 along with the control
sequences
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Figure 5.4.2 (A) After rounds 5 and 6, the PCR output decreased due to increased
pressure. The output increased in later rounds, and amplification can even be seen after
only 15 cycles of PCR as opposed to 25 cycles. In panel B, the fluorescence intensity of
the Oligreen dye from aptamer samples incubated with posaconazole (target)-labeled
beads increased relative to control beads as binders were enriched.

Figure 5.4.3 After the addition of fluconazole, there were bands that were higher in
molecular weight than the starting library, N40 (lane N), and the original sequences. A
denaturing polyacrylamide gel (panel C) highlights the fact that these bands were, in
fact, aptamers with unique molecular weights and not aggregates of the smaller original
library sequence N40. The relative binding capabilities of the heavy and light bands were
different from those of the control (counter-SELEX) and target (posaconazole) labeled
beads, respectively. Light bands from rounds 12 and 13 showed little preference for
either type of beads. The heavy bands, however, bound significantly better to the target
labeled beads than the control beads. Negative values occurred when emission at 525 nm
was below that at 505 nm. Lanes C, B, and A in panel D correspond to the separated
bands C, B, and A in panel C.
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Selection of best sequence
After separation, the “heavy” and “light” bands were analyzed separately for their
binding capabilities. The light bands of rounds 12 and 13, those the same length as the
library, do not bind to the target (Fig. 5.4.3). The heavy bands, however, bound
significantly better to the posaconazole-labeled beads versus the control beads and were
used for further studies. The heavy bands from round 13 as well as the sample from
round 9 were sequenced.
The sequence for Rd 9 is the same size, 40 bases, as the original library. The sequence for
Rd 13 is almost double that size at 79 bases. A significant portion of the Rd 9 sequence
(in red in Fig. 5.4.1) is found in the Rd 13 sequence. Additionally, QGRS mapping was
used to predict the existence of G-quadruplex structure in these sequences63. The Rd 9
sequence contains one predicted G-quadruplex stretch, highlighted in Fig. 5.4.1.
Interestingly, the Rd 13 sequence contains two regions of predicted G-quadruplex
structure. Stem-loop structure-predicting software was used to map the room temperature
(298-K) structures of these aptamers64. These predictions show that while Rd 9 forms a
stem-loop structure with a single arm, Rd 13 has two separate arms. These features
became a major focus of the further study of these aptamers.

Binding affinity of azole drug aptamers
Fluorescence anisotropy experiments were used to determine the dissociation constants
(Kds) for the posaconazole-aptamer complex63,64. These experiments measured the ability
of a boron-dipyrromethene (BODIPY)-labeled posaconazole (PosBD) to rotate in
solution. Inhibited rotation, due to aptamer binding, was detected as a change in
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anisotropy. In these experiments, only the Rd 13 aptamer caused an increase in
anisotropy from titrations of a constant PosBD concentration with increasing amounts of
DNA aptamers (Fig. 5.4.4). The control library and Rd 9 fail to bind to the PosBD. It
should be noted that the control library contains the primer sequences, bringing the total
length to 86 nucleotides. This fact suggests that the difference in molecular weights
between Rd 13 and Rd 9 is not the sole reason for the difference in anisotropy. The
dissociation constant when fitting to the fraction bound (Fbound) is 2.7 ± 1.2 μM. The
overall dissociation constant for PosBD might be weaker than that of posaconazole given
the fact that PosBD was not used for SELEX. The differences in anisotropy changes were
further used to probe the specificity of the aptamer for the target. Specificity was
interrogated with respect to two other BODIPY-labeled molecules: isavuconazole (ISV),
which is chemically similar to posaconazole, and caspofungin (CSF), which is chemically
dissimilar since it is an echinocandin class drug. Titration of 100 pmol of Rd 13 aptamer
into a 125-μl solution containing 100 pmol of PosBD causes a greater anisotropy change
than titration into 100 pmol of BODIPY-labeled ISV or CSF (Fig. 5.4.5). Titration of Rd
9 or the library into 100 pmol of PosBD causes little to no change in anisotropy. The
truncated versions T6 and T1 cause less of an anisotropy change, although Rd 13 T6 is
not significantly different (Fig. 5.4.5 b). The Rd 13 Scrambled aptamer did not cause a
significant anisotropy change compared to a control such as EDTA and hence did not
bind to PosBD. These results indicated that the G-quadruplex structure is necessary for
binding.
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Figure 5.4.4 PosBD anisotropy changed when the aptamer was titrated into 100 pmol of
PosBD per 125 μl. (Example traces are shown.) The anisotropy changed neither with the
earlier round (round 9) nor with the control library.

Figure 5.4.5 One hundred picomoles of aptamer (Rd 13, Rd 9, or the library) was
titrated into 100 pmol of various BODIPY-labeled drugs (posaconazole [Pos],
isavuconazole [ISV], and caspofungin [CSF]) (A). Titration of Rd 13 into PosBD caused
a significant change in anisotropy. Titration of Rd 13 into other BODIPY-labeled drugs
or Rd 9/library into PosBD caused little changes in anisotropy. These data suggested that
Rd 13 binds best to posaconazole. Aptamers of different lengths were titrated into
100 pmol of PosBD (B). The full-length Rd 13 aptamer caused the greatest change in
anisotropy, and the truncated and scrambled versions showed decreased amounts of
anisotropy change. The scrambled version only caused a change proportional to that
caused by a chelator, EDTA.
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Binding competition assay
The aptamers developed in this study bind to azole class antifungal drug targets,
specifically to those with the exposed terminal azole group like posaconazole. High
specificity is important for downstream diagnostic devices to prevent false-positive
readings. The anisotropy experiments were modified slightly to develop a competitive
assay to further probe specificity. This experiment showed the relative abilities of various
drugs to replace PosBD in the aptamer complex (Fig. 5.4.6). As expected, posaconazole
displaces the greatest amount of PosBD. The related drugs fluconazole and itraconazole
replace fewer PosBD molecules. The chemically distinct echinocandin antifungal drugs
micafungin and caspofungin had little effect. Of the azole drugs, itraconazole is the most
hydrophobic. The smaller amount of PosBD replacement with itraconazole versus
posaconazole suggests that binding is not solely driven by hydrophobic effects.
Secondary structure plays a large part in the binding of azole targets to these aptamers.

Figure 5.4.6 After initial PosBD incubation, the aptamer was heated at 70°C in the
presence of posaconazole (Pos), fluconazole (Flu), itraconazole (Itra), voriconizole
(Vori), micofungin (MF), or caspofungin (CSF) and then cooled on ice. The percentage
replaced was calculated as a function of the loss in anisotropy.
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CD spectroscopy and secondary structure analysis
Circular dichroism (CD) spectroscopy experiments were conducted to probe the folding
of these aptamers in the presence of salts and posaconazole. CD spectroscopy is a
technique that is widely used in biophysics to predict secondary structures of
biomolecules65. Molecules such as nucleotides and proteins can contain structures that
will interact differently with left- and right-polarized light, which can be detected by CD
spectroscopy. Secondary structure controls the complex formation of aptamers and target
molecules. As these aptamers all contained multiple stretches of guanine residues, there is
a high possibility that they form G-quadruplex structures. The CD spectra of Rd13 are
characteristic of G-quadruplex folded DNA, with a maximum at 260 nm and a minimum
at 240 nm (Fig. 5.4.7 a)66,67. Addition of magnesium chloride to the solution both
increases the signal at 260 nm and decreases the signal at 240 nm. This suggests that the
aptamer forms a G-quadruplex structure in low-salt buffer, which is slightly enhanced
with the addition of salts. In contrast, the signal is not altered significantly by adding
posaconazole in the absence of divalent salts (Fig. 5.4.7 b). The most drastic change
occurs when the aptamers are exposed to a combination of both posaconazole and salts.
The aptamers Rd 9 and Rd 13 show similar CD signals in 0.2 mM magnesium chloride.
A G-quadruplex structure formed with Rd 9 and Rd 13 but not with Rd 13 Scrambled
(Fig. 5.4.7 c). When 100 μM posaconazole was added, there was a change in the CD
signal for Rd 9 and Rd 13. With posaconazole, the spectrum for Rd 9 changes to contain
a maximum at 230 nm and a drastic minimum at 280 nm (Fig. 5.4.7 d). The spectra for
Rd 13 in magnesium chloride with posaconazole contain two maxima at about 230 and
270 nm with a minimum above 300 nm. The Rd 13 Scrambled sequence does not
101

undergo any further change in secondary structure. The G-quadruplex structure of Rd 13
forms in the presence of salt, and this structure then changes when the target is added.

Figure 5.4.7 Addition of magnesium chloride to the Rd 13 aptamer enhances Gquadruplex folding (A), but addition of posazonazole alone does not (B). This is seen in
an increase in the maximum at 260 nm and a decrease in the minimum at 240 nm. Both
Rd 13 and Rd 9 exhibit G-quadruplex structure in 0.2 mM magnesium chloride salt (C).
The structure changes drastically in the presence of magnesium chloride and 100 μM
posaconazole (D). The Rd 13 Scrambled aptamer does not change, but Rd 9 now contains
a peak of 230 nm and a minimum at 280 nm and Rd 13 contains two peaks at 230 nm and
260 nm with a new minimum peak above 300 nm.

GFETs
Graphene field effect transistors (GFETs) are a robust platform for detecting the binding
of small molecules to a surface68. As a transistor, GFETs allow for the flow of charge
between a gate and a source over a single sheet of carbon atoms. This sheet is extremely
sensitive to changes or binding above it, seen as a change in the Dirac voltage needed for
charge to flow. When combined with GFET devices, these aptamers act in an induced-fit
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manner, which allows them to function as a small-molecule capture arm on a supported
surface. GFET devices functionalized with amino-Rd 13 were used to measure the
posaconazole concentration (Fig. 5.4.8). Posaconazole was diluted from dimethyl
sulfoxide (DMSO) into SELEX buffer as described above. The sensor output signal was
taken to be the Dirac voltage shift, measured relative to the shift induced upon exposure
to pure buffer. As concentrations of posaconazole were increased from 0.01 μg/ml to
100 μg/ml, the relative Dirac voltage shift increased to upwards of −6 V. The variation of
the relative Dirac voltage shift with concentration was well fit by a model based on the
Langmuir-Hill theory of equilibrium binding, where the dissociation constant of the
aptamer is a fitting parameter5. The best-fit value of 1.8 ± 0.5 μg/ml (2.6 ± 0.7 μM) is in
good agreement with the value of 2.7 ± 1.2 μM derived from the anisotropy assay. In a
negative-control experiment, treatment with the echinocandin drug caspofungin produced
a negligible shift in the gate threshold voltage, providing strong evidence that the sensor
response reflects specific binding of the target to the aptamer probe. The observed values
of the relative Dirac voltage shift are in a range similar to that of a similarly designed
aptamer-based GFET biosensor biosensing for an HIV drug33. These data suggest that Rd
13 aptamer chemically attached to the GFET surface binds posaconazole in a similar
fashion to free Rd 13 aptamer in solution.
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Figure 5.4.8 The aptamer-based GFET devices showed a detectable threshold Dirac
voltage shift between 0.1 mg/ml and 0.1 μg/ml with posaconazole (Pos) and none with
CSF. The red curve indicates a fit to a Hill-Langmuir equation. The fit values, especially
the low microgram-per-milliliter range are therapeutically relevant concentrations of
azole class antifungal drugs.

Discussion
Therapeutic drug monitoring requires a method of capturing molecules and separating
them from a sample for analysis. This report highlights the development of an azole drugcapturing oligonucleotide using the SELEX process and the discovery of a unique
structure that allows it to bind azole antifungal drugs. Circular dichroism
spectrophotometry showed that this oligonucleotide works as a scaffold with two sections
of G-quadruplex folds. Large protein target aptamers have been made before using two
separate G-quadruplexes linked chemically to bind at separate sites69. These types of
folds rarely interacted with smaller, hydrophobic molecules due to the highly charged
nature of single-stranded DNA (ssDNA). The larger Rd13 aptamer was likely generated
as a result of the interaction between single G-quadruplex-containing aptamers. When

104

azole drugs bind to these aptamers, a structural change occurs. The CD spectra of these
changes are similar to CD spectra for B→Z DNA transitions70,71. This type of dual-Gquadruplex aptamer proved ideal for capturing small hydrophobic molecules. The
anisotropy binding experiments show that the poly(G) region is essential for target
binding. When bound to the surface of a graphene field effect transistor, the aptamer
works as a capture arm. This arm collects posaconazole from the sample, which leads to a
change in the GFET gate voltage. The azole “aptasensor” adds to the list of other
aptamer-based sensing devices72,73. Unlike these other devices, however, GFET aptamer
biosensors have the potential to function without the need for secondary antibodies,
fluorophores, or electrochemical mediators29. The versatility of the oligonucleotide-based
biosensor opens the door to numerous different applications.
Taken together, the unique structure and binding properties of the oligonucleotide
provided with the sensitivity of graphene field effect transistors could prove useful for
therapeutic drug monitoring. Posaconazole and the other azole class antifungal drugs
exhibit strong hydrophobicity and protein binding. Despite this fact, this aptamer binds
specifically to azole drugs. There are other aptamers directed toward clinically interesting
drugs, such as the aminoglycoside antibiotics and antiretroviral drugs among others74,75.
The work presented here provides the first basic step toward effective therapeutic drug
monitoring: a method of capturing and sensing the drug. These other aptamers could also
be utilized as capture arms for a graphene-based sensing platform. The next step will
involve testing patient samples and validating their usefulness in clinic. In the near future,
aptamer-based GFET biosensors could be mass produced for a fraction of the cost of
other methods such as liquid chromatography-mass spectrometry (LC-MS). These tests
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can be performed in a manner of minutes, negating the need for culture-based methods,
which can take upwards of 24 to 48 h. Such devices will allow clinicians to quickly
assess azole concentrations in a patient’s blood and provide them with the additional care
that they need.

Materials and Methods
The N40 DNA aptamer library was purchased from TriLink BioTechnologies, Inc.
(Ronkonkoma, NY). Other oligonucleotides, including amino-functionalized
oligonucleotides, were synthesized by IDT (Coralville, IA), Sigma-Aldrich (St. Louis,
MO), and Biosearch Technologies (Novato, CA). Carboxyl Dynabeads (14305D), the
Oligreen single-stranded DNA (ssDNA) assay kit, and BODIPY fluorescent dye were
purchased from Life Technologies, Inc. (Carlsbad, CA). Streptavidin-conjugated
magnetic beads and λ exonuclease were purchased from New England Biolabs (Boston,
MA). Azole drugs were purchased from Santa Cruz Biotechnologies (Dallas, TX). All
other reagents and solvents were purchased from Thermo Fisher Scientific (Waltham,
MA). Graphene devices were fabricated in-house using methods described in previous
work.

SELEX process
The aptamer library from TriLink BioTechnologies was prepared by dissolving 1 nmol of
DNA in 100 μl of SELEX buffer (140 mM sodium chloride, 2 mM potassium chloride,
5 mM magnesium chloride, 2 mM calcium chloride, 0.05% Tween in 20 mM pH 7.4 Tris
buffer). The library was heated at 94°C for 3 min, placed on ice for 5 min, and then
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incubated at room temperature (25°C) for 5 min. Next, the DNA library was incubated
for 1 h at 50°C and 2 h at room temperature and then in later rounds for 10 min at 50°C
and 20 min at room temperature. For the first round, the library was incubated with 1 mg
of unlabeled carboxyl Dynabeads (counter-SELEX). The beads were carefully
concentrated using a magnet. The library was then incubated with 1 mg of posaconazolelabeled beads for 1 h at 50°C and 2 h at room temperature. The beads were washed 3
times with 100 μl SELEX buffer and once with 100 μl Millipore water incubated with
1 nmol posaconazole in 20 µl of water with 0.01% DMSO for 1 h. The recovered DNA
was purified using a Zymo Research DNA preparation column. Recovered DNA was
amplified under two PCR conditions. First, the 20 μl of DNA was amplified using a
TaKaRa rTaq DNA polymerase enzyme. The mixture contained 2.5 μl (10 μM) forward
primer, 2.5 μl (10 μM) phosphorylated reverse primer, 5 μl (2.5 mM) deoxynucleoside
triphosphates (dNTPs), 5 μl 10× MgCl2 buffer, 0.5 μl (2.5 U) rTaq enzyme, 20 μl DNA,
and 14.5 μl Millipore water. PCR was performed under the following conditions: an
initial round at 94°C for 5 min and then 15 cycles of 94°C for 30 s, 50°C for 30 s, and
72°C for 1 min followed by a final 5 min of extension at 72°C. This sample was then
treated as is with 1 μl (5 U) λ exonuclease and incubated at 37°C for 30 min. This
mixture was purified using a Zymo column, and the output was checked for absorbance
at 260 nm using a Nanodrop spectrophotometer. If the yield was less than 1 pmol, an
additional PCR was conducted as described above but substituting 10 cycles for the 15
cycles. Further rounds of SELEX included the following modifications: for rounds 2
through 5, 200 pmol beads was used instead of 1 nmol. After round 5, incubation times
were decreased to 30 min for counter-SELEX and then 10 min at 50°C and 20 min at
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room temperature. After round 6, the bead capacity was decreased to 20 pmol. In rounds
11 to 13, beads were incubated for 1 h with 1 μl of 1 M fluconazole in 20 μl, first as an
additional competitive wash, before washing with posaconazole.

SELEX result tracking
In each round, 1 μl of DNA-incubated control beads and 1 μl of DNA-incubated
posaconazole-labeled beads were saved after washing with water but before posaconazole
elution. The DNA content was assessed using a 1:800 solution of Oligreen dye in 20 mM
Tris buffer with 2 mM EDTA at pH 7.5, and the samples were analyzed using a Photon
Technology International (PTI) fluorometer. PCR output was measured using a Nanodrop
spectrophotometer. DNA size was investigated by running an 8% polyacrylamide gel,
and denaturing gels were run using an 8% polyacrylamide gel with 8 M urea in SDS
buffer after loading DNA treated with formamide at 100°C. Sequencing of various
rounds was performed by Macrogen (Rockville, MD) to determine the sequence for that
round.

Fluorescence binding experiments
Purified bands and synthesized sequences were prepared by taking 2 pmol and dissolving
them in 100 μl SELEX buffer. These solutions were heated at 94°C for 3 min, on ice for
5 min, and at room temperature for 5 min. The samples were incubated with 20 pmol
posaconazole-labeled and unlabeled beads at 50°C for 10 min and room temperature for
20 min. The samples were then washed 2 times with water, and 125 μl of a 1:800 dilution
of Oligreen dye was added. Samples were then heated at 94°C for 3 min, the beads were
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concentrated, and the supernatant was collected. Samples were excited at 480 nm with
emission scanning from 500 to 550 nm. The fluorescence was recorded as counts per
second at 520 nm minus the counts per second at 505 nm.

Fluorescence anisotropy binding experiments
Fluorescence anisotropy experiments were conducted using a PTI fluorometer with
fluorescence polarizers. One hundred picomoles of BODIPY-labeled posaconazole
(PosBD) was added from DMSO (1 μl) to 125 μl of modified SELEX buffer (140 mM
sodium chloride, 2 mM potassium chloride, 5 mM magnesium chloride, 2 mM calcium
chloride in 20 mM Tris buffer, pH 7.4)64. Fluorescence anisotropy experiments were
recorded using a polarizer system, and the G-factor was calculated manually for each run
but consistently fell within 0.44 to 0.45. Anisotropy measurements were recorded first for
2 min. After the initial 2 min, aliquots of aptamers from 1 to 2,000 pmol were added, and
samples were equilibrated for 5 min. The value of the anisotropy was taken to be the
average anisotropy of the last 60 s after equilibration. Anisotropy values were plotted as
the change in anisotropy:
(5.3)

These values were used to calculate a bound fraction (Fbound):

(5.4)

The bound fraction was further used to calculate a dissociation constant (Kd) by
fitting to

(5.5)
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Fluorescence anisotropy competition assays
Competition assays were performed using the same measurement techniques described
above for binding assays. In this experiment, 50 pmol of PosBD was added from DMSO
into 125 μl of modified SELEX buffer, and the anisotropy was recorded for 2 min. One
thousand picomoles of aptamer was then added and allowed to equilibrate for 10 min.
After this time, 1,000 pmol of an unlabeled drug molecule was added, and the solution
was heated up to 70°C for 3 min and cooled on ice for 2 min. The heat-ice cycle was
performed twice. The anisotropy was then recorded again for another 5 min. The
percentage of PosBD replaced was calculated as

(5.6)

The percentage replaced equals 100 multiplied by the anisotropy with aptamer and drug
replacement minus the initial anisotropy divided by the anisotropy caused by the aptamer
alone minus the initial anisotropy.

CD experiments
Experiments were performed using an Aviv model 420 CD spectrophotometer. All
aptamer samples were prepared at a 10 μM concentration in 20 mM Tris buffer (pH 7.4).
Increasing amounts of salts and/or azole antifungal drugs were added, and the CD spectra
were recorded from 300 nm to 200 nm.

GFET functionalization and testing
The chemical vapor deposition (CVD) method with a methane source was used to grow
graphene, which was then transferred via electrolysis onto a patterned Si/SiO2 surface.
This surface contained chromium and gold electrodes, and the graphene channels
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between them were further defined through photolithography and annealed in an argonhydrogen environment. GFETs were incubated in 1-pyrenebutyric acid Nhydroxysuccinimide ester (P-base) and dimethylformamide for 20 h. After this
incubation, the devices were further incubated in a solution of phosphate-buffered saline
(PBS; pH 7.6) containing the Rd 13 aptamer for 3 h. The devices were heated from 70 to
90°C, held at this temperature for 15 min, and then allowed to cool down to room
temperature. In order to test the devices, the I-VG properties (ideal transistor’s current-togate voltage) of GFETs were determined with posaconazole and caspofungin.
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Chapter 5 Conclusions
Despite graphene’s lack of a band gap, its immense sensitivity can be exploited for
sensing purposes, where graphene sensors are adept at detecting single base-pair
mismatches, the placement of the mismatch in the chain, and target DNA strands down to
concentrations of 1 aM.

Furthermore, graphene aptasensors are effective at detecting market drugs down to
ng/mL concentrations, which provides an alternative to current chemical detection
methods, such as LC-MS, which are expensive and laborious.

This type of technology is advantageous for in-clinic, point-of-care diagnostics, due to its
rapid methodology and low cost. The next chapter explores the uses of graphene sensors
for detection of other molecules beyond nucleic acids and drug targets.
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Chapter 6: Graphene Devices for Sensing of Other Biomolecular and
Chemical Targets: From Biomarker Proteins to pH in Complex Fluids
Aside from graphene sensors for nucleic acid detection, such devices can be devoted to
the detection of other targets. This chapter contains details about graphene devices used
for protein biomarker detection, protein-nanoparticle assemblies, pH sensing, and
measuring neuropeptide and receptor binding.
Section 6.1 discusses the uses of GFETs, functionalized with platinum nanoparticles, for
detection of the breast cancer HER3 protein biomarker. Section 6.2 recounts the use of
graphene microelectrodes (GEs) on a kapton, of flexible plastic substrate, for sensing pH
of complex fluids, including phosphate buffer solution (PBS), human serum, and a
ferritin solution.
Section 6.3 also uses GEs for sensing the binding of the protein, ferritin, and a gold
nanoparticle (AuNP). When the ferritin protein is in an “open” orientation, the AuNP can
transfer Faradaic current through the device. When this pore is closed, no such charge
transfer is possible. This project is unique, in that it demonstrates that graphene can also
be used for understanding how two elements bind together. This leads into section 6.4,
where GEs are used for measuring the binding between neuropeptides and their receptors.
This chapter is especially significant because it proves that graphene devices do not need
to be confined to one specific target type, and that, in essence, graphene sensors can be
used for any type of target, as long as an appropriate biochemical recognition element is
identified, and provided the necessary steps are taken to account for background signal
noise from the target solution medium.
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6.1 Graphene Biosensors for Breast Cancer Protein Biomarker
Detection

The work presented here also appears in the publication: Rajesh, Gao, Vishnubhotla,
Ducos, Diaz Serrano, Ping, Robinson, Johnson, Advanced Material Interfaces, 2016, 3
(17), 1600124

Abstract
Biosensors based on graphene field effect transistors (GFETs) decorated with antibody‐
functionalized platinum nanoparticles (PtNPs) are developed for the quantitative
detection of breast cancer biomarker HER3. High‐quality chemical vapor deposited
graphene is prepared and transferred over gold electrodes microfabricated on an SiO2/Si
wafer to yield an array of 52 GFET devices. The GFETs are modified with PtNPs to
obtain a hybrid nanostructure suitable for attachment of HER3‐specific, genetically
engineered thiol‐containing single‐chain variable fragment antibodies (scFv) to realize a
biosensor for HER3. Physical and electrical characterization of Bio‐GFET devices is
carried out by electron microscopy, atomic force microscopy, Raman spectroscopy, and
current–gate voltage measurements. A concentration‐dependent response of the biosensor
to HER3 antigen is found in the range 300 fg mL−1 to 300 ng mL−1 and is in quantitative
agreement with a model based on the Hill–Langmuir equation of equilibrium
thermodynamics. Based on the dose–response data, the dissociation constant is estimated
to be 800 pg mL−1, indicating that the high affinity of the scFv antibody is maintained
after immobilization. The limit of detection is 300 fg mL−1, showing the potential for
PtNP/G‐FETs to be used in label‐free biological sensors.
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Introduction
Cancer is a leading cause of death worldwide and a major public health concern. Breast
cancer is the most common cancer among American women, except for skin cancers and
is the second leading cause of cancer‐related death for women in the United
States1. During the past decade researchers have given enormous attention to the search
for biomarkers for early detection of breast cancer. The human epidermal growth factor
receptor family (HER) comprising four transmembrane receptors: HER1 (EGFR or
ERBB1), HER2 (ERBB2), HER3 (ERBB3), and HER4 (ERBB4) play a key role in
regulation of mammalian cell survival, proliferation, adhesion, and
differentiation2. HER3 is implicated in tumorigenesis of numerous cancers including
breast cancers3,4, pancreatic cancers5, gastric cancers6, and colorectal cancers7. HER3
expression has prognostic value, since high levels of receptor expression are associated
with significantly shorter survival time compared with patients who overexpress
HER28. For instance, it has been reported that both HER3 messenger RNA and protein
were up‐regulated in human breast cancers, where HER3 overexpression was found in
the ratio of 50%–70%9,10.
Normal physiological levels of HER3 range from 60 pg mL−1 to 2.55 ng mL−1. However,
in a pathological case, the HER3 level is abnormally increased up to 12 ng mL−1 .11 High‐
sensitivity detection and accurate analysis of biomarker molecules in human fluid
samples are vital for early detection, treatment, and management of cancer. The clinical
measurement of cancer biomarkers has provided a great promise for early cancer
detection and highly reliable predictions12,13. A typical heterogeneous immunoassay
involves antibody immobilization, multiple steps of incubation and washing cycles,
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followed by signal amplification and readout. From the initial antibody immobilization
step to the final reading stage, the immunoassay result can usually take hours to days to
obtain. Various techniques have been developed for cancer cell detection, including
cytologic testing, fluorescent imaging, magnetic resonance imaging, computerized
tomography, X‐ray radiography, and ultrasound14-17. However, these techniques have
disadvantages of high cost and long time required for either experimental process or
instrumentation. Therefore, it is highly desirable to develop rapid, simple, and cost‐
effective methods for early detection of cancer cells in preclinical diagnosis for reduction
in mortality for certain cancers. In this respect, point‐of‐care hand held devices offer
promising alternatives to existing laboratory‐based immunochemical assays.
Electrical detection methods like field‐effect transistor (FET) based biosensors exhibit
highly sensitive detection of chemical and biological species when designed so surface–
analyte or ligand–receptor binding occurs very close to the FET channel18. Carbon‐based
nanomaterials such as carbon nanotubes19-24, reduced graphene oxide (rGO)25, and
graphene26-31 have received considerable attention for label‐free FET‐biosensors with
high sensitivity because of their unique electrical properties and suitability for
miniaturization in an array format. Compared to nanotubes and rGO, large‐area graphene
grown by chemical vapor deposition (CVD) offers advantages of overall electrical
conductivity32, device reproducibility, low noise, and superior carrier mobility33, which
are expected to lead to greater sensitivity. The direct immobilization of proteins on
CNTs34 or graphene oxide25 has been reported to be unstable and washed off easily
(unless covalent immobilization through special surface treatment and additional steps of
carbodiimide chemistry of protein binding is involved), which results in undesirable
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effects such as poor device sensitivity, poor reliability, and nonspecificity of the sensor.
This has been avoided by stable biomolecular immobilization through metal
nanoparticles on graphene35, as their 3D geometry enables high bioreceptor loading with
controlled orientation for ligand binding and thus are widely used in biosensing
applications36,37. In this work, we use platinum nanoparticles (PtNPs; Φ = 6.4 eV) instead
of the more commonly used gold nanoparticles (AuNP; Φ = ≈5.3 eV) because PtNPs are
reported to provide improved electrical signals in carbon nanotube‐based FET
biosensors38,39. This was attributed to enhanced electron transfer from the carbon
nanotube channel (Φ = 4.9 eV) to the PtNPs, thereby increasing the hole carrier density,
leading to improved biosensor characteristics. Since the transduction mechanism in FET‐
based biosensors is largely electrostatic18,40, the use of single‐chain variable fragment
antibodies (scFvs; 2–3 nm in size) in place of conventional antibodies (10–15 nm) is
expected to offer performance advantages23.
Here we report a novel strategy for scalable fabrication of arrays of graphene field effect
transistors (GFETs) modified with Pt nanoparticles and then functionalized with HER3‐
specific scFv antibodies, as a proof‐of‐concept, to demonstrate selective and sensitive
detection of the breast cancer biomarker protein HER3 in a buffer solution. The devices
showed high sensitivity (limit of detection ≈ 300 fg mL−1) and excellent specificity as
indicated by multiple control experiments.

Results and Discussion
GFET devices were fabricated as described in the Experimental Section. Briefly, large‐
area monolayer graphene was prepared by low‐pressure catalytic chemical vapor
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deposition process on a copper foil with CH4 as a precursor source. The graphene thin
film was then transferred using a polymethyl methacrylate (PMMA) assisted “bubbling”
transfer method onto a pre‐patterned SiO2/Si substrate with an array of 52 pairs of metal
electrodes each having a dimension 100 μm wide separated with a 10 μm gap between
the source and the drain electrode. After transfer, GFET channels were patterned using
standard photolithography and oxygen etching, as described in Figure 6.1.1 with a
schematic representation of the GFETs fabrication. The GFETs were then annealed at
250 °C under flowing N2 gas to remove residual photoresist contamination.

Figure 6.1.1 Schematic representation of fabrication process for an array of 52 GFETs.

The Raman spectrum of the GFET channel showed the G band at ≈1580 cm−1 and the 2D
band at ≈2670cm−1, with an IG/I2D intensity ratio of ≈0.6 (see Figure S1, “Supporting
Information”). The symmetric 2D peak was well fit by a single Lorentzian with a full
width half‐maximum of 31 cm−1, and the D (disorder) peak located at ≈1350 cm−1 was
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nearly undetectable. All these findings are indicative of high‐quality monolayer
graphene41,42, channel in GFETs after processing.
Figure 6.1.2 shows the stepwise chemical/biochemical modifications of the GFET
channel used to create the biosensor device.

Figure 6.1.2 Schematic of chemical and platinum nanoparticle modification of a GFET to
create the biosensor structure.
The GFETs were first modified with PtNPs by using the bifunctional linker, 1‐methyl
pyrene amine (PyNH2), where the pyrene moiety binds to graphene via π–π linkage, and
the terminal NH2 binds to the PtNP by donating an electron pair43. High‐resolution
transmission electron microscopy was carried out on samples of graphene decorated with
PtNPs (Figure 6.1.3 a) and showed that the ultrafine PtNPs were uniformly dispersed on
the graphene surface. Typically the size distribution of Pt nanoparticles varied between 1
and 3.7 nm, with an average size of about 1.8 and 2.4 nm (inset in Figure 6.1.3 a). This
has been further elucidated by scanning electron microscopy images (Figure 6.1.3 b)
showing PtNPs uniformly distributed without agglomeration over the entire graphene
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surface channel of the GFET; this platform successfully survived multiple washing and
drying steps.

Figure 6.1.3 a) TEM image of the PtNP‐graphene nanohybrid. Inset: Size distribution of
Pt nanoparticles, with an average size of about 1.8–2.4 nm; b) scanning electron image
of a PtNP‐graphene nanohybrid FET. Magnification is 100 000×, and the accelerating
voltage is 10.0 kV.

The PtNPs on the GFET were then functionalized by site‐specific immobilization of
HER3‐specific scFv antibodies, which act as bio‐receptor for immunoreaction with target
HER3 antigen. We engineered the HER3 monoclonal antibody into an scFv
antibody44 with a pair of cysteine (thiol) residues inside the loop sequence bridging
the VH and VL segments, allowing it to be immobilized on PtNPs embedded on graphene
for the production of GFET‐based biosensors. The electronic properties of Pt‐decorated
graphene change more significantly than that of intrinsic graphene after molecular
adsorption of cysteine, which makes it a promising candidate for sensor development45.
The atomic force microscopy (AFM) image in Figure 6.1.4 shows further details of the
device structure. Three height profiles were taken to probe the topography of CVD
graphene, PtNP‐graphene, and scFv immobilized on PtNP‐graphene. From the height
126

profile, the thickness of the CVD‐graphene sheet (Figure 6.1.4 a) is 0.3–0.5 nm,
consistent with monolayer graphene. After modification with PtNPs, the sample showed
a height profile of 2.0 ± 0.5 nm. This together with a fine particulate feature (Figure
6.1.4 b) of the hybrid structure showed that the PtNPs were well‐distributed over the
graphene surface. After further modification with scFv antibodies (Figure 6.1.4 c), the
device showed a height profile of 4.0 ± 0.5 nm with globular features that are
significantly larger than the PtNP‐graphene; the height difference of ≈2.0 nm is
consistent with the expected height of the scFv antibody (2.5 nm), indicating the
formation of scFv‐PtNP conjugates bound to the GFET channel. Since scFv
immobilization occurs at room temperature, it is anticipated that the scFv is not denatured
during this process, which is confirmed by the sensing results presented below.

Figure 6.1.4 Atomic force microscopy image of a) graphene, b) PtNP‐graphene hybrid,
and c) scFv/PtNP‐graphene, all on Si/SiO2. d) AFM line scans of the bare GFET,
PtNP/GFETs, and scFv‐functionalized PtNP/GFETs.
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We measured the source–drain current–gate voltage (I–Vg) characteristic of each device
in an array of 52 GFETs fabricated on a single chip, before and after successive steps of
(1) metal (Au) electrode surface passivation with 1‐mercaptohexane (MCH), (2) GFET
modification with PtNPs, and (3) scFv immobilization, to confirm the formation of the
bio‐GFET hybrid devices (see Figure 6.1.5). The Au source and drain electrodes were
passivated with an MCH self‐assembled monolayer to block nonspecific protein binding
and thus avoid undesired surface contamination with scFv protein during bio‐
functionalization of the GFET channel. The device was rinsed thoroughly in water, and
dried in a compressed air stream before taking measurements. All measurements were
performed with a source–drain voltage of VSD = 50 mV.

Figure 6.1.5 Electrical characteristics of GFET devices at different stages of surface
modification, with a representative set of 52 I–Vg curves in each case. a) As‐fabricated
GFET, b) after electrode passivation with MCH, c) PtNP/GFET hybrid, and d) scFv‐
PtNP/GFET nanohybrid device. Insets in each case are histograms of carrier mobility
and Dirac voltage along with Gaussian fits (black curves).
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The Dirac point voltage of the as‐fabricated GFET was typically in the range −4.0 to +2.0
V, with an average carrier mobility (μ) of 1197 ± 56 cm2 V−1 s−1 (Figure 6.1.5 a), which
indicates a relatively clean transfer of graphene. After MCH passivation of the Au
electrodes, a positive shift in the Dirac point was observed to be 6.5 ± 0.5 V with a
comparatively high charge mobility, μ = 1719 ± 31 cm2 V−1 s−1 (Figure 6.1.5 a). This
may be understood in terms of a shift of the electrode Fermi level to an energy closer to
the graphene valence bond, which reduces the Schottky barrier at the Au–graphene
interface and enhances hole injection, as reported earlier for carbon nanotube FETs46. The
PyNH2:PtNP attachment on the GFET channel reduced the carrier mobility (μ = 651 ± 21
cm2 V−1 s−1) and caused a negative shift in the Dirac voltage to 0.92 ± 0.25 V, which is
ascribed to increased scattering by the basic PyNH218,47. Following antibody attachment,
the carrier mobility increased (μ = 1330 ± 14 cm2 V−1 s−1) with a positive shift in the
Dirac voltage (VD = 26.4 ± 1.0 V), suggesting a decrease in carrier scattering by scFv
attachment.
Figure 6.1.6 shows the I–Vg characteristics of an individual GFET device functionalized
as described above and then treated with a blocking reagent (0.1% Tween 20 + 0.1%
bovine serum albumin), which served as a barrier to nonspecific protein adsorption on the
metal nanoparticles and GFET channel48, followed by immunoreaction upon exposure to
the HER3 antigen in buffer (pH 7.3) at concentrations in the range 300 fg mL−1 to 300 ng
mL−1. For each measurement, the GFET was incubated in a solution with a given HER3
concentration for 1 h, gently dried with compressed air, and then the I–Vg characteristic
was measured. The Dirac voltage of the Bio‐GFET showed a successive positive shift
with increasing HER3 concentration. Figure 6.1.6 a shows the shifts in VD for an
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individual GFET at each successive stage of chemical modification/bio‐functionalization
with a shift (∆VD) of ≈+7.0 V upon exposure to 300 ng mL−1 HER3. Figure 6.1.6 b
shows the response of an individual device to 30 ng mL−1 HER3 concentration in buffer
with insets showing response to 300 fg mL−1 HER3 (∆VD ≈ +1.7 V) and pure buffer (with
no HER3 antigen) as a negative control (∆VD < +1.0 V). A significant positive shift
in VD was observed upon exposure to HER3 antigen, which is readily distinguishable
from the very small response observed for a pure buffer sample. The observed Dirac
voltage shifts may be attributed to electrostatic “chemical gating” of the GFET associated
with increasing binding of antigen to scFv receptors bound on the graphene surface.

Figure 6.1.6 a) Current–gate voltage (I–Vg) characteristics of a representative GFET
device after fabrication and after each successive surface modification leading to
formation of anti‐HER3 scFv functionalized PtNP/GFET and on exposure to 300 ng
mL−1 HER3 in PBS; b) The sensing performance of the device against 30 ng mL−1 HER3;
Insets: (upper left) shows sensor response to 300 fg mL−1 HER3, and (upper right) sensor
response to 1 × 10−3 M PBS (without antigen).

There was a systematic dependence of the VD shift with varying antigen HER3
concentration in the range 300 fg mL−1 to 300 ng mL−1, with each concentration tested
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independently on 6–10 functionalized devices for signal averaging and to avoid sample
contamination across trials. The variation of the average measured shift in the Dirac
voltage as a function of HER3 concentration is displayed in Figure 6.1.7, where the error
bars reflect the standard error of the mean. The sensor responses agree with a model
based on the Hill–Langmuir equation describing the equilibrium binding of a ligand by a
receptor49.

(6.1)

Figure 6.1.7 Calibration curve of the biosensor device showing Dirac voltage shift (ΔV)
response as a function of HER3 concentration (300 fg mL−1 to 300 ng mL−1). The data
are fit to a model based on the Hill–Langmuir equation (red curve); Inset: Comparison of
device responses (ΔVDirac) for various control experiments. Fully prepared biosensor to
target HER3 at 30 ng mL−1 (light blue bar). Fully prepared biosensor to negative
controls plain PBS buffer (red bar) and non‐complementary protein marker osteopontin
(OPN; dark blue bar). Also shown is the response in a negative control experiment where
a device prepared without the scFv antibody was exposed to the target HER3 at 30 ng
mL−1(green bar).
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Here c is the HER3 antigen concentration, A is the sensor response at saturation when all
binding sites are occupied, Z is an offset to account for the response to pure buffer, Kd is
the dissociation constant describing the concentration at which half of available binding
sites are occupied, and n is the Hill coefficient describing cooperativity of binding.
To construct the fit, the maximum response A and offset parameter Z were constrained to
values that were sensible based on the response data and buffer response (A = 6.85
and Z = 0.90) while the parameters Kd and n were allowed to vary. The best‐fit
parameters were Kd = 790 ± 160 pg mL−1 and n = 0.29 ± 0.01. The low value
of Kd indicates strong binding affinity of the scFv for HER3 antigen at the electrode
surface, which may reflect high antibody loading of the PtNPs. A low value of n = 0.29
corresponds to negative cooperativity, under the (as yet untested) assumption of a linear
relationship between sensor response and analyte binding. The value of the offset
parameter Z = 0.90 is in good agreement with measured responses of devices to pure
buffer (0.89 ± 0.2 V; indicated by the dashed line in Figure 6.1.7). The results indicate
that a collection of 6–10 bio‐GFET devices can readily differentiate between pure buffer
(∆VD = 0.89 ± 0.2 V) and a solution containing 300 fg mL−1 (4.4 × 10−15 M) HER3
(∆VD = 1.76 ± 0.2 V). Multiple control experiments were conducted to gauge the
specificity of the device (inset to Figure 6.1.7). A fully functionalized bio‐GFET device
was tested against 30 ng mL−1 osteopontin and the resulting response (∆VD = 0.91 ± 0.2
V) was indistinguishable from the device response to pure buffer (∆VD = 0.89 ± 0.2 V). A
representative I–Vg characteristic is included as Figure S2 (“Supporting Information”).
The response of an unfunctionalized GFET device (negative control) to 30 ng

132

mL−1 HER3 (∆VD = 1.19 ± 0.2 V) was again comparable to the buffer response, which is
significantly smaller than the response of a functionalized bio‐GFET to the same HER3
concentration (∆VD = 5.71 ± 0.49 V) suggesting that bio‐GFET response to HER3 target
reflects specific ligand–receptor binding with a negligible contribution from nonspecific
binding. Although a precise quantitative understanding of the transduction mechanism
remains to be developed, our results motivate the possibility that the present method
could be further optimized to develop a new class of scalable graphene‐based nanohybrid
biosensors with the highly sensitive and specific chemical recognition characteristic of
the protein for a useful diagnostic test.

Conclusions
We demonstrated a novel scalable fabrication process for biosensor arrays based on
PtNP/graphene devices functionalized with an scFv with specific affinity for the breast
cancer biomarker protein HER3. The device exhibited a concentration‐dependent
response over a wide concentration range of HER3, 300 fg mL−1 to 300 ng mL−1(4.4 ×
10−15 – 4.4 × 10−9 M) in PBS that was in excellent quantitative agreement with a model
based on the Hill–Langmuir equation of equilibrium thermodynamics. Since a wide range
of HER3 concentration is present in tumors cell lines, this is a much wider range of
detection than those (up to 2.4 pg mL−1) reported by labeled impedimetric biosensors
using [Fe3CN6]4− redox probe, as label, for HER3 detection50,51. Control experiments
indicated that the HER3 specific scFv antibody retains its highly specific binding
characteristics on the PtNP/graphene hybrid structure, signifying the suitability of PtNPs
for efficient biomolecular immobilization for enhanced loading of antibodies on graphene
transistors. These observations of a good analytic range, high antigen–antibody
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specificity, rapid response, and ease of use with a small sample volume makes this device
superior to traditional immunoassay, suggesting its use as a point‐of‐care diagnostic tool.

Experimental Section
Device Fabrication: A source and drain electrode array was patterned on an SiO2/Si
water using a standard photolithographic liftoff process, based on a bilayer resist process
of PMGI and Shipley 1813.5 nm Ti/40 nm Pd was then deposited by thermal evaporation,
followed by the liftoff process with 1165 striper. Graphene synthesis was conducted with
a low pressure chemical vapor deposition process. Cu foils were first cleaned with
acetone and isopropyl alcohol (IPA), and then dried by N2 gas. After the sample loading,
the reaction chamber was pumped to a base pressure of ≈50 mTorr, followed by
introduction of 80 sccm hydrogen (H2) into the chamber. The furnace was heated to the
process temperature of 1020 °C, followed by annealing of the Cu foil for 30 min.
Methane (CH4) was then introduced at a flow rate of 50 sccm for 35 min for graphene
growth. The reactor was subsequently rapidly cooled to room temperature under a flow of
80 sccm H2 and 50 sccm CH4. The graphene monolayer was transferred onto the SiO2/Si
chip with metal electrodes by the PMMA‐assisted “bubbling” transfer method52. After
graphene transfer, GFET channels were patterned using standard photolithography,
followed by oxygen plasma etching (1.25 Torr, 80 W, 30 min) and removal of residual
photoresist by 1165 striper to yield an array of 52 GFET devices. GFETs were incubated
in a colloidal mixture of 100 ppm PtNPs (Pt nanoparticles dispersion purchased from
Sigma) and 5 × 10−3 M 1‐methyl pyrene amine in methanol for 2 h, followed by extensive
washing with methanol and IPA, and dried under flowing N2 to yield the PtNP/GFET
hybrid structure.

134

Expression and Purification of Anti‐HER3 ScFv: The complete amino acid sequence of
the variable heavy and light chains of the anti‐HER3 A5 antibody was described
previously44. An scFv version of the A5 antibody was expressed and purified as
previously described53. Briefly, the pSYN‐A5 scFv expression vector, which encodes for
a 6×‐HIS tagged version of the scFv, was transformed into TG1 E. coli and protein
expression was induced through addition of 1 × 10−3 M IPTG (Isopropyl β‐D‐1‐
thiogalactopyranoside, Fisher Biotech) to a logarithmically culture. After 4 h of induction
at 25 °C fully folded scFvs were extracted from the periplasmic space by osmotic shock
in 30 × 10−3 M Tris‐HCl (pH 8), 1 × 10−3 M EDTA, 20% sucrose (w/v). Protein was
dialyzed into phosphate buffered saline and purified by sequential immobilized metal
affinity chromatography (IMAC) and size exclusion chromatography.
Functionalization: A solution of scFv antibodies (3.2 μg mL−1; pH 7.3) was pipetted onto
the PtNP/GFET array in a humid environment to keep the solution from evaporating,
over an incubation period of 1 h, causing PtNPs to be functionalized with scFv through
binding of thiol groups of cysteine residues. After incubation, the chips were cleaned
sequentially in two DI water baths under agitation for a total of 2 min, and then blown
dry in a gentle stream of nitrogen.

Supporting Information
Supporting information can be found at DOI: 10.1002/admi.201600124
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6.2 Flexible Graphene Biosensors for pH Sensing in Complex Fluids
The work presented here also appears in the publication: Jinglei Ping†, Jacquelyn E.
Blum‡, Ramya Vishnubhotla†, Amey Vrudhula§, Carl H. Naylor†, Zhaoli Gao†, Jeffery G.
Saven‡, & A. T. Charlie Johnson*,†, Small, 2017, 13 (30),

Abstract
Advances in techniques for monitoring pH in complex fluids could have significant
impact on analytical and biomedical applications ranging from water quality assessment
to in vivo diagnostics. We developed flexible graphene microelectrodes (GEs) for rapid
(< 5 seconds), very low power (femtowatt) detection of the pH of complex biofluids. The
method is based on real-time measurement of Faradaic charge transfer between the GE
and a solution at zero electrical bias. For an idealized sample of phosphate buffer solution
(PBS), the Faradaic current varied monotonically and systematically with the pH with
resolution of ~0.2 pH unit. The current-pH dependence was well described by a hybrid
analytical-computational model where the electric double layer derives from an intrinsic,
pH-independent (positive) charge associated with the graphene-water interface and
ionizable (negative) charged groups described by the Langmuir-Freundlich adsorption
isotherm. We also tested the GEs in more complex bio-solutions. In the case of a ferritin
solution, the relative Faradaic current, defined as the difference between the measured
current response and a baseline response due to PBS, showed a strong signal associated
with the disassembly of the ferritin and the release of ferric ions at pH ~ 2.0. For samples
of human serum, the Faradaic current showed a reproducible rapid (<20s) response to pH.
By combining the Faradaic current and real time current variation, the methodology is
potentially suitable for use to detect tumor-induced changes in extracellular pH.
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Introduction
In vivo monitoring of pH is important in investigations of tissue metabolism,
neurophysiology, and diagnostics54. Extracellular pH-sensing, though of great interest for
cancer diagnosis and medical treatment54-57, is currently based mainly on relatively slow
fluorescent techniques such as fluorogenic pH probes58,59 and fluorophore-decorated
micelles60. Moreover, although optical methods hold promise for in vivo applications,
improvement in detection platforms is still needed.61 Other methods for in vivo
measurement of tumor pH, including positron emission tomography (PET) radiotracers,
magnetic resonance (MR) spectroscopy, and magnetic resonance imaging (MRI), are
limited in sensitivity and require expensive instrumentation and exogenous and even
radioactive indicators.61 Electrical or electrochemical devices have the potential to be
developed for in vivo pH monitoring but they are typically based on metal and glass,
making them fragile and bulky. Existing approaches have additional disadvantages
including the need for frequent recalibration, excessive power consumption, and lack of
biocompatibility54.
Flexible field-effect transistors (FETs) based on graphene, a biocompatible62, chemically
inert, and scalable29 two-dimensional material with high quality pH-sensing properties6370

, are promising for monitoring pH changes in biological systems. One important

application is in cancer research and diagnostics since tumors demonstrate substantial
reduction in extracellular pH56,71,72 by 1.5 pH unit (from ~7.5 for healthy tissue to ~6.0
for tumor) but only moderate fluctuations in sodium concentration (~ 7%)73 with respect
to normal tissue. However, graphene FETs are commonly operated with ~ 100 mV
source-drain bias and ~ 400 mV liquid-gate voltage. The application of these
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potentials/biases may complicate device fabrication, scaling, and stability; perturb the
system under investigation; and set a power (and thus size) constraint on the device.
Since each gate-sweep measurement requires ~100 seconds to identify the charge
neutrality point that characterizes the pH value, the pH measurement process with a FET
is also relatively slow and may not be suitable for real-time monitoring.
Here we demonstrate the use of flexible graphene microelectrodes (GEs) 74 for rapid,
bias-free pH measurement in phosphate buffer solution (PBS), ferritin solution in PBS
(0.1 μM), and human serum. The GE fabrication process is based on scalable
photolithographic approaches, and the measurements are conducted without using an
external bias voltage 74, so the methodology is intrinsically low-power and minimally
perturbative. We find that the spontaneous Faradaic charge transfer between the GE and
PBS is modulated by the pH. The Faradaic current extracted from 5 seconds of charge
measurement (20 times faster than graphene FETs)63-70,75 varies systematically with the
pH of PBS and is very insensitive to moderate fluctuations of the extracellular ionic
strength that would be induced by a tumor (~7%). The GE response to pH is well
described by a hybrid analytical/computational model where the electric double layer
derives from an intrinsic, pH-independent (positive) charge associated with the graphenewater interface and ionizable (negative) charged groups described by the LangmuirFreundlich adsorption isotherm. For the ferritin solution, we focus on the relative
Faradaic current obtained by subtracting the baseline Faradaic current for PBS from that
for the ferritin solution. The relative Faradaic current shows a very strong feature that we
associate with the disassembly of the ferritin cage and the associated release of ferric ions
into the solution. For human serum, the GE reaches equilibrium with the solution in short
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time (~20 s) and also demonstrates remarkable performance: the Faradaic current
responds systematically to pH in the range from 6.0 to 7.6 with high resolution (<0.2 pH
unit); the differential current with respect to the pH flips sign and changes by ~ 150% as
the pH decreases from 7.1 to 6.4. Together these findings suggest the suitability of the
GE for both monitoring of biomolecular activity or protein disassembly in solution and
for measurement of pH reduction expected for tumor extracellular fluid (1.5 pH
unit)55,71,72 in vitro or in vivo.

Results and Discussion
Inch-size graphene sheets for scalable electrode fabrication29 were synthesized via lowpressure chemical vapor deposition on copper76, and then transferred onto a flexible
Kapton polyimide film with a pre-fabricated array of gold contacts. An Al2O3 sacrificial
layer was deposited onto the sample by e-beam evaporation, and then the GE structures
were defined using photolithography and oxygen plasma etching. This was followed by
spin-coating of a 7-μm thick SU-8 2007 (Microchem) passivation layer, which was
patterned to define 100 μm × 100 μm wells over the graphene electrodes. (See
Experimental Section for further details of the device fabrication) An example of asfabricated flexible devices is shown in Figure 6.2.1 a.
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Figure 6.2.1. (a) Graphene electrode devices on a flexible polyimide substrate. (b)
Schematic of the device and the measurement configuration.

The sub-pA Faradaic current between the GEs and the solution under test was measured
using an electrometer (Keithley 6517a) with high resolution (~ fC) and low noise (0.75
fC/s peak-to-peak), as shown in Figure 6.2.1 b. The noninverting input of the
electrometer was initially grounded. The GE was exposed to fluid samples with various
pH values. To conduct the measurement, the graphene electrode was connected to the
inverting input of the operational amplifier of the electrometer, and the charge transferred
from the solution to graphene accumulated on the feedback capacitor Cf to provide the
readout of the electrometer.

Modulation of Faradaic Current through pH Variation
First, we monitored the Faradaic charge transfer as a function of time for PBS (ionic
strength 150 mM) as the pH was decreased from 11.2 to 2.2 and then increased back to
7.1 (Figure 6.2.2 a). For each pH value, the charge transferred from the solution to the
graphene increased linearly with time, with the slope used to determine the Faradaic
current 𝑖. In contrast to gate-sweep measurements for graphene FETs, where several
140

minutes might be needed to determine the shift in Dirac voltage that indicates the pH, the
Faradaic current measurement described here was completed in less than 5 sec. The
Faradaic current decreases monotonically with increasing pH, with excellent
reproducibility, and minimal hysteresis (Figure 6.2.2 b). For pH > 3, the Faradaic current
is negative, i.e., electrons are transferred from the solution to the graphene. At low pH (<
3), the Faradaic current is positive indicating that the proton concentration in the solution
is large enough to reverse the direction of the current. The dependence of the Faradaic
current on pH is approximately (but not exactly) linear, with a sensitivity of ~0.12 ± 0.01
pA/pH for pH in the range 2.2 – 11.2. We get an excellent fit to the data (red curve in
Figure 6.2.2 b) using a model that incorporates the electric double layer and ionizable
defect groups on graphene, as described in the following paragraphs.

Figure 6.2.2. (a) Real-time Faradaic charge transfer for phosphate buffer solution of
various pH values. The solid lines are linear fits to the data. (b) The Faradaic current
extracted from a as a function of the pH. The starting pH was 11.2. The Faradaic current
was measured as the pH was decreased to 2.2 (solid symbols) and then increased to 7.1
(open symbols). The solid curve is a fit to an equation derived from Equations 6.1-6.3 in
the main text. Inset: Equivalent circuit for the graphene-solution interface. (c) Molecular
simulations were used to calculate electrostatic potential Φ(z) (black) and densities of
water hydrogen atoms (blue) and water oxygen atoms (red) as functions of z, the distance
from the plane containing the graphene carbon nuclei. The densities of oxygen 𝜌O and
hydrogen 𝜌H are presented relative to the bulk values for these quantities, 𝜌O,bulk and
𝜌H.bulk. Superimposed on the figure are space-filling representations of graphene (green)
and representative configurations of water molecules at three different orientations and
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distances relative to the graphene surface; graphene and water molecules are rendered
on the scale of the abscissa (z).
The equivalent circuit model77 describing the graphene-solution interface is shown in the
inset of Figure 6.2.2 b. The interfacial capacitance 𝐶𝑖 (~ μF cm-2)78 of the
graphene/solution interface can be ignored in the DC measurement used here, so the
Faradaic current 𝑖 is determined by the electrostatic potential 𝜓𝑆 of the Stern plane due
to adsorbed charges near the graphene surface and the charge transfer resistance 𝑅𝑐𝑡 (~
6.7 MΩ cm2)74 between the graphene and the ionic solution: 𝑖 = 𝜓𝑆 ⁄𝑅𝑐𝑡 . The measured
sensitivity of the GE, 0.12 ± 0.01 pA/pH, is equivalent to 6.8 ± 0.7 mV/pH at the Stern
plane, in good agreement with the value67 of ~ 6 mV/pH reported by others for
experiments on graphene FETs in ionic aqueous solution using an electrolytic gate.
The current-pH dependence can be fit quantitatively using a model where the Grahame
equation79 is used to quantify the potential at the Stern plane associated with a surface
charge density, 𝜎𝑆 , with two components: a constant (i.e., pH-independent) offset charge
density and a set of ionizable defect sites in the graphene whose charge state varies with
proton concentration through the the Langmuir-Freundlich isotherm64,65:
𝑖 = 𝜓𝑆 ⁄𝑅𝑐𝑡
𝜓𝑆 =

2𝑘𝐵 𝑇
𝑒

sinh−1

(6. 2)
𝜎𝑆

√8𝜖𝜖0 𝑘𝐵 𝑇𝑐

σ

max
𝜎𝑆 = 1+10𝑛(pKa −pH) exp(−𝑛𝑒𝜓

𝑆 ⁄ 𝑘𝐵 𝑇 )

+ σoff

(6.3)

(6.4)

In Equation 6. 3, 𝑘𝐵 is the Boltzmann constant, 𝑇 the absolute temperature, 𝑒 the
electronic charge, 𝜖 (𝜖0 ) the relative (vacuum) permittivity, and 𝑐 = 150 mM the ionic
strength of the solution. In Equation 6.4, σmax is the areal charge density of ionizable
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groups (i.e., graphene defects), pKa is the dissociation constant, and 𝑛 the degree of
heterogeneity. The parameter σoff allows for the presence of a surface charge density that
is independent of pH.
Combining Equation 6.2-6.4, we obtain an excellent fit to the measured current-pH
response, where 𝜎max , 𝑛, pKa , and σoff are the fit parameters (solid line in Figure 6.2.2
b). The best fit value for 𝜎max is - 0.077 ± 0.005 C m-2, consistent with earlier reports for
graphene and carbon nanotubes70,80,81 with values in the range from - 0.01 to - 0.08 C m-2.
The best fit value for σoff is 0.007 ± 0.002 C m-2, which we discuss further in the
following paragraph. The best fit values for 𝑛 = 0.24 ± 0.03 and pKa = 6.5 ± 0.1 show
reasonable agreement with values of 𝑛 = 0.3 and pKa = 7.6 found by others for singlewall carbon nanotubes (SWCNs) in KCl solution81. Our value for pKa is also in the range
4.3 – 9.8 from earlier reports for ionizable groups on graphene82.
The pH-independent areal charge density σoff characterizes an intrinsic electric double
layer at the graphene-water interface. To provide a molecular basis for this quantity, we
first simulated the distribution of water molecules associated with defect-free graphene in
contact with pure water with molecular dynamics. The charge density obtained from the
simulation was then used to calculate the potential difference as a function of distance
from the graphene (Figure 6.2.2 c). (See Simulation Section for details.) At the
graphene surface, a potential of Φ = +360 mV is calculated relative to bulk water. Excess
hydrogen density compared to oxygen density close to the graphene surface (z < 0.3 nm)
leads to the positive potential. Considering the double-layer capacitance at the graphenesolution interface, ~ 1.3 μF cm-2 (assuming the hydrogen-graphene distance of 0.12
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nm)78, the corresponding charge density is approximately 0.005 C m-2, in good agreement
with the value of σoff inferred from the experiment (0.007 ± 0.002 C m-2).

pH Response of Graphene Electrode to Complex Biofluids
Building on this understanding of GE operation in an idealized PBS sample, we
conducted experiments to explore the use of GEs in more complex biological solutions.
As a first step, we used a GE to measure the Faradaic current as a function of pH in a 0.1
M equine spleen ferritin (Sigma Aldrich F4503) solution in PBS. Ferritin is a globular
protein complex of 24 subunits found in most tissues and in serum (pH ~ 7.0) that stores
iron oxide and releases it in a controlled fashion. Ferritin is known to disassemble and
release the stored iron ions for pH below ~ 2.0 83, with partial disassembly beginning to
occur for pH below 4.2 84. Since kapton degrades at low pH below 2.085, the GEs for this
experiment were fabricated on oxidized silicon substrates. First, we measured the
Faradaic current for the ferritin solution as a function of pH over the range 1.0 – 7.0, and
then we conducted the same measurement for a pure PBS solution to determine a baseline
response (data not shown). The pH of all solutions was adjusted in steps of ~ 1.0 pH unit
by adding 150 mM hydrochloride acid solution.
In order to observe the signature of ferritin disassembly, we focused on the relative
Faradaic current (Figure 6.2.3), obtained by subtracting the baseline Faradaic current for
PBS from that for the 5 M ferritin solution. The relative Faradaic current increases
abruptly at pH near 2.0, exactly in the range where ferritin disassembles and positively
charged iron ions enclosed in the intact globular ferritin 24-mer are released.
Furthermore, there is a noticeable increase in the relative Faradaic current in the pH range
2.0 - 4.0, in agreement with the expectation that partial disassembly of horse spleen
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ferritin occurs in this range84. Thus, the pH dependence of the relative Faradaic current
for the ferritin solution, although not analytically interpretable, is a sensitive probe of
biomolecular processes that substantially change the electrostatic environment of the GE.

Figure 6.2.3. pH-dependence of the relative current for the ferritin solution, defined as
the difference between the Faradaic current for the ferritin solution and the baseline
current for PBS.

To test the GE performance in a complex human bio-fluid, we investigated its response to
pH changes in a sample of human serum (ThermoFisher) diluted with PBS to bring it to
physiological ionic strength ~ 150 mM. The pH range tested was 6.0 (typical
extracellular pH for a tumor) to 7.6 (typical for normal tissue), which covers the range of
pH variation that can be induced by non-metastatic/metastatic tumor.5556,71,72 The GE
Faradaic current was measured over the same pH range in PBS at ionic strengths of
139.5mM, 150 mM, and 160.5 mM (Figure 6.2.4 a), corresponding to the variation ionic
strength expected in extracellular fluid (~7%)73. Over the relevant pH range, the Faradaic
current varied by nearly 0.3 pA (~ 45%), with an estimated pH resolution < 0.2 pH unit
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and sensitivity of 0.144 ± 0.0098 pA/pH. For fixed pH, the variation of Faradaic current
over the range of ionic strengths tested was only 0.01 – 0.02 pA, more than an order of
magnitude smaller.
For human serum, the Faradaic charge transfer (Figure 6.2.4 b) had a more gradual time
dependence than that for PBS (Figure 6.2.2 a). The variation of the GE Faradaic current
with time in serum was well described by simple relaxation with a single time constant 𝜏
to a constant value that we term the steady-state Faradaic current (Figure 6.2.4 b). At a
pH of 7.60 (Figure 6.2.4 b,c), the time constant was 𝜏 = 3.81 ± 0.09 s, and over the
range of pH tested, this time constant varied by ± 0.5 s. This relaxation time is presumed
to reflect equilibration processes such as non-specific adsorption of organic and inorganic
components in human serum86 onto the graphene surface, in rough agreement with earlier
reports of the saturation time scale for non-specific adsorption of protein onto graphene
(~ 30 s) measured with graphene FETs75.
The magnitude of the Faradaic current measured in serum (Figure 6.2.4 d) is smaller by
0.1 – 0.4 pA over the whole pH range than that for PBS. The reduced current magnitude
is ascribed to the inhibition of electronic communication to the GE by biomolecules
adsorbed onto its surface87,88.
The differential current with respect to the pH (∆𝐼/∆[𝑝𝐻])can be derived from the
current-pH response (Figure 6.2.4a), with results shown in Figure 6.2.4 d. The
differential current response shows two different behaviors over the tested range: it is
positive for pH 6.1 to 6.6 (saturating at ~ 0.47 pA/pH), and it is negative for pH 6.6 to 7.6
(saturating at ~ -0.23pA/pH) with an abrupt transition at pH ~ 6.6. Since tumor
development almost exclusively leads to acidosis with very rare exceptions89, tumor146

induced pH decrease will result in either Faradaic current reduction in the pH range of 6.1
to 6.6 or increase in the range of 6.6 to 7.6 (Figure 6.2.4e). Thus for tumor diagnosis, the
range of the pH can be determined from the current variation and further the pH can be
identified based on the current-pH response.

Figure 6.2.4. (a) Faradaic current for human serum sample diluted to ionic strength of
150.0 mM (solid circles) and for phosphate buffer solution (PBS) as a function of pH in
the physiological range. PBS measurements were made at ionic strength values of 139.5
mM (hollow squares), 150.0 mM (solid squares), and 160.5 mM (hollow triangles). The
red curve is a linear fit to the PBS data. (b, c) Time-dependence of the Faradaic charge
transfer (panel b) and Faradaic current (panel c) for human serum at pH = 7.60. The red
curves in b and c are fits to a model where the Faradaic current is described by a single
relaxation time. (d) Differential current with respect to pH calculated based on the
current response to serum in a.

Conclusions
In summary, we have demonstrated the use of flexible graphene microelectrodes for
monitoring of pH in idealized and complex bio-solutions, specifically PBS, 5 M ferritin
solution, and human serum. The measurement signal is the zero-bias, sub-pA Faradaic
current between the GE and the solution, making this a low-power, minimally
perturbative approach. For PBS, the variation of the current with pH can be understood
quantitatively in a model where the current reflects the potential of the Stern layer, which
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is derived from an intrinsic (positive) charge associated with the graphene-water interface
and ionizable (negative) charged groups whose density is described by a LangmuirFreundlich adsorption isotherm. The charge density intrinsic to the graphene-water
interface derived from the model is in excellent agreement with that found via molecular
dynamics simulation. For the ferritin solution, the relative Faradaic current, compared to
a PBS baseline, shows a strong feature at pH ~ 2.0, reflecting the disassembly of the
ferritin cage and release of iron atoms. For human serum, the microelectrode rapidly (~
20 s) reaches equilibrium with the solution. The Faradaic current and the current variation
together can be used for identifying pH changes on the scale of that induced by a tumor.
This electrode-based technique is therefore potentially suitable for use as a miniature
portable or implantable pH-sensor for early-stage cancer diagnosis.

Graphene growth Please refer to Appendix A
Graphene device fabrication Please refer to chapter 4.1 of this thesis.
Biosample preparation Equine spleen ferritin (Sigma Aldrich F4503) samples were
prepared at 0.1 M concentration in full PBS solution (ionic strength 150 mM).
Delipidated and dialyzed human serum (ThermoFisher 31876) was diluted by 1.73 times
in DI-water, resulting in ionic strength of ~ 150 mM. The pH for solutions of ferritin or
human serum was adjusted by adding diluted chloride acid or sodium hydroxide solution.

Simulation Section
The simulations consisted of two sheets of graphene, generated by the Nanotube Builder
plug-in of the Visual Molecular Dynamics software (VMD)90, separated by 20 Å each in
contact with atomistic water molecules. Periodic boundary conditions were used and the
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graphene sheets were positioned parallel to the x-y plane. The x-y dimensions of a
periodic rectangular box were selected such that each sheet and its images formed a
defect-free, continuous sheet of graphene. Each sheet had dimensions of 50.348 Å by
45.376 Å. The pair of parallel sheets was centered within the box in the z-dimension, and
the distance between the two sheets was 20.000 Å. Each sheet contained 924 carbon
atoms, the positions of which were constrained throughout the simulation. Water
molecules were added with VMD’s Solvate plug-in. Water was present above and below
the sheets with a vacuum between them. The initial dimensions of the box were 51.577
Å by 46.794 Å by 119.942 Å and the system contained a total of 7153 water molecules.
The simulations were carried out in the NPT ensemble at 300 K and 1.0 atm. The area of
the periodic box in the x-y plane was held constant, and the cell length in the z direction
was allowed to vary. The CHARMM3691-93 force field parameters were used with the
NAMD software package94. The water model was the three-site TIPS3P model95-97. The
charge on each hydrogen atom is + 0.417e and - 0.834e on each oxygen atom, where e is
the elementary charge. Bond distances in water molecules were constrained using the
SHAKE algorithm98. Temperature was controlled with a Langevin thermostat with a
damping coefficient of 1.0 ps-1. Pressure was controlled with a Langevin piston
barostat99,100 with a period of 200 fs and a damping time of 100 fs. The particle mesh
Ewald method was used to calculate long-range electrostatics beyond 14.0 Å, with a grid
spacing of 1.0 Å. A 2 fs time step was used. The system was minimized for 20,000
steps, then heated incrementally to 300 K in steps of 5 K and 50 K over 160 ps. The
system was equilibrated for 200 ps, then run for 10 ns, with configurations sampled every
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1 ps. For each configuration, the charge density of the water molecules was calculated as
a function of distance from the plane containing the carbon atoms of graphene.
The electric potential (ϕ) as a function of distance from graphene (z) was calculated from
the charge density (ρ) using the Poisson equation101,102:

𝑑2 𝜙(𝑧)
𝑑𝑧 2

=−

𝜌 (𝑧 )

(6.5)

𝜀0

where ε0 is the vacuum permittivity, 8.854 × 10-12 C m-1 V-1 (F/m) or 5.526 × 10-5 e nm-1
mV-1. This equation is integrated twice under the boundary conditions that electric field
and potential are zero in bulk, to give
1

𝑧

𝑠

0

0

0

𝜙(𝑧) − 𝜙(𝑧0 ) = − 𝜀 ∫𝑧 𝑑𝑧′ ∫𝑧 𝜌(𝑧′′) 𝑑𝑧′′ (6.6)
𝑧

1
= − ∫(𝑧 − 𝑧 ′ ) 𝜌(𝑧 ′ )𝑑𝑧′
𝜀0
𝑧0

where the final expression is obtained using integration by parts. The bulk, reference
value of z0 used was 4.4 nm.
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6.3 Graphene Microelectrode Sensors for Ferritin-Nanoparticle
Assembly Detection
The work presented here also appears in the publication: Jinglei Ping, Katherine W.
Pulsipher, Ramya Vishnubhotla, Jose A. Villegas, Tacey L. Hicks, Stephanie Honig,
Jeffery G. Saven, Ivan J. Dmochowski, A. T. Charlie Johnson, Chemical Science (2017)

Abstract
The characterization of protein-nanoparticle assemblies in solution remains a challenge.
We demonstrate a technique based on a graphene microelectrode for structural-functional
analysis of model systems composed of nanoparticles enclosed in open-pore and closedpore ferritin molecules. The method readily resolves the difference in accessibility of the
enclosed nanoparticle for charge transfer and offers the prospect for quantitative analysis
of pore-mediated transport shed light on the spatial orientation of the protein subunits on
the nanoparticle surface, faster and with higher sensitivity than conventional catalysis
methods.

Introduction
The ability to attach functional biomolecules to nanoparticle surfaces has spurred
development of nano-therapeutic103, diagnostic,104 and biosensing105,106 agents, as
well as novel nano-structures107 and devices.108 Methods for controlling the number
and orientation of oligonucleotides and peptides at nanoparticle surfaces have been
established,108 but it remains challenging to create nanoparticle-protein assemblies
with native-like protein structure and function.109,110 One emerging paradigm is a
thermophilic ferritin protein111,112 whose 24 self-assembling four-helix bundles
maintain native stoichiometry and secondary structure when encapsulating a single
6-nm gold nanoparticle (AuNP).113-115 However, the assembly configuration in
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solution remains unknown because conventional methods for characterizing protein
structure, such as X-ray crystallography84 are not suitable for liquid-phase proteinnanoparticle conjugates.
Here, we demonstrate a non-perturbing method using a graphene microelectrode74 for
structural-functional analysis of an ordered AuNP-ferritin protein assembly that differs
substantively from an unstructured protein corona. Charge flowing from the AuNP
through ferritin pores transfers into the graphene microelectrode and is recorded by an
electrometer. The measurements are consistent with a pore diameter of 4.5-nm, providing
evidence that ferritin maintains native-like quaternary structure upon AuNP
encapsulation. This work highlights the design and characterization of nanoparticleprotein assemblies with tunable ionic conductivity and chemical reactivity, and
demonstrates a new tool for sensitively probing protein-nanomaterial interactions.

Results and Discussion
Ferritin is a multimeric iron-storage protein comprising 24 protein subunits that selfassemble to form a hollow, ~8 nm inner diameter cage. The Archaeoglobus fulgidus
ferritin (AfFtn) used here is a unique archaeal ferritin that forms a tetrahedral
arrangement of its four-helix-bundle subunits, yielding four wide (4.5-nm),
triangular pores spanning the 2-nm protein shell116 (Fig. 6.3.1a). Stoichiometric
addition of 6-nm gold nanoparticles (AuNPs) to disassembled apo-AfFtn induces
AfFtn assembly around individual AuNPs capped with bis(p-sulfonatophenyl)
phenylphosphine (BSSP),113-115 while maintaining its native thermal stability,
stoichiometry, ferroxidase activity, and secondary structure.113 However, it is not
understood whether AfFtn assembles in its native quaternary structure upon AuNP
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encapsulation, maintaining the large triangular pores, or whether subunits assemble
in a more typical ferritin closed-pore conformation or adsorb in an unordered
fashion.

Figure 6.3.1. (a) Schematic of the setup for measuring spontaneous Faradaic charge
transfer across a pore to a graphene microelectrode in buffer solution and circuit
diagram. (b) Faradaic current as a function of electrostatic potential in the buffer
solution above graphene. The red line is a linear fit to the data.
A graphene microelectrode was used to quantify Faradaic current through a
ferritin-AuNP assembly and thereby gain information about the arrangement of
AfFtn subunits on the AuNP surface (i.e. differentiate between open- and closedpore forms of the AfFtn shell). The experimental setup (Fig. 6.3.1a) consisted of a
graphene-based microelectrode connected to the inverting input of an electrometer74
(Keithley 6517a). The electrostatic potential above a protein assembly in fluid, 𝜓𝑓 ,
drives a sub-picoampere Faradaic current, i, through the series resistance of the
charge-transfer at the graphene-solution interface74 (𝑅𝑐𝑡 ~ 100 GΩ), the graphene
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sheet (𝑅☐ ~ 102 – 103 Ω/☐), and the graphene-gold contact117 (𝑅c ~ 10 Ω).
Transferred charge accumulates on the feedback capacitor and is read out on the
electrometer. Because there is no extrinsic bias voltage between the solution and the
microelectrode, heat dissipation (aW µm-2) and electrical perturbation (~pA) to the
protein structure118 are minimized. In a previous report75 we documented the
intrinsic low noise level for microelectrode measurements in an idealized buffer
solution as well as excellent agreement between the data and theoretical models of
the behaviour of the electric double layer above graphene.
The Faradaic current 𝑖 is proportional to the potential 𝜓𝑓 : 𝑖 = 𝜓𝑓 /𝑅𝑐𝑡 . We
applied a phosphate buffer solution to the graphene microelectrode and measured
the Faradaic

current while the electrostatic potential above the graphene surface

was tuned by varying the buffer ionic strength 𝑐 (Fig. 6.3.1b). The variation of 𝜓𝑓
with ionic strength was inferred from the graphene equation for the electric double
layer. The fit to the data corresponds to a constant charge-transfer resistance 𝑅𝑐𝑡 =
69 ± 2 GΩ, and the fit passes through the origin as expected (0.6 ± 0.9 fA).
The assembly state of AfFtn in solution is affected by ionic strength: it assembles
into the native 24mer cage at high ionic strength and disassembles into dimers at
low ionic strength.116 For quantifying trans-pore current via the enclosed AuNP, the
current baseline for the AuNP-ferritin system was determined by measuring the
Faradaic current of an AfFtn mutant (E65R, termed AfFtn-R), which remains a
24mer even in low ionic strength solution. (See Supplementary Fig. S1.) The
solution (200 µL; 20 nM) was applied to the microelectrode, and a sparse layer of
non-specifically bound protein allowed to form and equilibrate (Supplementary Fig.
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S2). As the ionic strength of the solution was varied from 40 mM to 640 mM, a 15sec time trace of Faradaic charge transfer (Fig. 6.3.2a) for AfFtn-R or AfFtn was
used to extract the corresponding Faradaic current (Fig. 6.3.2b). Because of its
excellent linearity, this 15-sec time trace is sufficient to determine the Faradaic
current with high accuracy: indeed, for all figures in this report, the statistical errors
associated with the electronic measurement are smaller than the size of the plotted
points, and the observed scatter in the data is ascribed to experimental variation in
the biofluid that is difficult to control. The solutions showed nearly identical
Faradaic current at high ionic strength where both ferritins form stable 24mer
assemblies, but the currents differed significantly at low ionic strength, where only
AfFtn disassembles into dimers. The measured current for the AfFtn-R solution
(black circles in Fig 6.3.2b) and the Faradaic current difference between the
solutions of AfFtn and AfFtn-R (Fig. 6.3.2c) are well explained by models based on
known properties of the electric double layer and AfFtn assembly. In particular, we
infer a dissociation constant for AfFtn of 210 ± 60 mM, in agreement the value found
from liquid chromatography measurements. (See Supplementary Section for
details.)
To assess the configuration of AfFtn subunits on the surface of an AuNP, we
measured the real-time Faradaic charge transfer for solutions of AuNPs (𝐼AuNP , see
Supplementary Fig. S3), and of AuNP-ferritin assemblies based upon the wild-type
ferritin AfFtn and a recently identified mutant, AfFtn-AA (K150A/R151A), which
features an octahedral arrangement of its subunits with “closed” (< 1 nm) pores.119
Representative data are shown in Supplementary Fig. S4. If AfFtn and AfFtn-AA
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maintain their native quaternary structure upon AuNP encapsulation, the AuNP
surface should be less accessible for AfFtn-AA compared to AfFtn, and there should
therefore be less charge transfer.
We used the Faradaic current of AfFtn-R as the baseline for assembled (24mer)
ferritin, which leads to several strict requirements for accurate quantification of
trans-pore current. First, ferritin must remain assembled with the AuNP enclosed.
This is satisfied as 24mer assemblies of both AuNP-AfFtn and AuNP-AfFtn-AA are
stable in the range of ionic strengths tested (40 – 340 mM).113 Second, all AuNPs
must be encapsulated by ferritin with no free AuNPs in solution. As shown in
Supplementary Fig. S5 and S6, more than 99% of AuNPs were enclosed in a ferritin
protein shell as confirmed by TEM and gel electrophoresis. We also verified that
AuNPs were stable in the range of ionic strengths used without aggregation
(Supplementary Fig. S7).

Figure 6.3.2. (a) Time trace of the charge transfer between a graphene microelectrode
and mutant A. fulgidus E65R ferritin solution (AfFtn-R), and wild-type A. fulgidus ferritin
solution (AfFtn). The ionic strength of the solution increases as the grey-level of the data
increases. (b) Faradaic current for AfFtn-R (black circles) and AfFtn (red squares) based
on the data in panel a. The black curve is a fit to the data for AfFtn-R using Supplemental
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Eqn. (1S). (c) Faradaic current difference for AfFtn compared to AfFtn-R; the red curve
is a fit based on Supplemental Eqn. (25).

To quantify Faradaic current contributed by enclosed AuNPs, we calculated the
difference between the current for AuNP-AfFtn (AuNP-AfFtn-AA), 𝐼AuNP-AfFtn
(𝐼AuNP-AfFtn-AA ) and the baseline (𝐼AfFtn-R ): ∆𝐼=𝐼AuNP-AfFtn − 𝐼AfFtn-R (𝐼AuNP-AfFtn-AA −
𝐼AfFtn-R ), with results plotted in Fig. 6.3.3a. For AuNP-AfFtn, ∆𝐼 varied by ~0.12 pA
through the range of ionic strength, with a minimum at ~240 mM. For AuNP-AfFtnAA, ∆𝐼 was much smaller and essentially constant at -0.020 ± 0.005 pA. For AuNPAfFtn, the plot of ∆𝐼 vs. 𝐼AuNP (Fig. 6.3.3b) followed a linear trend with slope a =
0.59 ± 0.05, suggesting that the efficiency of Faradaic charge transfer via AuNPs
enclosed in open-pore AfFtn is ~60% of that for bare AuNPs. In contrast, for AuNPAfFtn-AA, we found a slope a = 0.03 ± 0.03, suggesting that the ferritin closed pores
completely suppress this charge transfer pathway.

Figure 6.3.3. (a) Difference in Faradaic current for solutions of AuNP-enclosed in A.
fulgidus mutant ferritin K150A/R151A (AuNP-AfFtn-AA, blue triangles) and AuNPenclosed in wild-type ferritin (AuNP-AfFtn, red squares) compared to the baseline
current set by a solution of E65R ferritin (AfFtn-R). Two data points, which almost
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overlap with each other, were tested at the concentration of 340 mM for both samples.
(b) Faradaic current difference for AuNP-AfFtn-AA (blue triangles) and AuNP-AfFtn
(red squares) as a function of the Faradaic current for AuNP. The lines are linear fits to
the data. (c) Charge-transfer efficiency 𝜉 as a function of ionic strength fitted by the
formula for the model based on electrical double layer.
This analysis suggests that the Faradaic current carried by the ferritin-AuNP system has
two components: i) pore-mediated current via the AuNP and ii) current associated with
the protein shell, quantified by 𝐼AfFtn-R . We define the trans-pore efficiency 𝜉(𝑐) =
|a𝐼AuNP (𝑐)|⁄(|a𝐼AuNP (𝑐)| + |𝐼AfFtn-R (𝑐)|) to quantify the fraction of the total current
carried by the enclosed AuNPs. The efficiency increases monotonically by ~100% as the
ionic strength increases from 40 mM to 340 mM (Fig. 6.3.3c). In contrast to molecular
diffusion through the pore, which is driven by a concentration gradient, the Faradaic
current depends on the gradient of the electrostatic potential. Thus, negative charge at the
edge of the AfFtn pores can suppress the (negative) Faradaic current via the enclosed
AuNP over length scales given by the Debye screening length 𝜆D [𝑛𝑚] = 0.304⁄√𝑐[𝑀].
Thus we expect that the efficiency will be affected by ionic strength approximately as
𝜉 = 𝐴(4.5 − 𝑘𝜆D [nm])2 where 𝐴 is a factor scaling area to efficiency, 4.5 nm is the pore
diameter for AfFtn, and 𝑘 is ~1. The charge-transfer efficiency is well fit by this equation
(Fig. 6.3.3c) with best fit value 𝑘 = 1.2 ± 0.1. This experiment demonstrates the
capability of graphene microelectrode measurements to differentiate between open- and
closed-pore structures in ferritin-nanoparticle assemblies, confirms the solvent
accessibility of enclosed AuNPs, and provides strong evidence that the AfFtn pore
maintains a native-like structure in the presence of the enclosed AuNP.
For confirmation and comparison, we used conventional catalysis methods to
differentiate between wild-type AuNP-AfFtn and AuNP-AfFtn-AA: dehalogenation
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of a bisiodinated boron dipyrromethene derivative (I-BODIPY) and reduction of 4nitrophenol. More AuNP surface area should be exposed in the AfFtn-containing
sample compared to AfFtn-AA, and should therefore have greater AuNP catalytic
activity. The reactions were monitored by different spectroscopic techniques: an
increase in fluorescence at 507 nm was observed for the I-BODIPY dehalogenation
reaction,120 and a decrease in absorbance at 400 nm was observed for the 4nitrophenol reduction.121 The mechanism for AuNP-catalyzed dehalogenation of IBODIPY is not well-understood but appears to be pseudo-zero order based on our
data, similar to what was observed for dehalogenation of iodobenzene by AuNPs. 122
An induction period was observed in the 4-nitrophenol reduction, similar to
polymer-coated AuNP systems.123-126 This induction period has been attributed to
diffusion of reagents to the AuNP surface and surface rearrangement of the AuNP
before reaction can occur.124 We expect similar effects to be in play for our AfFtncoated AuNPs.
As shown in Fig. 6.3.4 a, the rate of increase in the fluorescence intensity in the
AuNP-AfFtn solution (0.0081 ± 0.0002 A.U./min) is approximately 4 times larger
than the AuNP-AfFtn-AA solution (0.0019 ± 0.0002 A.U./min). For the 4nitrophenol reduction, AuNP-AfFtn had roughly twice the catalytic rate constant, k
= (7.4 ± 0.7) x10-3 s-1 vs. (4.0 ± 0.3) x10-3 s-1 for AuNP-AfFtn-AA (Fig. 6.3.4 b).
Neither ferritin contributed to the catalytic activity; see Supplementary Fig. S8. For
the catalytic assays, the difference in signal for AuNP-AfFtn versus AuNP-AfFtnAA is only four-fold and two-fold for the I-BODIPY and 4-nitrophenol reactions,
respectively. In contrast, the difference between AuNP-AfFtn and AuNP-AfFtn-AA

159

for the microelectrode is nearly 20-fold (Fig. 6.3.3 c). Thus, our methodology based
on graphene microelectrode is comparatively rapid (seconds vs tens of minutes), has
the potential for a quantitative estimate of the pore diameter through direct chargetransfer measurement through the protein shell, and could overcome limitations in
sensitivity imposed by the AuNP catalytic reactions. Finally, the electrode-based
method only requires relatively small amounds of sample solution (~ tens of μL)
compared to the catalytic method, which also requires significant amounts of
additional reagents (I-BODIPY, 4-nitrophenol, and NaBH4).

Figure 6.3.4 (a) Real-time fluorescence intensity of I-BODIPY dehalogenation catalyzed
by AuNP-AfFtn-AA (blue triangles) and AuNP-AfFtn (red squares) solutions. For each
measurement, 10 nM AuNP-AfFtn and 1 M I-BODIPY were mixed in 50 mM HEPES,
pH 7.0 (100 L total volume). (b) Real-time UV-visible spectroscopy of reduction of 4nitrophenol catalyzed by AuNP-AfFtn-AA and AuNP-AfFtn solutions. For each
measurement, 5 nM AuNP-AfFtn and 50 M 4-nitrophenol were mixed in a cuvette.
Freshly prepared aqueous NaBH4 was added to a final concentration of 2.5 mM and total
sample volume of 1 mL. The solid curves are fits based on first-order kinetics. The
corresponding catalytic reactions are shown in panels a-b.
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Conclusions
We have developed a graphene microelectrode device as a sensitive tool for structurefunction analysis of AuNP-ferritin assemblies in solution. This all-electronic method has
multiple advantages for identifying protein pores compared to conventional AuNP
catalysis methods, and it has the potential to be developed into a direct measurement of
the pore-mediated charge-transfer process. Our approach could provide a way to explore
protein structure at nm-scale and, more broadly, to explore interactions of biomolecules
with inorganic nanomaterials in complex biofluids--systems shown to offer significant
promise in bio-imaging, sensing,106 catalysis and templated nanoparticle synthesis.7

Graphene growth Please refer to Appendix A
Graphene device fabrication The graphene-copper growth substrate was coated
with 500-nm layer of poly(methylmethacrylate) (PMMA, MicroChem), and the PMMAgraphene film was floated off the surface by immersion in 0.1 M NaOH solution with the
graphene-copper growth substrate connected to the cathode of a power supply. The
PMMA-graphene film was transferred onto a 300 nm SiO2 /Si wafer with an array of 5
nm/40 nm Cr/Au contact electrodes that were previously fabricated using
photolithography. Al2O3 (5 nm) was deposited on the whole wafer as a sacrificial layer,
and 50 µm × 100 µm graphene microelectrodes were defined by photolithography with
photoresist PMGI (MicroChem) and S1813 (MICROPOSIT) and oxygen plasma etching.
The Al2O3 layer on top of the microelectrode areas was removed by the basic photoresist
developer MIF-319 (MICROPOSIT). After removal of the photoresist residues with 1165
(MICROPOSIT), another passivation layer of photoresist SU-8 (MicroChem) was
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applied to the device, and the wells exposing the microelectrodes were defined via
photolithography.

Computational Design of AfFtn-R The crystal structure of wild-type AfFtn
(PDB 1SQ3) reveals a trimeric interface lined with negatively charged amino acids.
We hypothesized that a high ionic strength solution allows for assembly by shielding
the electrostatic repulsion between subunits at this interface. Therefore, a point
mutation that inserts a positive charge along the interface, with potential for forming
salt bridges to a neighboring subunit, could stabilize the 24mer cage at low ionic
strengths.
We employed the statistical computational aided design strategy to guide the
selection of stabilizing point mutations.127-130 Calculations were carried out using
atomic coordinates from chains G, H and J of AfFtn in PDB structure 1S3Q 2. For
each calculation, all amino acids were considered at the site selected, except for
cysteine and proline. All other sites other than the site of interest were constrained
to the wild-type identity and crystal structure conformation. Side-chain
conformational states were taken from a rotamer library, and all possible
conformations were considered.131 Hydrogen atoms were placed according to the
CHARMM19 topology files93. Energies were calculated using the CHARMM19
dihedral, van der Waals, and electrostatic terms were considered, with a non-bonded
cut-off of 8 Å. Amino acid probability profiles were generated by summing the
rotamer probabilities of each amino acid type. Sites 34 and 65 of AtFtn are at the
center of the carboxylate-rich pore. Analysis of these sites using the statistical
computational design strategy recovered wild-type (glutamic acid, E) as the most
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probable amino acid at site 34. The most probable conformation possesses a
favorable interaction with a neighboring positively charged lysine residue at site 39.
This site was not selected for mutation. At site 65, the positively charged arginine
(R) was the most probable residue. This site was chosen for mutation, and the
arginine variant E65R was selected for expression.

Ferritin mutagenesis The pAF0834 plasmid containing the AfFtn gene was
provided by the laboratory of Dr. Eric Johnson at the California Institute of
Technology. AfFtn-R was made by site-directed mutagenesis using the Stratagene
QuikChange kit. The primers were obtained from Integrated DNA Technologies:
sense (5ʹ-3ʹ) GATTTCGTTTCCCGTCGCGGTGGCCGTG, antisense (5ʹ-3ʹ)
CACGGCCACCGCGACGGGAAACGAAATC. The mutated cDNA was
transformed into XL1-Blue Supercompetent E. coli cells (Stratagene) according to
the manufacturer’s protocol. The plasmid was isolated using a QIAprep Spin
Miniprep kit (Qiagen). All sequencing was performed by the University of
Pennsylvania DNA Sequencing Facility. The AfFtn-AA plasmid was purchased
from DNA2.0 and transformed the same as AfFtn-R.

Ferritin expression/purification Production and purification of AfFtn and
mutants was performed as previously published, 115 with some modifications. The
plasmid was transformed into BL21-Codon Plus(DE3)-RP competent E. coli cells
(Stratagene) in TB medium (1 L containing 100 mg ampicillin, 35 mg
chloramphenicol) at 37 °C with shaking at 225 rpm until OD600 ~0.8 was reached.
Expression was induced with 1 mM isopropyl β-D-1-thiogalactopyranoside (IPTG,
Lab Scientific) and incubation at 37 °C was continued for 4 h. Cells were centrifuged
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and stored at -20 °C, followed by resuspension in buffer (20 mM phosphate, 20 mM
NaCl, pH 7.6) with an EDTA-free protease inhibitor cocktail tablet (ThermoFisher
Scientific). Cell lysis was performed by treatment with lysozyme (~1 mg/mL final
concentration) and sonication (amplitude of 30, 1 s on, 1 s off, 10 min total
processing time). Cellular debris was removed by centrifugation (6 krpm, 30 min, 4
°C), and the supernatant was treated with nuclease (Pierce universal nuclease,
ThermoFisher Scientific) after addition of MgCl 2 to a final concentration of 2 mM
for 15 min at room temperature. The solution was heat shocked to remove most
endogenous E. coli proteins (10 min at 80 °C). After pelleting the precipitated E.
coli proteins by centrifugation (9 krpm, 60 min, 4 °C), the supernatant was buffer
exchanged to ensure complete ferritin assembly (2.5 M NaCl, 2 mM EDTA, 20 mM
phosphate, pH 7.6), and purified further using size exclusion chromatography
(HiLoad 16/60 column, GE Healthcare). The purity of the protein was determined
to be >95% by denaturing PAGE gel (4-15% Tris-HCl, Mini-Protean TGX gel), as
seen in Supplementary Fig. S9a. Protein concentration was determined using the
Bio-Rad Protein Assay (based on the Bradford method), using bovine gamma
globulin as the standard. Proteins were also characterized by MALDI-TOF-MS,
TEM, and DLS (see Fig. S9b, Fig. S9c and Table S1 in Supplementary Information).
Protein stock solutions were 0.22 m filtered and stored at 4 °C until use in
experiments. Multiple stock solutions of ferritins were used for experiments to
ensure reproducibility.

AfFtn solution and AfFtn-R solution preparation Protein samples were
prepared at 10 M concentration in phosphate buffer (20 mM phosphate, pH 7.6),
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using NaCl to vary ionic strength (40, 90, 140, 190, 240, 340, 440, 540, 640 mM).
To ensure accurate ionic strengths, samples were buffer exchanged on a Zebaspin
column (ThermoFisher Scientific) equilibrated with the appropriate buffer. Samples
were incubated overnight at 4 °C to allow for equilibration.

AuNP-AfFtn solution and AuNP-AfFtn-AA solution preparation
Citrate-capped 6-nm AuNPs were purchased from TedPella. The citrate was
exchanged for bis(p-sulfonatophenyl)phenylphosphine (BSPP, Strem Chemicals) as
described previously132. For device measurements, 1 mL samples were prepared at
0.3 mg/mL protein, 0.6 M 6-nm AuNP-BSPP in 20 mM phosphate pH 7.6 and
equilibrated at room temperature for 48 h with gentle agitation to ensure
encapsulation. Protein NP samples were buffer-exchanged into various ionic
strengths (40, 90, 140, 190, 240, 340 mM) using 10DG columns (Bio-Rad)
equilibrated with the appropriate phosphate buffer. The 10DG column also helped
ensure that only encapsulated AuNPs remained in the samples, as confirmed by
TEM and native gel electrophoresis (see Supplementary Fig. S5 and S6). The first
two fractions were combined, and AuNP concentration was verified by UV-vis
spectroscopy. Because bare AuNPs cannot elute on a 10DG column, buffer
exchange for the AuNP samples without protein was done using Zebaspin columns
equilibrated at the same ionic strengths. All samples were diluted to 2 mL to match
the lowest concentration sample (20 nM). All samples were measured on the same
device on the same day they were prepared, to minimize bulk AuNP aggregation.

Preparation of I-BODIPY I-BODIPY was prepared following the method of
Zuber et al.133 A dark red solid product was obtained with a mass of 31.8 mg (69.7%
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yield). 1H NMR (CD2Cl2): 7.54 (3H, m), 7.29-7.28 (2H, m), 2.62 (6H, s), 1.40 (6 H,
s). Mass was verified using MALDI-TOF-MS with α-cyano-4-hydroxycinnamic
acid (CHCA) as matrix. For characterization data, see Supplementary Fig. S10.

Fluorescence measurements For the AuNP-catalyzed dehalogenation
reaction, 10 nM AuNP-AfFtn and 1 M I-BODIPY were mixed in 50 mM HEPES
buffer (pH 7.0). Steady-state fluorescence was monitored using a Varian Cary
Eclipse fluorimeter, with PMT detector voltage at 800 V, excitation wavelength of
465 nm, and temperature of 25 °C.

4-Nitrophenol reduction A solution of 5 nM AuNP-AfFtn and 50 M 4nitrophenol (Fluka) was mixed in a cuvette. Freshly prepared aqueous NaBH 4
(Fluka) was added to a final concentration of 2.5 mM and total sample volume of 1
mL. Absorbance at 200—1100 nm was measured every 15 s at 25 °C using an
Agilent 8453 UV-visible spectrometer. To determine the rate constant 𝑘, the data
were fit to a first-order reaction, after subtracting the induction time (197 s):
Abs = 𝜀[𝐴]0 𝑒 −𝑘𝑡

(6.7)

where Abs is the measured absorbance, 𝜀 the extinction coefficient of 4-nitrophenol
at 400 nm (18000 M-1 cm-1), [𝐴]0 the initial concentration of 4-nitrophenol (50 μM),
and t the time.
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6.4 Graphene Sensors for Quantification of Neuropeptide-Receptor
Interaction
The work presented here also appears in the publication: “Ping, Vishnubhotla, Xi, Ducos,
Saven, Liu, Johnson”, ACS Nano, 2018, 12 (5)

Abstract
Opioid neuropeptides play a significant role in pain perception, appetite regulation, sleep,
memory, and learning. Advances in understanding of opioid peptide physiology are held
back by the lack of methodologies for real-time quantification of affinities and kinetics of
the opioid neuropeptide−receptor interaction at levels typical of endogenous secretion
(<50 pM) in biosolutions with physiological ionic strength. To address this challenge, we
developed allelectronic opioid−neuropeptide biosensors based on graphene
microelectrodes functionalized with a computationally redesigned water-soluble μ-opioid
receptor. We used the functionalized microelectrode in a bias-free charge measurement
configuration to measure the binding kinetics and equilibrium binding properties of the
engineered receptor with [D-Ala2, N-MePhe4, Gly-ol]-enkephalin and β-endorphin at
picomolar levels in real time.

Introduction
Endogenous opioid neuropeptides are an important class of neurotransmitters that play a
critical role in stress response, analgesia, addiction, pain management, and cardiovascular
control134. The dysregulation of endogenous opioid neuropeptides may result in
neurologic and psychiatric disorders such as depression, borderline personality disorder,
as well as Alzheimer’s, Huntington’s, and Parkinson’s135-137. Thus, understanding
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opioid−neuropeptide physiology and the downstream applications in pharmacology138,
anesthesia and surgery139, and therapeutics140 is highly significant. Conventional
voltammetry methods can be used to real-time detect neuropeptides, with relatively low
sensitivity, >100 nM 141. Quantification of opioid neuropeptides at low levels typical in
human plasma (<50 pM) 142,143, a crucial enabling step in neuropeptide investigation,
currently relies on liquid chromatography and n-rounds mass spectroscopy (LC-MSn),
which is incompatible with real-time analysis. This method is highly invasive as the
biofluid must be sampled for analysis, and it suffers from low spatial resolution, low
throughput, and high cost144. Another emerging technique for neuropeptide
quantification, biotransistors based on low-dimensional nanomaterials such as silicon
nanowires145 and graphene29, is not suitable for use in vivo or in ionic complex biofluids
due to limitations on sensitivity caused by the Debye screening effect78. Here, we
demonstrate all-electronic real-time recording of neuropeptide−receptor interactions in
solution with physiological ionic strength (∼150 mM) using graphene
microelectrodes74,146,147 functionalized with an engineered water-soluble μ-opioid
receptor (wsMOR)29,148,149. The wsMOR is a computationally redesigned variant of the
membrane protein that, unlike the native MOR, is stable in aqueous solution. The target
molecules for our experiments were [D-Ala2, N-MePhe4, Glyol]- enkephalin and βendorphin, both opioid peptides with high specificity for the native MOR. Conventional
electrochemical methods, which include one or more additional electrodes to apply a
voltage bias and/or to measure the potential of the solution, may lose sensitivity at low
target concentration due to nonspecific adsorption on the additional electrodes150. To
overcome this limitation, our approach is to monitor the spontaneous, zero-bias Faradaic
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charge transfer from the solution into the microelectrode (∼pC/s)74,146. We show that this
current varies systematically with the analyte concentration, providing picomolar
sensitivity in a solution with physiological salt content. We used this approach to quantify
the association rate constant, 2.8 ± 0.1 × 107 M−1 min−1, and the dissociation rate
constant, 0.089 ± 0.001 min−1, for binding between the engineered wsMOR and
enkephalin. The Faradaic current measured after the electrode equilibrated with the
solution varied systematically with the concentration of the target analytes, enkephalin
and β-endorphin, with a limit of detection at the picomolar level. This methodology
offers a pathway toward in vivo quantification of neuropeptide secretion with high
sensitivity and spatiotemporal resolution for interrogating and understanding
neurophysiological and biopsychological effects of neuropeptides.

Results and Discussion
The experimental setup for Faradaic charge measurement74 is shown in Figure 6.4.1 a
(see “Methods” for more information regarding the measurement). All measurements
were conducted in full-strength phosphate buffer solution (1× PBS). Faradaic charge
transfer occurred through the series combination of the solution diffuse layer resistance
(∼10 kΩ)151, the graphene−solution interface charge transfer resistance (Rct ∼ 100 GΩ)74,
the sheet resistance of graphene (∼102−103 Ω/□), and the graphene−gold contact
resistance (∼10 Ω)117. The charge transfer rate, ∼pC/s, was thus primarily determined by
the charge transfer resistance Rct, which is independent of ionic strength146. Charge
transferred from the solution to graphene accumulated on the feedback capacitor, Cf, of
the electrometer to produce the readout voltage. For graphene microelectrodes, the
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effective potential that drives the spontaneous Faradaic current decays logarithmically
with increasing ionic strength74, instead of the much faster exponential decrease that is
characteristic of transistor-based devices. The charge transfer signal was, for this reason,
readily detected at physiological ionic strength. As discussed below, our observations are
consistent with the view that target binding modulates charge transfer through physical
blocking of charge transfer sites.

Figure 6.4.1. (a) Schematic of the electronic setup for measurement of charge transfer
from a biosolution to a graphene microelectrode functionalized with water-soluble μopiod receptor (wsMOR). (b) AFM image of monolayer graphene on SiO2/Si. (c) AFM
image of wsMOR functionalized graphene on SiO2/Si. (d) Line scans indicated in panels
b and c, showing the change in apparent height due to functionalization with wsMOR. (e)
Response of a graphene transistor-based neuropeptide biosensor to solutions of varying
concentration of [D-Ala2, N-MePhe4, Gly-ol]-enkephalin in low-salt buffer (0.002×
PBS). Red curve is a fit to a model based on the Hill−Langmuir equation. The green data
point is the result of a negative control experiment against oxytocin.
For fabrication of graphene-based microelectrode arrays, large-area graphene sheets were
prepared by chemical vapor deposition and transferred using a low-contamination
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bubbling method52 onto a Si/SiO2 substrate with prefabricated 45 nm thick Cr/Au
electrodes. Graphene microelectrodes (50 μm × 50 μm) were then defined with
photolithography and plasma etching, and the metal contacts were passivated by a
hardbaked, ∼20 μm thick SU-8 (MicroChem) layer so that charge transfer could occur
only at the graphene−solution interface (see Methods for further details of the fabrication
process). The graphene microelectrodes were functionalized with the computationally
redesigned wsMOR. The functionalization process parameters (i.e., solution
concentrations and incubation times) were optimized to maximize the density of
immobilized wsMOR. One key factor was a relatively long incubation time (>20 h) in a 1
mM solution of the linker molecule 1- pyrenebutyric acid N-hydroxysuccinimide ester
(PBASE, Sigma-Aldrich) in methanol, a crucial enabling step for highquality
functionalization (see the “Supporting Information” section for details). PBASE is a
bifunctional linker with an aromatic pyrenyl group that irreversibly adsorbs onto the basal
plane of graphene through a noncovalent π−π interaction152,153. The PBASE-covered
microelectrodes were next exposed to wsMOR (3 μg/mL) in 1× PBS. The succinimide
groups in the PBASE layer conjugated with primary amine groups on the surface of
wsMOR molecules to form stable amide bonds that immobilized wsMOR. The process
led to a high density of PBASE and wsMOR on the graphene surface74,154, which
appeared as a uniform brush-like layer when imaged by atomic force microscopy (AFM),
as shown in Figure 6.4.1c. The apparent height of wsMOR as determined from AFM line
scans (Figure 6.4.1 d) was ∼4.3 nm, in good agreement with expectations given the
wsMOR mass of 46 kDa78. We used the measured Dirac voltage shift induced by
wsMOR binding and the expected charge state of the wsMOR to estimate the density of
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the wsMOR functionalization at 550 μm−2 (details are provided in the “Supporting
Information” section). This value is smaller than that in our earlier report155 of 1300
μm−2 for single stranded DNA 22-mers immobilized on graphene using a very similar
procedure, which is attributed to the effect of the larger size of the wsMOR on the surface
packing efficiency. Before performing graphene microelectrode measurements of the
real-time binding properties of wsMOR in ionic solution, we characterized the
equilibrium dissociation constant and verified specific binding between wsMOR and
enkephalin by using biosensors based on wsMOR-functionalized graphene field-effect
transistors (GFETs)29. The experimental details are provided in the ‘Supporting
Information” section. Typically, a biosensor response R against the target at
concentration c is described by the Hill−Langmuir equation156:

𝑛

𝑅=

(𝑐⁄𝐾 )
𝐴
𝐴
𝑛
1+(𝑐⁄𝐾 )
𝐴

(6.7)

where A is the magnitude of the sensor response, KA is the concentration producing half
occupation, and n is the Hill coefficient. We measured the current−gate voltage (I−VG)
characteristics of the wsMOR/GFETs in the dry state and quantified the sensor response
R as the shift of the Dirac voltage, ΔVD, which varied systematically with the
concentration
of enkephalin in a low-salt buffer (0.002× PBS). As shown in Figure 6.4.1e, ΔVD was
well fit by Equation 6.7, with the fit parameters A = 4.4 ± 0.1 V, KA = 0.79 ± 0.10 nM,
and n = 0.6 ± 0.1. The fit value for the value of KA was in very good agreement with the
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value of 1.2−3.1 nM obtained by optical assays for the binding between native MOR and
enkephalin157,158. The best fit value for the Hill coefficient n was smaller than the value
obtained from radioligand binding assays, ∼1.0, 159 but consistent that in our earlier
report for DNA hybridization on graphene, 0.56 ± 0.07,155 which is ascribed to the
interaction between graphene, the receptor, and the analyte (wsMOR and enkephalin in
this case). We also tested the GFET biosensor response against oxytocin, an endogeneous
neuropeptide that is known not to bind specifically to native MOR 160. The response of
the biotransistors to 1 nM oxytocin solution was very small, 0.17 V (Figure 6.4.1 e),
indicating a low level of nonspecific binding of oxytocin to the wsMOR. We note that the
transistor-based biosensor, although suitable for quantifying the enkephalin−receptor
dissociation constant, suffers from the Debye screening effect78, which required that
the target be presented in a low-salt buffer solution for real-time testing. Now we discuss
real-time measurements of the neuropeptide− wsMOR interaction using the graphene
microelectrodes. The graphene microelectrode was exposed to 1× PBS at full ionic
strength (∼150 mM). To determine the sensor response to enkephalin at different
concentrations, drops of enkephalin solution at successively larger concentrations were
placed onto the device; after each drop was applied, the feedback capacitor of the
electrometer was discharged, and then a charge transfer time trace was acquired. Time
traces of the Faradaic charge transfer, Q(t), for three different concentrations are shown
in Figure 6.4.2 a, with the corresponding Faradaic currents, i(t) = dQ/dt, shown in
Figure 6.4.2 b. From Figure 6.4.2 b, we see that the Faradaic current for 0.2 pM
enkephalin decreased gradually over tens of minutes and saturated after more than 30
min, which is ascribed to an increase in Rct caused by enkephalin binding to wsMOR on
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the graphene microelectrode so that charge transfer sites were physically blocked146. In
contrast, for a target concentration of 22 nM, the current decreased much more quickly
and saturated after about 6 min. To quantify the binding kinetics, we fit the current i(t)
with a single-time relaxation model161 describing ligand−receptor binding:

𝑖(𝑡) = 𝑖𝐴 (𝑐) − 𝑖𝐵 (𝑐)(1 − 𝑒

−𝑡⁄
𝜏)

(6.8)

where iA(c) is an offset current at t = 0, τ is the saturation time constant, and iA(c) − iB(c)
is the saturation current for long times as the system reaches equilibrium (for practical
purposes, this requires t ≥ 3τ). For 0.2 pM enkephalin, the best fit value is τ = 11.2 ± 0.7
min, whereas for 22 nM, τ = 1.40 ± 0.02 min, a factor of about 8.0 times smaller.

Figure 6.4.2. (a) Real-time Faradaic charge transfer into graphene for 0.2 pM (blue),
2.2 nM (green), and 22 nM (yellow) [D-Ala2, NMePhe4, Gly-ol]-enkephalin in
phosphate buffer solution. (b) Extracted Faradaic current as a function of time. The red
curves in both panels are exponential fits characterized by a single time constant τ, as
discussed in the main text. (c) Plot of the inverse of the time constant (kob = 1/τ) as a
function of concentration. The red line is a linear fit to the data.
For ligand−receptor binding, the observed saturation rate kob = 1/τ depends on the target
concentration c through the relation kon = (kob − koff)/c, where kon and koff are the
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association rate constant and the dissociation rate constant, respectively161. The
measurement presented in Figure 6.4.2 c, is well described by this relationship, and the
best fit values for kon and koff are 2.8 ± 0.1 × 107 M−1 min−1 and 0.089 ± 0.001 min−1,
respectively. These values are in good agreement with those determined using
radioligand binding assays: kon = 8.5 × 107 M−1 min−1,162 and koff = 0.155 ± 0.001
min−1.163 The corresponding dissociation constant KA = koff / kon, is 3.1 ± 0.2 nM,
slightly higher than the value derived from the FET sensor measurement, 0.79 ± 0.10 nM,
but in good agreement with that found using optical assays, 1.2−3.1 nM 157,158, for native
MOR and enkephalin binding. To investigate the use of the functionalized graphene
microelectrode as an enkephalin biosensor, the limiting value of Faradaic current as t →
∞, iA(c) − iB(c), was obtained by fitting the measured charge transfer to Equation 6.8,
and the sensor response was taken to be a relative Faradaic current compared to that
measured when the microelectrode was exposed to pure PBS. As shown in Figure 6.4.3,
the variation of the relative Faradaic current with enkephalin concentration was well fit
by the Hill−Langmuir formula Equation 6.7, with high signal-to-noise ratio. The best fit
values of the parameters are the amplitude A = −0.56 ± 0.01 pA, the concentration
producing half occupation, KA = 3.6 ± 0.4 nM (in excellent agreement with the value
obtained by kinetic measurements discussed above), and the Hill coefficient, n = 0.5 ±
0.1, again reduced below 1.0 by interactions between graphene, the receptor, and the
enkephalin target.
We applied the same methodology to β-endorphin, a second neuropeptide known to bind
to native MOR. As demonstrated in Figure 6.4.3, the neuropeptide biosensor response
varied systematically with target concentration with high signal-to noise ratio and again

175

could be well fit by Equation 6.7. The best fit value for the dissociation constant was KA
= 1.5 ± 0.2 nM, in good agreement with the value obtained via radioligand arrays, 2−6
nM 164; the value for n was 0.6 ± 0.1, in the range typical of functionalized graphene
sensors. We found that the best fit value for the amplitude A = −0.89 ± 0.03 pA for βendorphin is ∼1.6 times larger than the amplitude found for enkephalin. This is ascribed
to greater inhibition of charge diffusion87,88 by β-endorphin compared to that of
enkephalin due to the former’s greater molecular weight and thus size. It is possible that
the signal strength for the microelectrode sensor depends on multiple attributes of the
target, such as size, chirality, and charge, making this an interesting topic for future
exploration. Remarkably, for both enkephalin and β-endorphin, the excellent signal-tonoise performance leads to a detection limit in the picomolar range, suggesting this
sensor system is capable of resolving the mean secretion level of enkephalin (∼15 pM)142
or β-endorphin (∼40 pM)143 characteristic of human plasma.

Figure 6.4.3. Relative Faradaic current for the [D-Ala2, N-MePhe4, Glyol]- enkephalin,
β-endorphin, and oxytocin as a function of concentration. The error bars (<femtoamp
level) are smaller than the data points.
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To evaluate the reproducibility of the opioid−neuropeptide biosensors, we tested six
different devices for enkephalin and two devices for β-endorphin. The device-to-device
variation in the response amplitude was ±15%, whereas the dissociation constants for
both targets were consistent at ±10%. We also investigated the selectivity of the wsMORfunctionalized neuropeptide biosensors by testing against oxytocin as a negative control
(Figure 6.4.3). The response of the biosensor to oxytocin was essentially negligible at
concentrations below 1 μM, providing strong evidence that the sensor response reflects
specific binding of the target and wsMOR.

Conclusions
We demonstrated the use of graphene microelectrodes functionalized with a soluble
variant of the human MOR for neuropeptide detection with high sensitivity (picomolar
level) and specificity in biofluids with physiological ionic strength. The kinetics and
equilibrium binding properties of two neuropeptides, [D-Ala2, N-MePhe4, Gly-ol]enkephalin and β-endorphin, were investigated and quantified. The results were in
excellent agreement with benchmarks set by conventional radioligand and optical assays,
as well as neuropeptide biosensors based on field-effect transistors that were measured in
the dry state. The size of the active sensor region for this work was 50 μm × 50 μm, on
the scale of larger neurons, but this could be reduced to the scale of the smallest neurons
(∼4 μm) using optical lithography. The measurement time was ∼30 min, which enabled
determination of the relevant fitting parameters with high precision. If a microelectrode
sensor was precalibrated so the time constant for a given concentration was known, then
it might be possible to determine the concentration more rapidly by simply fitting the first
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few minutes of the time trace (Figure 6.4.2). These all-electronic biosensors are therefore
potentially suitable for development for use in in vitro clinical testing or implantable
systems for interrogating neuropeptide secretion with high spatial and time resolution.

Methods
Graphene Growth Please refer to Appendix A
Graphene Device Fabrication The graphene−copper growth substrate was coated
with a 500 nm layer of poly(methyl methacrylate) (PMMA, MICROCHEM), and the
PMMA−graphene film was floated off the surface by immersion in a 0.1 M NaOH
solution with the graphene−copper growth substrate connected to the cathode of a power
supply. The PMMA−graphene film was transferred onto a silicon wafer with an array of
5 nm/40 nm Cr/Au contact electrodes that was previously fabricated using
photolithography. After removal of PMMA with acetone, the graphene film was cleaned
by annealing at 250 °C in 1000 sccm argon and 400 sccm hydrogen for 1 h. For the FETbased devices, 2 μm × 10 μm graphene channels were defined by photolithography
(photoresist S1813, MICROCHEM) and oxygen plasma etching. For the graphene
microelectrodes, 50 μm × 50 μm graphene electrodes were defined by photolithography
(photoresist AZ 5214 E, MICROCHEM) followed by oxygen plasma etching. A layer of
photoresist SU-8 (MICROCHEM) was then applied to the device, and the passivation
layer covering the electrodes was defined by photolithography.

Graphene Functionalization Graphene electrodes were incubated in 1 mM 1pyrenebutyric acid N-hydroxysuccinimide ester solution in ethanol for 20 h and then
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washed thoroughly with methanol and deionized water to fully remove residual solute
and solvent. Next, the devices were incubated in 3 μg/mL wsMOR solution in PBS (137
mM sodium chloride, 2.7 mM potassium chloride, 10 mM phosphate, pH 7.4) for 1 h for
protein immobilization. After wsMOR functionalization, the PBASE that had not bound
to wsMOR was passivated by exposing the chips to PBS with pH 8.6 for 1 h, much
longer than the half-life of PBASE at this pH (∼10 min) 165.

Charge Transfer Measurement Using Graphene Microelectrodes.
The noninverting input of the operational amplifier in an electrometer (Keithley 6517a)
was grounded. The inverting input was connected to the graphene microelectrode, which
connected the microelectrode to a virtual ground, so all charge transferred into the
microelectrode was delivered to the feedback capacitor Cf in Figure 6.4.1 a to produce
the measured voltage readout. To start the measurement, the microelectrode was exposed
to a solution of wsMOR at known concentration in 1× PBS (137 mMsodium chloride, 2.7
mM potassium chloride, 10 mM phosphate, pH 7.4), and a time trace of the sensor
response was taken immediately.

Supporting Information
The Supporting Information is available at DOI: 10.1021/acsnano.7b07474
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Chapter 6 Conclusions

The unique properties of graphene make it suitable for detection of small molecules in
both the dry and liquid states, and on rigid and flexible substrates. This chapter explores
the ways that graphene can be used beyond nucleic acid and drug target sensing, which
include protein biomarker detection and pH sensing for fluids ranging from phosphate
buffer solution (PBS) to human serum. In addition, graphene may also be used for
detecting the open-closed structure of a protein, in this case, ferritin, based on a Faradaic
charge transfer due to enclosing a gold nanoparticle within and open- pore protein.
Finally, this chapter shows that graphene may be used for quantifying opioid
neuropeptide-receptor interactions, which could be useful for physiological sensing such
as pain perception and appetite regulation.
From this chapter, it is evident that graphene is an excellent material for sensing
individual molecules, and for studying the interactions between a probe and its target.
Furthermore, this chapter demonstrates that graphene sensing can be carried out without
the more traditional field-effect transistor sensing mechanisms, and instead, with the use
of graphene microelectrodes (GE).
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Chapter 7: Thesis Conclusions and Future Work
Graphene is a relatively new material, having been discovered in 2004 through
mechanical exfoliation, and winning its discoverers the Nobel Prize in physics in 2010.
Since then, it has been widely studied, intriguing scientists with its remarkable properties,
including its high electron mobility, robustness, and sensitivity. Over the last decade,
scientists have found many ways to incorporate graphene into applications and
engineerable devices.
At the beginning of this work, we discussed the growth of graphene via CVD on a copper
foil substrate, which, arguably, is the most critical step in the process, as without good
quality graphene, multiple problems can arise, such as: 1) difficulty transferring the
graphene, causing tears and wrinkles in the film, 2) discontinuous films, causing “peel
off” of the graphene during lithography, resulting in low device yield, 3) poor quality
devices not suitable for low-concentration detection. Because Raman spectroscopy,
atomic force microscopy and optical microscopy have all separately characterized
different aspects of the graphene and verified its high quality, the graphene described
here was suitable for a myriad of sensing projects.
The low-contamination transfer process of graphene was carried out via an electrolysis
bubble method, leading to minimal tearing as well as a clean graphene film. The
fabrication of these graphene field-effect transistors was explained, which produced
dozens of devices in one array (52 per chip, and up to > 500 in one round of lithography)
with a yield greater than 90%.
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Using these graphene sensor arrays, this thesis focused on the detection of synthetic small
biomolecules and market drugs for eventual drug diagnostics and therapeutic drug
monitoring (TDM).
From Chapter 5, we conclude that graphene functionalized with single strand DNA is
adept at detecting target ssDNA down to concentrations of ~ 1 aM, which is a promising
limit of detection, as certain nucleic acid strands are proven biomarkers for various
cancers1-3, and up-regulate or down-regulate in human samples in the attomolar range4.
Additionally, these GFETs can be used to sense a long target with a short probe.
Graphene devices functionalized with aptamers can detect therapeutic drugs in
concentrations much lower than what is found in the human body, ~ 1-10 ng/mL,
indicating that this technique is viable for point-of-care diagnostics.
Chapter 6 highlights further uses of graphene beyond nucleic acid detection and
therapeutic drug monitoring. This chapter presents experiments for the detection of
protein biomarkers and pH sensing of complex fluids through flexible devices. It also
establishes a method for detecting micro-assemblies, in this case, protein-nanoparticle
assemblies through charge transfer, and, finally, shows that it can be used for measuring
the binding properties of neuropeptides and their receptors, further demonstrating the
versatility of this nanomaterial as a sensing medium.
With the technology to detect biomolecules in small concentrations at the point-of-care,
the medical community could finally have a standard, early-disease diagnostic method,
and could diagnose ailments for which there are currently no standard forms of early
detection, such as ovarian cancer5, colon cancer6, or pancreatic cancer7. Additionally,
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doctors would be able to determine drug compliance of medications used to treat
dangerous diseases like HIV, or monitor the pH of a patient’s body fluids.
Early disease detection, through a rapid and inexpensive methodology, would serve the
purpose of prolonging life spans. Furthermore, rapid therapeutic drug monitoring would
replace the need for expensive lab techniques which are time-inefficient, and
simultaneously, through the monitoring of drug compliance for dangerous diseases like
HIV, can also prolong a patient’s lifespan by decades.
Apart from saving lives, there is a less evident benefit to biosensors, and that is a lower
cost of medical treatments for ailments such as cancer, which can cost the average patient
tens of thousands of dollars, and sometimes, hundreds of thousands, depending on
insurance policies or additional treatment for relapse. Therapeutic drug monitoring for
HIV can help prevent the development of AIDS, and the treatment of illnesses due to
AIDS. By reducing the cost of these medical treatments through diagnosing and treating
cancer in its early stages, or by preventing the development of a more dangerous disease
through TDM, the average medical costs per patient could be drastically lowered, and
could impact the entire American health care system.
Because graphene is biocompatible, it serves as an appropriate medium for diagnostics
with human samples. Future work in the area of sensing with graphene could extend
towards biomarker detection in low concentrations in blood plasma, therapeutic drugs in
urine, VOCs through breath/plasma samples, or glucose in sweat. However, many
challenges exist for testing in human samples that do no present themselves in synthetic
samples, such as high background signals from urea or daily diet in urine samples, signals
from proteins, hormones, and electrolytes in blood plasma, and salt in sweat samples.
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Consequently, the first step in this type of experiment would be to measure the
background signal of the sample’s solution compared to the signal of deionized water.
This step would determine if the background signal of the sample creates a significant
background noise. The noisier the background signal, the more difficult lowconcentration detection will be.
Next, one would need to procure samples from patients with various degrees of the
ailment when detecting biomarkers, for example, early stage, late stage, and healthy, to
record a signal difference between these groups and use this information to learn more
about the progression of the disease in the body. For therapeutic drug monitoring, one
would need to obtain urine samples from patients taking a certain medication versus
those taking a similar medication, or no medication at all, for comparison.
For this type of technology to come to fruition and be a viable clinical option, it needs to
be mass-produced and marketed properly. This means that high-quality graphene needs to
be grown in industry in very large areas, and the whole sensing system needs to be easily
operable (hand-held), affordable, and of course, accurate. There are still many steps to be
taken before this method can be considered a standard detection method for real-life
situations, although there is documentation of these types of devices being manufactured
and used for disease diagnostics8.
These biosensing techniques could also extend towards other types of chemical sensing
apart from market drugs, for example, explosive detection by the military, or more
effective sensors for gas leaks in labs or homes. Each of the biomolecular or chemical
sensors described herein could be applicable for low-concentration detection, for which
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there are either no existing technologies, or for which existing technologies are
unaffordable and difficult to operate.
Biosensing and chemical sensing with nanomaterials represents a relatively new and
promising field of interdisciplinary science and engineering that might someday replace
certain forms of current medical technology. As of now, graphene is the only material
known to exceed the electron mobility of any other at room temperature, with high
sensitivity and mechanical strength, making it ideal for sensitive detection.
This thesis demonstrates the versatility and promise of a sensing material that was
discovered less than 20 years ago. Provided that all the appropriate challenges are
addressed and overcome, such graphene sensors could one day be used for applications in
a variety of sectors, most notably, the healthcare sector.
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Chapter 8: Note about Thesis Dedication
This thesis is dedicated first and foremost to my maternal grandmother, Radha Rani
Kuruganti, and to my maternal grandfather, Dr. K.V.L. Sarma.
Born in India in 1937, my grandfather was a physicist who earned his PhD at the
University of Wisconsin, Madison in 1967 in theoretical neutrino physics. He went on as
a postdoctoral researcher at Carnegie Mellon University and eventually returned to India
to be a researcher at the Tata Institute of Fundamental Research (TIFR) in Mumbai,
where he continued to work until his death in 1997.

Figure 8.1.1 My grandfather at work at the University of Wisconsin, 1960s.
My grandmother, also born in India in 1941, did not finish high school, as was common
for Indian women of that generation. Nonetheless, she followed my grandfather to the
United States during his time as a graduate student, leaving her two small children, my
mother and uncle, in India for two years to be cared for by her in-laws. Despite not
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speaking any English upon her arrival in America, she managed to secure a job helping
PhD student Edward Dettmann in his research with scanning, measuring and data
analysis to encode the coordinates of proton tracks in the physics department at the
University of Wisconsin, Madison. It was through this position that she learned English,
and her contributions have been mentioned in Dr. Dettmann’s thesis. With the money she
earned from this job, she purchased plane tickets for my mother and uncle to join her and
my grandfather in America.

Figure 8.1.2 My grandmother at the University of Wisconsin in the lab where she worked
(1960s)

This dedication is bittersweet, as I feel regretful of the fact that my grandfather passed
before I could discuss science with him, but simultaneously inspired, not just by his
work, but by the work my grandmother took part in without knowing English and without
an education. With such little freedom and few resources, she still made her contribution
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to science, which makes me believe that for myself and my peers, there are no limits, as
we have been given many more opportunities for success.
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Appendix A: CVD Graphene Growth Recipe
1) Clean furnace, thermal blocks and quartz plate with propanol-2 (IPA) only 
acetone leaves a residue and can contribute to contamination of the furnace, so
avoid it.
2) Cut a piece of copper foil (Alfa Aesar, 99.8%, 25 μm thickness) to approximately
3 x 4 inches
3) Sonicate foil in acetone for 10 minutes, rinse with IPA and dry with compressed
N2. (This cleaning step is to ensure that there are fewer defects on the surface of
the foil, and that the surface is clean upon entering the furnace.)
4) Place foil on quartz plate and orient the plate and thermal blocks in the following
positions in the furnace, shown below in Figure AA.1.

Figure AA.1 CVD furnace showing placement of copper foil and gas flow direction.
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5) Place small amount of vacuum grease on the O-ring of the furnace and spread
evenly to ensure a tight seal, and close the furnace with the metal plate and screws
located on the chiller.
6) Turn the N2 switch from “off” to “auto” on the furnace and set the flow rate to
200 sccm on the computer program.
7) After about 20 seconds, flip the N2 switch to “purge” to increase the flow rate
from 200 sccm to 500 sccm.
8) After 5 minutes of N2 flow at 500 sccm, open the pressure valve very slowly to
begin pumping gases out of the tube.
9) After another 5 minutes of N2 flow, flip the switch back to “auto”, at which point
the flow rate will turn down to 200 sccm and, after 30 seconds, to “off”, to lower
the rate to 0 sccm. (The reason for this middle step is to prevent a drastic pressure
change, which can shift the placement of the thermal blocks in the sealed furnace.
At this point, the pressure should read somewhere between 50-60 mTorr.
10) Close the nitrogen tank and open the methane and hydrogen tanks, and turn the
appropriate switches from “off” to “auto”.
11) The desired growth recipe is chosen in the program on the computer connected to
the furnace – all recipes are automated.
12) Gases will flow for about 30 minutes to purge the system of the nitrogen, at
which point the timer will beep.
13) Click “OK” on the computer screen pop-up, and immediately after, hold down
the “run/hold” button the furnace. This will begin the heat ramp-up step.
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14) The recipe will run for about 2.5 hours, which includes ramp up, anneal, and
graphene growth. When the recipe is done, the system will beep.
15) A notification pop-up will appear on the screen – click “OK” on the notification
and immediately “stop” the furnace (do NOT turn it off) and crank it open 2
inches. Clicking “OK” allows the program to go to the next step.
16) When the second alarm sounds, wait until the furnace reaches at most 900 C (for
both thermocouples), click “OK” on the notification, and slide the furnace to the
right, to increase the cooling rate. (It is very important not to slide the furnace
until both thermocouples are at most 900 C, as doing so before could crack the
ceramic inside the furnace, due to a drastic temperature change).
17) After sliding the furnace, one must wait for the temperature of both
thermocouples to reach at most 500 C, click “OK” on the notification, and open
the furnace all the way, at which point the methane turns off.
18) Keep the furnace in this position until the next alarm sounds, which will be when
the furnace reaches around 80 C. Click “OK” on the notification and the H2 will
turn off. (For safety reasons, it is beneficial to continue waiting another 20 or 30
minutes after the hydrogen is turned off to allow the system to cool further, as 80
C could easily cause burns).

Note: the alarm always sounds a minute or two before the thermocouples reach
the appropriate temperature. Allow the alarm to sound, and it will stop ringing on
its own after a few seconds. Always wait for the thermocouples to reach the
necessary temperature before clicking “OK” on the notification.
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19) To vent the system, open the N2 tank and slowly increase the flow rate to 500
sccm.
20) Close the pressure valve, allowing the nitrogen to fill the tube. When the pressure
on the pressure gauge reaches room pressure (760 Torr), unscrew the metal plate and
remove the thermal blocks and the foil on the quartz substrate. All tanks should be
closed and the furnace (and all the quartz that goes in the furnace) should be cleaned
with IPA. The Cu foil, now with graphene, can be wrapped in aluminum foil, gently,
so as not to cause any wrinkles, and stored in a dry box at room temperature.

Additional growth method: A second method of cleaning involves sonicating in nitric
acid for 40 seconds, followed by three sonication baths of DI water, each for 2 minutes,
to remove the nitric acid residue and dried with N2. The desire for nitric acid use over
acetone is the strength of the acid over acetone, and its ability to etch away the top most
layers of the Cu foil, leaving as few defects as possible. This results in a larger grain size
of the graphene. One must be careful not to leave the foil in the nitric acid for too long,
because too few defects on the Cu foil is also detrimental, as the graphene in fact grows
around defects on the Cu foil’s surface. In this thesis, the main method for foil cleaning is
acetone, as it has been extremely effective and less dangerous than nitric acid use.
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Appendix B: CVD Hexagonal Boron Nitride Growth Recipe
1) Cut a piece of copper foil roughly 1 x 3 inches (Alfa Aesar, 99.8%, 25 μm thickness)
and sonicate in acetone for 10 minutes, then rinse with IPA and dry with N2.
2) Center the appropriate growth tube in the center of the furnace.
3) Place the foil in the center of the 1 inch tube, so as to ensure even temperature
spread and therefore uniform growth.
4) Using a pair of tweezers, place an ammonia borane (AB) pellet (Sigma Aldrich)
in the center of a glass tube on the precursor holder.
5) Place the precursor holder at the right end of the tube (downstream of gas flow)
about 20 cm from the right edge of the furnace.
6) Secure both ends of the furnace with the available O-rings and endcaps, to prevent gas
leaks.
7) Open the argon and hydrogen tanks and associated mass flow controllers
8) Set the flow rates to the following: Argon: 500 sccm, H2: 50 sccm
9) Set the furnace to 1050 C and wait 30 minutes for the ramp up/anneal steps.
10) After 30 minutes, lower the H2 flow to 20 sccm and slide the precursor closer to the
furnace, about 7.5 cm away from the edge.
11) Keep the precursor here for about 10 minutes, or until the pellet begins to expand
12) After 10 minutes, slide the precursor back to its original position about 20 cm away
from the furnace.
13) Next, increase the Ar flow rate to 1000 sccm and lower the H2 to 10 sccm.
14) Turn off the furnace and slide it to the left (down stream of gas flow), about 1.5-2
inches from the foil.
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15) Cool the furnace to below 100 C, and turn off the gases.
16) Remove copper foil, wrap in aluminum foil, and store in dry box for future use.
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Appendix C: GFET Fabrication Recipe
1) Spin-coat wafer with a protective layer of polymethylglutarimide (PMGI,
Microchem) at 4,000 rotations per minute (rpm) for 45 seconds.
2) Bake wafer at 210 C for 5 minutes.
3) spin coated a layer of S1813 (Microchem) at 5,000 rpm for 45 seconds atop the
PMGI layer.
4) Bake wafer at 100 C for 2 minutes.
5) Place wafer in Suss Microtech mask aligner with appropriate contact mask and
expose to UV light .
6) Develop wafer in MF-319 developer (Microposit) for ~30 seconds to reveal the
pattern on the wafer.
7) Place wafer in thermal evaporator (PVD-75 Lesker) and deposit electrodes of
chromium (5 nm) and gold (40 nm), the purpose of the chromium being to ensure
proper adhesion of the gold to the wafer.
8) After evaporation, place wafer in 1165 (Microposit) to lift off excess metals. Mild
pipetting and/or sonication is required to help remove these excess metals.
9) Place wafer in acetone to remove 1165 residue.
10) Rinse wafer with isopropyl alcohol (propanol-2, “IPA”). The patterning process
and final substrate are shown in Fig. AC.1 below.
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Figure AC.1 Patterning schematic of a Si/SiO2 wafer with chromium and gold electrodes
(of thicknesses 5 nm and 40 nm, respectively). Each rectangle shown on the wafer in the
bottom right hand corner represents one “chip”, with each chip comprised of 52 devices,
each with its own source and drain. In one round of lithography, we can have several
hundred devices.

11) Break wafer into individual chips using diamond scribe along vertical and
horizontal axes of wafer.
12) Transfer graphene onto a chip through the electrolysis bubble transfer method
(Chapter 3.1).
13) Leave graphene/PMMA film to dry on substrate for ~ 1 hour.
14) Bake chip at 150 C for 2 minutes to ensure proper adhesion of graphene to the
SiO2.
15) Wash chip with acetone and soak in an acetone bath for 10 minutes to remove
PMMA.
16) Rinse with IPA and dry with compressed N2.
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17) Spin-coat chip with a protective layer of PMGI at 4,000 rpm for 45 seconds. This
protective layer prevents the graphene from coming into contact with the next
photoresist, which adheres more strongly to the graphene.
18) Bake chip at 125 C for 5 minutes.
19) Spin-coat a layer of S1813 onto the chip at 5,000 rpm for 45 seconds atop the
PMGI layer.
20) Bake chip a second time, at 100 C for 2 minutes.
21) Place chip in Suss Microtech mask aligner with appropriate alignment mask
22) Expose chip to UV light to expose unwanted areas of graphene (everything
except channels) in dimensions 10 x 100 µm
23) Develop in MF-319 for ~30 seconds to remove unwanted photoresist.
24) Rinse with DI water.
25) Place chip in plasma etcher to remove excess graphene, that is, not part of the
FET channels, under the following conditions: O2 plasma at 1.25 Torr under a
power of 50 Watts for 30 seconds.
26) Clean chip in 1165, acetone, and IPA to remove excess photoresist on the
channels in the following time order/time increments: 1165 (Microposit) for 2
minutes, 1165 for 5 minutes, acetone for 10 minutes, IPA for two minutes
27) Dry chip with compressed N2. The steps are shown in Figure AC.2.
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Figure AC2. Fabrication of graphene channels on patterned substrate, resulting in an
array of graphene field effect transistors (GFETs)
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